WO2019075265A1 - Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors - Google Patents

Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors Download PDF

Info

Publication number
WO2019075265A1
WO2019075265A1 PCT/US2018/055502 US2018055502W WO2019075265A1 WO 2019075265 A1 WO2019075265 A1 WO 2019075265A1 US 2018055502 W US2018055502 W US 2018055502W WO 2019075265 A1 WO2019075265 A1 WO 2019075265A1
Authority
WO
WIPO (PCT)
Prior art keywords
heterocycle
optionally substituted
heteroaryl
monocyclic
halogen
Prior art date
Application number
PCT/US2018/055502
Other languages
French (fr)
Inventor
Jie Jack Li
Elena S. Koltun
Adrian Liam Gill
Andreas BUCKL
Walter Won
Naing Aay
Kevin MELLEM
Christos TZITZILONIS
Ashutosh Jogalekar
James Joseph CREGG
Original Assignee
Revolution Medicines, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RU2020115095A priority Critical patent/RU2020115095A/en
Priority to KR1020207013076A priority patent/KR20200070295A/en
Application filed by Revolution Medicines, Inc. filed Critical Revolution Medicines, Inc.
Priority to JP2020519790A priority patent/JP2020536881A/en
Priority to CA3078565A priority patent/CA3078565A1/en
Priority to EP18795913.5A priority patent/EP3694848A1/en
Priority to BR112020007058-0A priority patent/BR112020007058A2/en
Priority to SG11202002941WA priority patent/SG11202002941WA/en
Priority to AU2018347516A priority patent/AU2018347516A1/en
Priority to CN201880066291.0A priority patent/CN111212834B/en
Priority to MX2020003579A priority patent/MX2020003579A/en
Publication of WO2019075265A1 publication Critical patent/WO2019075265A1/en
Priority to CONC2020/0003714A priority patent/CO2020003714A2/en
Priority to PH12020550216A priority patent/PH12020550216A1/en
Priority to IL273756A priority patent/IL273756A/en
Priority to US16/845,539 priority patent/US11702411B2/en
Priority to US18/131,226 priority patent/US20240067636A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

  • the present disclosure relates to inhibitors of protein tyrosine phosphatase SHP2 useful in the treatment of diseases or disorders. Specifically, this disclosure is concerned with compounds and compositions inhibiting SHP2, methods of treating diseases associated with SHP2, and methods of synthesizing these compounds.
  • SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN77 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT or the phosphoinositol 3- kinase- AKT pathways.
  • SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail.
  • the two SH2 domains control the subcellular localization and functional regulation of SHP2.
  • the molecule exists in an inactive, auto-inhibited conformation stabilized by a binding network involving residues from both the N-SH2 and PTP domains. Stimulation by, for example, cytokines or growth factors leads to exposure of the catalytic site resulting in enzymatic activation of SHP2.
  • SHP2 myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • SHP2 therefore, represents a highly attractive target for the development of novel therapies for the treatment of various diseases.
  • the compounds of the present disclosure fulfill the need for small molecules to that inhibit the activity of SHP2.
  • the present disclosure relates to compounds capable of inhibiting the activity of SHP2.
  • the disclosure further provides a process for the preparation of compounds disclosed herein, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C6alkynyl, -C 3 -C 8 cycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 ,
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is -H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 ,
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- Cealkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocycl
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • One aspect of the disclosure relates to compounds of Formula lib:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S-
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 ,
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C6alkynyl, -C 3 -C 8 cycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH 2 , halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH;
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C6alkynyl, -C 3 -C 8 cycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 ,
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH 2 )n-R , or -(CH 2 )nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH 2 , -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH;
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C6alkynyl, -C 3 -C 8 cycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 ,
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH 2 )n-R , or -(CH 2 )nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH 2 , -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12- member
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5
  • n is independently 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • compounds disclosed herein e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
  • Another aspect of the disclosure relates to methods of inhibiting SHP2.
  • the method comprises administering to a patient in need thereof, an effective amount of one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • compounds disclosed herein e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
  • compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier can further comprise an excipient, diluent, or surfactant.
  • the pharmaceutical composition can be effective for treating a disease associated with SHP2 modulation in a subject in need thereof.
  • Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • Another aspect of the disclosure relates to methods of inhibiting SHP2 comprising administering to a patient in need thereof, an effective amount of a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
  • Another aspect of the disclosure relates to one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use in treating or preventing a disease associated with SHP2 modulation.
  • compounds disclosed herein e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof
  • compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier, for use in treating of preventing a disease associated with SHP2 modulation.
  • compounds disclosed herein e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof
  • a pharmaceutically acceptable carrier for use in treating of preventing a disease associated with SHP2 modulation.
  • Another aspect of the disclosure relates to the use of one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and
  • compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • Another aspect of the disclosure relates to one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament.
  • Another aspect of the disclosure relates to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament.
  • the medicament is used for treating or preventing a disease associated with SHP2 modulation.
  • the present disclosure also provides compounds and pharmaceutical compositions that are useful in inhibiting SHP2.
  • an alkyl group that is optionally substituted can be a fully saturated alkyl chain (i.e. a pure hydrocarbon).
  • the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein.
  • optionally substituted means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any further functional groups.
  • alkyl refers to a straight or branched chain saturated hydrocarbon.
  • Ci- C 6 alkyl groups contain 1 to 6 carbon atoms. Examples of a Ci-C6alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.
  • alkenyl means an aliphatic hydrocarbon group containing a carbon— carbon double bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkenyl groups have 2 to about 4 carbon atoms in the chain.
  • Branched means that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkenyl chain.
  • exemplary alkenyl groups include ethenyl, propenyl, n- butenyl, and z ' -butenyl.
  • a C2-C6 alkenyl group is an alkenyl group containing between 2 and 6 carbon atoms.
  • alkynyl means an aliphatic hydrocarbon group containing a carbon— carbon triple bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkynyl groups have 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkynyl chain. Exemplary alkynyl groups include ethynyl, propynyl, w-butynyl, 2-butynyl, 3-methylbutynyl, and w-pentynyl.
  • a C2-C6 alkynyl group is an alkynyl group containing between 2 and 6 carbon atoms.
  • cycloalkyl refers to a single saturated or partially unsaturated all carbon ring having 3 to 20 annular carbon atoms (i.e., C3-C20 cycloalkyl), for example from 3 to 12 annular atoms, for example from 3 to 10 annular atoms.
  • cycloalkyl also includes multiple condensed, saturated and partially unsaturated all carbon ring systems (e.g., ring systems comprising 2, 3 or 4 carbocyclic rings).
  • cycloalkyl includes multicyclic carbocycles such as a bicyclic carbocycles (e.g., bicyclic carbocycles having about 6 to 12 annular carbon atoms such as bicyclo[3.1.0]hexane and bicyclo[2.1.1]hexane), and poly cyclic carbocycles (e.g., tricyclic and tetracyclic carbocycles with up to about 20 annular carbon atoms).
  • the rings of a multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, 1- cyclopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl and 1- cyclohex-3-enyl.
  • cycloalkenyl means monocyclic, non-aromatic unsaturated carbon rings containing 4-18 carbon atoms.
  • examples of cycloalkenyl groups include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and norborenyl.
  • a C 4 -Cs
  • cycloalkenyl is a cycloalkenyl group containing between 4 and 8 carbon atoms.
  • aryl refers to a single all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic.
  • an aryl group has 6 to 20 annular carbon atoms, 6 to 14 annular carbon atoms, or 6 to 12 annular carbon atoms.
  • Aryl includes a phenyl radical.
  • Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 20 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic (i.e., carbocycle).
  • Such multiple condensed ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple condensed ring system.
  • the rings of the multiple condensed ring system can be connected to each other via fused, Spiro and bridged bonds when allowed by valency requirements. It is also to be understood that when reference is made to a certain atom-range membered aryl (e.g., 6-12 membered aryl), the atom range is for the total ring (annular) atoms of the aryl.
  • a 6-membered aryl would include phenyl and a 10-membered aryl would include naphthyl and 1, 2, 3, 4-tetrahydronaphthyl.
  • aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, and the like
  • the aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment.
  • substituents include, but are not limited to, -H, halogen, -O-Ci-Cealkyl, -Ci-Cealkyl, -OC 2 -C 6 alkenyl, -OC2-C 6 alkynyl, -C 2 -C 6 alkenyl, -C 2 -C6alkynyl, -OH, -OP(0)(OH) 2 , -OC(0)Ci-C 6 alkyl, -C(0)Ci-C 6 alkyl, -OC(0)OCi- Cealkyl, -NH 2 , -NH(Ci-C 6 alkyl), -N(Ci-C 6 alkyl) 2 , -S(0) 2 -Ci-C 6 alkyl, -S(0)NHCi-C 6 alkyl
  • heteroaryl refers to a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; the term also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below.
  • the term includes single aromatic rings of from about 1 to 6 annular carbon atoms and about 1-4 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the rings.
  • the sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic.
  • Such rings include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl.
  • the term also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, can be condensed with one or more rings selected from heteroaryls (to form for example a naphthyridinyl such as 1,8-naphthyridinyl), heterocycloalkyls, (to form for example a 1,2,3,4-tetrahydronaphthyridinyl such as 1,2,3,4- tetrahydro- 1,8-naphthyridinyl), cycloalkyls (to form for example 5,6,7,8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensed ring system.
  • heteroaryls to form for example a naphthy
  • a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 annular carbon atoms and about 1-6 annular heteroatoms.
  • Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the condensed ring.
  • the rings of the multiple condensed ring system can be connected to each other via fused, Spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another.
  • the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the multiple condensed ring system including a heteroaryl, heterocycle, aryl or carbocycle portion of the multiple condensed ring system and at any suitable atom of the multiple condensed ring system including a carbon atom and heteroatom (e.g., a nitrogen).
  • heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl and thianaphthenyl.
  • heterocycloalkyl refers to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple ring system that has at least one heteroatom in the ring (at least one annular heteroatom selected from oxygen, nitrogen, and sulfur).
  • a heterocycloalkyl group has from 3 to about 20 annular atoms, for example from 5 to 20 annular atoms, for example from 5 to 14 annular atoms, for example from 5 to 10 annular atoms, for example from 3 to 12 annular atoms.
  • the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7- membered rings) having from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring.
  • the term also includes single saturated or partially unsaturated rings (e.g., 5, 6, 7, 8, 9, or 10- membered rings) having from about 4 to 9 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring.
  • the rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements.
  • Heterocyclyl also includes radicals where heterocycle radicals are fused with a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring.
  • Heterocycloalkyl groups include, but are not limited to, azetidine, aziridine, imidazolidine, imino-oxoimidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone,
  • spirocycle or "spirocyclic” means carbogenic bicyclic ring systems with both rings connected through a single atom.
  • the ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane.
  • One or both of the rings in a spirocycle can be fused to another carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
  • One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g., O, N, S, or P).
  • a Cs- Ci2 spirocycle is a spirocycle containing between 5 and 12 carbon atoms.
  • a C5-C12 spirocycle is a spirocycle containing from 5 to 12 carbon atoms.
  • One or more of the carbon atoms can be substituted with a heteroatom.
  • spirocyclic heterocycle is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl).
  • a spirocyclic heterocycle can contain between 5 and 12 atoms, at least one of which is a heteroatom selected from N, O, S and P.
  • a spirocyclic heterocycle can contain from 5 to 12 atoms, at least one of which is a heteroatom selected from N, O, S and P.
  • halo or halogen means a fluoro, chloro, bromo, or iodo group.
  • compositions comprising an effective amount of one or more disclosed compounds and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier that has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • the disclosure includes pharmaceutically acceptable salts of the compounds described herein.
  • pharmaceutically acceptable salts include, but are not limited to, e.g., water-soluble and water- insoluble salts, such as the acetate, amsonate (4,4- diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, io
  • “Pharmaceutically acceptable salt” also includes both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise
  • inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
  • organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1 ,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic
  • “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. For example, inorganic salts include, but are not limited to, ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • basic ion exchange resins such as
  • tautomers refers to a set of compounds that have the same number and type of atoms, but differ in bond connectivity and are in equilibrium with one another.
  • a "tautomer” is a single member of this set of compounds. Typically a single tautomer is drawn but it is understood that this single structure is meant to represent all possible tautomers that might exist. Examples include enol-ketone tautomerism. When a ketone is drawn it is understood that both the enol and ketone forms are part of the disclosure.
  • prodrugs of the compounds described herein include prodrugs of the compounds described herein.
  • prodrug means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound.
  • a prodrug is a drug which is inactive in the body, but is transformed in the body typically either during absorption or after absorption from the gastrointestinal tract into the active compound.
  • the conversion of the prodrug into the active compound in the body may be done chemically or biologically (i.e., using an enzyme).
  • the disclosure includes solvates of the compounds described herein.
  • solvate refers to a complex of variable stoichiometry formed by a solute and solvent.
  • solvents for the purpose of the disclosure may not interfere with the biological activity of the solute.
  • suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH.
  • Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.
  • the disclosure includes isomers of the compounds described herein.
  • the term "isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of the present disclosure may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.
  • stereoisomers refers to the set of compounds which have the same number and type of atoms and share the same bond connectivity between those atoms, but differ in three dimensional structure.
  • stereoisomer refers to any member of this set of compounds. For instance, a stereoisomer may be an enantiomer or a diastereomer.
  • the disclosure includes stereoisomers of the compounds described herein.
  • the present disclosure embraces all geometric and positional isomers.
  • a compound of the present disclosure incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure.
  • the substituent may be in the E or Z configuration.
  • the cycloalkyl substituent may have a cis or trans configuration.
  • enantiomers refers to a pair of stereoisomers which are non- superimposable mirror images of one another.
  • enantiomer refers to a single member of this pair of stereoisomers.
  • racemic refers to a 1 : 1 mixture of a pair of
  • the disclosure includes enantiomers of the compounds described herein. Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound. The compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry. In some embodiments the compounds are the (5)-enantiomer. In other embodiments the compounds are the (i?)-enantiomer. In yet other embodiments, the compounds are the (+) or (-) enantiomers
  • compounds and compositions of the disclosure may be enriched to provide predominantly one enantiomer of a compound described herein.
  • An enantiomerically enriched mixture may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.5 or even 100 mol percent.
  • the compound described herein enriched in one enantiomer is substantially free of the other enantiomer, wherein substantially free means that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture.
  • substantially free means that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture.
  • a composition or compound mixture contains 98 grams of a first enantiomer and 2 grams of a second enantiomer, it would be said to contain 98 mol percent of the first enantiomer and only 2 mol percent of the second enantiomer.
  • diastereomers refers to the set of stereoisomers which cannot be made superimposable by rotation around single bonds. For example, cis- and trans- double bonds, endo- and exo- substitution on bicyclic ring systems, and compounds containing multiple stereogenic centers with different relative configurations are considered to be diastereomers.
  • diastereomer refers to any member of this set of compounds.
  • the synthetic route may produce a single diastereomer or a mixture of diastereomers.
  • the disclosure includes diastereomers of the compounds described herein.
  • the compounds and compositions of the disclosure may be enriched to provide predominantly one diastereomer of a compound disclosed herein.
  • a diastereomerically enriched mixture may comprise, for example, at least 60 mol percent of one diastereomer, or more preferably at least 75, 85, 95, 96, 97, 98, 99, or even 100 mol percent.
  • the compounds described herein further include all pharmaceutically acceptable isotopically labeled compounds.
  • An “isotopically” or “radio-labeled” compound is a compound where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
  • hydrogen atoms are replaced or substituted by one or more deuterium or tritium.
  • radioactive isotopes tritium, i.e., 3 H, and carbon 14, i.e., 14 C are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, i.e., 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Suitable isotopes that may be incorporated in compounds described herein include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), n C, 13 C, 14 C, 13 N, 15 N, 15 0, 17 0, 18 0, 18 F, 35 S, 36 C1 , 82 Br, 75 Br, 76 Br, 77 Br, 123 I, 124 I, 125 I, and 131 I.
  • Substitution with positron emitting isotopes, such as n C, 18 F, 15 0, and 13 N can be useful in Positron Emission Topography (PET) studies.
  • PET Positron Emission Topography
  • an "effective amount" when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.
  • carrier encompasses excipients and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
  • treating refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.
  • preventing refers to keeping a disease or disorder from afflicting the subject. Preventing includes prophylactic treatment. For instance, preventing can include administering to the subject one or more compounds disclosed herein before a subject is afflicted with a disease and the administration will keep the subject from being afflicted with the disease.
  • disorder is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
  • administer refers to either directly administering one or more disclosed compounds or a pharmaceutically acceptable salt of one or more disclosed compounds or a composition comprising one or more disclosed compounds to a subject, or administering a prodrug derivative or analog of the compound or a pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.
  • a "patient” or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12- member
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH 2 )n-R , or -(CH 2 )nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -COOR , -CONHR , -CONH(CH 2 )nCOOR , -NHCOOR ,
  • R 4 is -H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S-
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12- member
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, Cs-Cscycloalkyl, -(CH 2 )n-R , or -(CH 2 )nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -COOR , -CONHR , -CONH(CH 2 )nCOOR , -NHCOOR ,
  • R 4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C4-C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Y 1 is -S- or a direct bond. In certain embodiments, Y 1 is -S-. In certain embodiments, Y 1 is a direct bond. [0079] As described above, X 1 is N or CH. In certain embodiments, X 1 is N. In certain embodiments, X 1 is CH.
  • X 2 is N or CH. In certain embodiments, X 2 is N. In certain embodiments, X 2 is CH.
  • X 3 is N or CH. In certain embodiments, X 3 is N. In certain embodiments, X 3 is CH.
  • X 1 , X 2 , or X 3 is N.
  • X 1 is N.
  • X 2 is N.
  • X 3 is N.
  • X 1 is N and X 2 is N.
  • X 1 is N and X 3 is N.
  • X 2 is N and X 3 is N.
  • X 1 is N; X 2 is N; and X 3 is N.
  • A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, monocyclic or poly cyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl.
  • A is 5- to 12-membered monocyclic or polycyclic cycloalkyl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic heterocycloalkyl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic aryl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic heteroaryl.
  • A is a monocyclic heteroaryl. In certain embodiments, A is a monocyclic aryl. In certain embodiments, A is a polycyclic heteroaryl. In certain embodiments, A is a polycyclic heterocycloalkyl.
  • A is selected from:
  • A is selected from:
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C4-Cscycloalkenyl, -C2-C 6 alkynyl, -C3- Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6
  • each R 1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR 5 R 6 .
  • R 5 and R 6 are H.
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12-member
  • each R 1 is an optionally substituted 3-to 12-membered monocyclic or polycyclic heterocycle. In certain embodiments, each R 1 is 3-to 12-membered monocyclic or polycyclic heterocycle substituted with heterocycle or -S(0)2R 5 . In certain embodiments, each R 1 is selected from the group consisting of halogen, -Ci-Cealkyl, - OR 6 , -CN, -C(0)NR 5 R 6 , and -NR 5 R 6 . In certain embodiments, R 5 and R 6 are H. [0091] As described above, n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C4-Cscycloalkenyl, -C 2 - C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN.
  • R 5 and R 6 are H.
  • A (shown with R 1 ) are selected from:
  • R 4 is- ⁇ , -D, -Ci-Cealkyl, -Ci- Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , - NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH, -C(0)NH(CH 2 ) n R , -C(0)R , -NH2, -OH, -CN, -C(0)NR 5 R 6 , -S(0) 2 NR 5 R 6 , Cs-C
  • heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen.
  • R 4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo.
  • R 4 is an optionally substituted -Ci-C6alkyl.
  • R 4 is -Ci-C6alkyl substituted with -OH.
  • R 4 1S-CH2-OH.
  • R 4 is -Ci-C6alkyl substituted with one or more halogen.
  • R 4 is -Ci-C6alkyl substituted with one or more fluoro.
  • R 4 is -CHF2.
  • R 4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci- Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 ,
  • R 4 is an optionally substituted -Ci-C6alkyl. In certain embodiments, R 4 is -Ci-C6alkyl substituted with -OH. In certain embodiments, R 4 1S-CH2-OH. In certain embodiments, R 4 is -Ci-C6alkyl substituted with one or more halogen. In certain embodiments, R 4 is -Ci-C6alkyl substituted with one or more fluoro. In certain embodiments, R 4 is -CHF2.
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci-C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl.
  • R 2 or R 3 is
  • R 3 can combine with R 2 to form a 3- to 12-membered
  • R 3 can combine with R 2 to form an optionally substituted heteroaryl or an optionally substituted heterocyclyl, wherein wherein the heteroaryl and heterocyclyl are optionally substituted with -CN.
  • R 3 can combine with R 2 to form a 3-to 12-membered optionally substituted monocyclic heterocycle. In certain embodiments, R 3 can combine with R 2 to form a 3-to 12-membered optionally substituted polycyclic heterocycle. In certain
  • R 3 can combine with R 2 to form a 5-to 12-membered optionally substituted spiroheterocycle. [00100] In certain embodiments, R 3 can combine with R 2 to form 3-to 12-membered monocyclic or poly cyclic heterocycle, wherein the heterocycle is optionally substituted with more -Ci-Cealkyl, halogen, -OH, -OR , -NH 2 , -NHR , heteroaryl, heterocyclyl, -(CH 2 )nNH 2 ,
  • R 3 can combine with R 2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with -Ci- Cealkyl, -OR , or -NH 2 .
  • R 3 can combine with R 2 to form 5-to 12-membered spiroheterocycle, wherein the spirocycle is optionally substituted with -Ci-C6alkyl, -OR , or
  • R 3 can combine with R 2 to form a moiety selected from:
  • R 3 can combine with R 2 to form a moiety selected from:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C4-C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C6alkynyl, -C 3 -C 8 cycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 ,
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH 2 , -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • X 1 is N or CH.
  • X 1 is N. In certain embodiments, X 1 is CH.
  • X 2 is N or CH. In certain embodiments, X 2 is N. In certain embodiments, X 2 is CH.
  • X 3 is N or CH.
  • X 3 is N. In certain embodiments, X 3 is CH.
  • X 1 , X 2 , or X 3 is N.
  • X 1 is N.
  • X 2 is N.
  • X 3 is N.
  • X 1 is N and X 2 is N.
  • X 1 is N and X 3 is N.
  • X 2 is N and X 3 is N.
  • X 1 is N; X 2 is N; and X 3 is N.
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or poly cyclic
  • heterocycloalkyl monocyclic or polycyclic aryl, or monocyclic or poly cyclic heteroaryl.
  • A is 5- to 12-membered monocyclic or polycyclic cycloalkyl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic heterocycloalkyl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic aryl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic heteroaryl.
  • A is a monocyclic heteroaryl. In certain embodiments, A is a monocyclic aryl. In certain embodiments, A is a polycyclic heteroaryl. In certain embodiments, A is a polycyclic heterocycloalkyl.
  • A is selected from:
  • A is selected from:
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each alky
  • each R 1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR 5 R 6 .
  • R 5 and R 6 are H.
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12-member
  • each R 1 is an optionally substituted 3-to 12-membered monocyclic or polycyclic heterocycle. In certain embodiments, each R 1 is 3-to 12-membered monocyclic or polycyclic heterocycle substituted with heterocycle or -S(0)2R 5 . In certain embodiments, each R 1 is selected from the group consisting of halogen, -Ci-Cealkyl, - OR 6 , -CN, -C(0)NR 5 R 6 , and -NR 5 R 6 . In certain embodiments, R 5 and R 6 are H. [00121] As described above in Formula III, V, and VI, n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN.
  • R 5 and R 6 are H.
  • A (shown with R 1 ) are selected from:
  • R 4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo.
  • R 4 is an optionally substituted -Ci-C6alkyl.
  • R 4 is -Ci-C6alkyl substituted with -OH.
  • R 4 1S-CH2-OH.
  • R 4 is -Ci-C6alkyl substituted with one or more halogen.
  • R 4 is -Ci-C6alkyl substituted with one or more fluoro.
  • R 4 is -CHF2.
  • R 4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo.
  • R 4 is -Ci-C6alkyl substituted with -OH.
  • R 4 1S-CH2-OH.
  • R 4 is -Ci-C6alkyl substituted with one or more halogen.
  • R 4 is -Ci-C6alkyl substituted with one or more fluoro.
  • R 4 is -CHF2.
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci-C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl.
  • a 3-to 12-membered monocyclic or polycyclic heterocycle a 5- to 12-membered spiroheterocycle
  • C3-Cscycloalkyl or -(CH2)n-R
  • each alkyl, heterocycle, or cycloalkyl is optionally substituted with
  • R 2 or R 3 can be -(CH 2 )nC(0)NR 5 R 6 .
  • R 3 can combine with R 2 to form an optionally substituted heteroary
  • R 3 can combine with R 2 to form a 3 -to 12-membered optionally substituted monocyclic heterocycle. In certain embodiments, R 3 can combine with R 2 to form a 3-to 12-membered optionally substituted polycyclic heterocycle. In certain
  • R 3 can combine with R 2 to form a 5-to 12-membered optionally substituted spiroheterocycle.
  • R 3 can combine with R 2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with -Ci- Cealkyl, -OR , or -NH 2 .
  • R 3 can combine with R 2 to form 5-to 12-membered spiroheterocycle, wherein the spirocycle is optionally substituted with -Ci-C6alkyl, -OR , or -NH 2 .
  • R 3 can combine with R 2 to form a moiety selected from:
  • R 3 can combine with R 2 to form a moiety selected from:
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I having one, two, three, four, or more of the following features:
  • X 1 is CH; and X 2 and X 3 are N;
  • A is monocyclic or polycyclic optionally substituted heteroaryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
  • R 4 is -CH2-OH.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and X 2 and X 3 are N;
  • A is monocyclic or polycyclic optionally substituted heteroaryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
  • R 4 is -CH2-OH.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and X 2 and X 3 are N;
  • A is monocyclic or polycyclic optionally substituted aryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and e) R 4 is -CH2-OH.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and X 2 and X 3 are N;
  • A is monocyclic or polycyclic optionally substituted aryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
  • R 4 is -CH2-OH.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and X 2 and X 3 are N;
  • A is monocyclic or polycyclic optionally substituted heteroaryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
  • R 4 is -Ci-C6alkyl substituted with one or more halogen.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and X 2 and X 3 are N;
  • A is monocyclic or polycyclic optionally substituted heteroaryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
  • R 4 is -Ci-C6alkyl substituted with one or more halogen.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and X 2 and X 3 are N;
  • A is monocyclic or polycyclic optionally substituted aryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
  • R 4 is -Ci-C6alkyl substituted with one or more halogen.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and X 2 and X 3 are N;
  • A is monocyclic or polycyclic optionally substituted aryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
  • R 4 is -Ci-C6alkyl substituted with one or more halogen.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I having one, two, three, four, or more of the following features:
  • X 1 is CH; and one of X 2 and X 3 is N;
  • A is monocyclic or polycyclic optionally substituted heteroaryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
  • R 4 is -CH2-OH or a -Ci-C6alkyl substituted with one or more halogen.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and one of X 2 and X 3 is N;
  • A is monocyclic or polycyclic optionally substituted heteroaryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
  • R 4 is -CH2-OH or a -Ci-C6alkyl substituted with one or more halogen.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
  • X 1 is CH; and one of X 2 and X 3 is N; b) A is monocyclic or polycyclic optionally substituted aryl;
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
  • R 4 is -CH2-OH or a -Ci-C6alkyl substituted with one or more halogen.
  • the present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and VI, having one, two, three, four, or more of the following features:
  • X 1 is CH; and one of X 2 and X 3 is N;
  • A is monocyclic or polycyclic optionally substituted aryl
  • R 1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R 3 can combine with R 2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
  • R 4 is -CH2-OH or a -Ci-C6alkyl substituted with one or more halogen.
  • the present disclosure provides a compound selected from:
  • the present disclosure provides a compound selected from:
  • the present disclosure provides a compound selected from
  • the compounds of the present disclosure may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the schemes given below.
  • the compounds of any of the formulae described herein may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes and examples.
  • protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry.
  • Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
  • the selection processes, as well as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of Formula I.
  • stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well.
  • a compound When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley- lnterscience, 1994).
  • the compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
  • the compounds of the present disclosure can be prepared in a number of ways well known to those skilled in the art of organic synthesis.
  • compounds of the disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. These methods include but are not limited to those methods described below.
  • a general synthesis of (3-amino-6-phenylpyrazin-2-yl)methanol is outlined in Scheme 1.
  • 3-Chloro-6-phenylpyrazine-2-ethylcarboxylate can be coupled to a substituted aryl- or heteroaryl boronic acid in the presence of a palladium catalyst (e.g., Pd(dppf)Ci2).
  • the resulting biaryl intermediate can then be coupled to a substituted primary or secondary amine under SNAr conditions, followed by reduction to give a (3-amino-6-phenylpyrazin-2- yl)methanol. Additional deprotection and/or functionalization steps can be required to produce the final compound.
  • 3-Chloro-6-phenylpyrazine-2-carboxylate can be coupled to a primary or secondary amines under SNAr conditions.
  • the resulting aminopyrazine ester can then be reduced to produce amino pyrazin-2-yl-methanol, following coupling to an appropriately substituted potassium (or sodium) salt of arylthiol or heteroarylthiol. Additional deprotection and/or functionalization steps can be required to produce the final compound.
  • Another aspect of the disclosure relates to a method of treating a disease associated with SHP2 modulation in a subject in need thereof.
  • the method involves administering to a patient in need of treatment for diseases or disorders associated with SHP2 modulation an effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or of one or more pharmaceutical
  • the disease can be, but is not limited to Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R).
  • PDGF-R platelet-derived growth factor
  • FGF-R fibroblast growth factor
  • EGF-R epidermal growth factor
  • SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer.
  • MAP mitogen activated protein
  • SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers.
  • SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
  • SHP2 plays a role in transducing signals originating from immune checkpoint molecules, including but not limited to programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
  • PD-1 programmed cell death protein 1
  • CTL-4 cytotoxic T-lymphocyte-associated protein 4
  • modulation of SHP2 function can lead to immune activation, specifically anti-cancer immune responses.
  • Another aspect of the disclosure is directed to a method of inhibiting SHP2.
  • the method involves administering to a patient in need thereof an effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or of one or more pharmaceutical compositions of the present disclosure.
  • compounds of the present disclosure e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
  • the present disclosure relates to compounds or compositions disclosed herein that are capable of modulating the activity of (e.g., inhibiting) SHP2.
  • the present disclosure also relates to the therapeutic use of such compounds and compositions.
  • One or more disclosed compounds or compositions can be administered in effective amounts to treat or prevent a disorder and/or prevent the development thereof in subjects.
  • SHP2 is inhibited after treatment with less than 1000 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with about 10 nM to about 100 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with 10 nM to 100 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with less than 10 nM of a compound of the disclosure.
  • Another aspect of the present disclosure relates to one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and
  • the disease is Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R).
  • PDGF-R platelet-derived growth factor
  • FGF-R fibroblast growth factor
  • EGF-R epidermal growth factor
  • SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer. Knock-down of SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers. SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and
  • the present disclosure relates to the use of one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, co-crystals, prodrugs, solvates, hydrates, tautomers, or isomers thereof), in the manufacture of a medicament for treating or preventing a disease.
  • the disease is associated with SHP2 modulation.
  • the present disclosure relates to one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and
  • the present disclosure relates to one or more compositions comprising one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament.
  • the medicament is used for treating or preventing a disease associated with SHP2 modulation.
  • compositions comprising one or more compounds of the present disclosure and a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carriers can further include excipients such as diluent, surfactant, lipid, solvent.
  • excipients such as diluent, surfactant, lipid, solvent.
  • compositions can be prepared according to conventional preparation methods of the dosage forms that are applicable for different route of adminstration, respectively.
  • the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume.
  • Administration of the disclosed compounds and pharmaceutical compositions can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, intravenous, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
  • systemic or local administration such as oral, nasal, parenteral, intravenous, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
  • the disclosed compounds or pharmaceutical compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, capsules, tablets, pellets, suppositories, pills, modified-release dosage forms, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, patches, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
  • injectables capsules, tablets, pellets, suppositories, pills, modified-release dosage forms, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, patches, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
  • they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular, transdermal form, and all using forms well known to those skilled in the pharmaceutical arts.
  • Illustrative pharmaceutical compositions are liquid and solid dosage forms, such as tablets and capsules, comprising one or more compounds of the present disclosure and a pharmaceutically acceptable carrier, such as, but not limited to, a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate
  • Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, lyophilization etc.
  • one or more disclosed compounds are dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, buffer, glycerol, ethanol, cyclodextrin, cremophor EL and the like, to thereby form an injectable isotonic solution or suspension or lyophilized cake for re-constitution.
  • a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, buffer, glycerol, ethanol, cyclodextrin, cremophor EL and the like, to thereby form an injectable isotonic solution or suspension or lyophilized cake for re-constitution.
  • Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
  • One or more disclosed compounds or compositions can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
  • One or more disclosed compounds or compositions can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines.
  • a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described for instance in U.S. Pat. No. 5,262,564, the contents of which are hereby incorporated by reference.
  • One or more disclosed compounds or compositions can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled.
  • the disclosed compounds can also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy
  • the one or more disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • one or more disclosed compounds are not covalently bound to a polymer, e.g., a polycarboxylic acid polymer, or a polyacrylate.
  • One or more disclosed compounds or compositions can be delivered by parental administration.
  • Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Injectables can be prepared in
  • the dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed.
  • a physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Effective dosage amounts of the disclosed compounds when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition.
  • Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses.
  • the compositions are in the form of a tablet that can be scored.
  • the effective daily dose of one or more compounds or compositions of this disclosure may be administered as one, two, three, four, five, six, or more sub-doses
  • the one or more compounds or compositions of this disclosure, or mixtures thereof may be administered two or three times daily. In some embodiments, the one or more compounds or compositions of this disclosure will be
  • one or more compounds or compositions described herein may be used alone or together or conjointly administered, or used in combination, with another type of therapeutic agent.
  • Conjoint administration or used in combination refers to any form of administration of two or more different therapeutic compounds or compositions such that the second compound or composition is administered while the previously administered therapeutic compound or composition is still effective in the body.
  • the different therapeutic compounds or compositions can be administered either in the same formulation or in a separate formulation, either simultaneously, sequentially, or by separate dosing of the individual components of the treatment.
  • the different therapeutic compounds or compositions can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another.
  • an individual who receives such treatment can benefit from a combined effect of different therapeutic compounds or compositions.
  • this disclosure also provides a pharmaceutical package or kit comprising one or more containers filled with at least one compound or composition of this disclosure.
  • a container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects (a) approval by the agency of manufacture, use or sale for human administration, (b) directions for use, or both.
  • the kit comprises at least two containers, at least one of which contains at least one compound or composition of this disclosure.
  • the kit contains at least two containers, and each of the at least two containers contains at least one compound or composition of this disclosure.
  • the kit includes additional materials to facilitate delivery of the subject compounds and compositions.
  • the kit may include one or more of a catheter, tubing, infusion bag, syringe, and the like.
  • the compounds and compositions are packaged in a lyophilized form, and the kit includes at least two containers: a container comprising the lyophilized compounds or compositions and a container comprising a suitable amount of water, buffer, or other liquid suitable for reconstituting the lyophilized material.
  • Embodiment I As follows:
  • Embodiment 1-1 A compound of the Formula I:
  • X 1 is N or CH
  • X 2 is N or CH;
  • X 3 is N or CH;
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 is-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment 1-2 A compound of the Formula II:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 is-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment 1-3 A compound of the Formula III:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment 1-4 The compound of any one of Embodiments 1-1 to 1-3, wherein X 1 is N.
  • Embodiment 1-5 The compound of any one of Embodiments 1-1 to 1-3, wherein X 1 is CH.
  • Embodiment 1-6 The compound of any one of Embodiments 1-1 to 1-5, wherein X 2 is N.
  • Embodiment 1-7 The compound of any one of Embodiments 1-1 to 1-5, wherein X 2 is CH.
  • Embodiment 1-8 The compound of any one of Embodiments 1-1 to 1-7, wherein X 3 is N.
  • Embodiment 1-9 The compound of any one of Embodiments 1-1 to 1-7, wherein X 3 is CH.
  • Embodiment 1-10 The compound of any one of Embodiments 1-1 to 1-9, wherein A is monocyclic or polycyclic aryl.
  • Embodiment 1-11 The compound of any one of Embodiments 1-1 to 1-9, wherein A is monocyclic or polycyclic cycloalkyl.
  • Embodiment 1-12 The compound of any one of Embodiments 1-1 to 1-9, wherein A is monocyclic or polycyclic heterocycloalkyl.
  • Embodiment 1-13 The compound of any one of Embodiments I-l to 1-9, wherein A is monocyclic or polycyclic heteroaryl.
  • Embodiment 1-14 The compound of any one of Embodiments I-l to 1-13, wherein each R 1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR 5 R 6 .
  • Embodiment 1-15 The compound of Embodiment 1-14, wherein R 5 and R 6 are H.
  • Embodiment 1-16 The compound of any one of Embodiments I-l to 1-15, wherein R 4 is an optionally substituted -Ci-C6alkyl.
  • Embodiment 1-17 The compound of any one of Embodiments I-l to 1-16, wherein R 4 is-CH 2 -OH.
  • Embodiment 1-18 The compound of any one of Embodiments I-l to 1-17, wherein R 3 can combine with R 2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH 2 , -NHR , heteroaryl, heterocyclyl, -(CH 2 ) n NH 2 , -(CH 2 ) n OH, -COOR , -CONHR ,
  • Embodiment 1-19 The compound of Embodiment 1-18, wherein the heterocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH 2 .
  • Embodiment 1-20 The compound of any one of Embodiments I-l to 1-17, wherein R 3 can combine with R 2 to form a 5-to 12-membered spiroheterocycle, wherein the
  • spiroheterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH 2 , -NHR , heteroaryl, heterocyclyl, -(CH 2 ) n NH 2 , -(CH 2 ) n OH, -COOR , -CONHR ,
  • Embodiment 1-21 The compound of Embodiment 1-20, wherein the spirocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH 2 .
  • Embodiment 1-22 A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
  • Embodiment 1-2 A pharmaceutical composition comprising a compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
  • Embodiment 1-24 A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
  • Embodiment 1-25 The method of Embodiment 1-24, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias,
  • neuroblastoma neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • Embodiment 1-26 A compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
  • Embodiment 1-27 A compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
  • Embodiment 1-28 Use of a compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • Embodiment 1-29. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of Embodiment I- 23.
  • Embodiment 1-30 The method of Embodiment 1-29, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • Embodiment 1-3 A pharmaceutical composition of Embodiment 1-23 for use as a medicament.
  • Embodiment 1-3 A pharmaceutical composition of Embodiment 1-23 for use in treating or preventing a disease associated with SHP2 modulation.
  • Embodiment 1-3 Use of a pharmaceutical composition of Embodiment 1-23 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • Embodiment II Some embodiments of this disclosure are Embodiment II, as follows:
  • Embodiment II- 1 A compound of the Formula I:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN; R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkeny
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment II-2 A compound of the Formula Ila:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment II-3 A compound of the Formula lib:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S-
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C 2 -C6alkynyl, -C 3 -C 8 cycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment II-4 A compound of the Formula III:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH 2 , halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • Embodiment II-5 The compound of any one of Embodiments II- 1 to II-4, wherein X 1 is N.
  • Embodiment II-6 The compound of any one of Embodiments II- 1 to II-4, wherein X 1 is CH.
  • Embodiment II-7 The compound of any one of Embodiments II- 1 to II-6, wherein X 2 is N.
  • Embodiment II-8 The compound of any one of Embodiments II- 1 to II-6, wherein X 2 is CH.
  • Embodiment II-9 The compound of any one of Embodiments II- 1 to II-8, wherein X 3 is N.
  • Embodiment 11-10 The compound of any one of Embodiments II- 1 to II- 8, wherein X 3 is CH.
  • Embodiment II- 11 The compound of any one of Embodiments II- 1 to 11-10, wherein A is monocyclic or poly cyclic aryl.
  • Embodiment 11-12 The compound of any one of Embodiments II- 1 to 11-10, wherein A is monocyclic or poly cyclic cycloalkyl.
  • Embodiment 11-13 The compound of any one of Embodiments II- 1 to 11-10, wherein A is monocyclic or polycyclic heterocycloalkyl.
  • Embodiment 11-14 The compound of any one of Embodiments II- 1 to 11-10, wherein A is monocyclic or polycyclic heteroaryl.
  • Embodiment 11-15 The compound of any one of Embodiments II- 1 to 11-14, wherein each R 1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR 5 R 6 .
  • Embodiment II- 16 The compound of claim 14, wherein R 5 and R 6 are H.
  • Embodiment 11-17 The compound of any one of Embodiments II- 1 to 11-16, wherein R 4 is an optionally substituted -Ci-C6alkyl.
  • Embodiment 11-18 The compound of any one of Embodiments II- 1 to 11-17, wherein R 4 is -CH 2 -OH [00237] Embodiment 11-19.
  • R 3 can combine with R 2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH,
  • Embodiment 11-20 The compound of Embodiment 11-19, wherein the heterocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH 2 .
  • Embodiment 11-21 The compound of any one of Embodiments II- 1 to 11-18, wherein R 3 can combine with R 2 to form a 5-to 12-membered spiroheterocycle, wherein the
  • Embodiment 11-22 The compound of Embodiment 11-21, wherein the spirocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH 2 .
  • Embodiment 11-23 A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
  • Embodiment 11-24 A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
  • Embodiment 11-25 A pharmaceutical composition comprising a compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
  • Embodiment 11-26 A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
  • Embodiment 11-27 The method of Embodiment 11-26, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias,
  • neuroblastoma neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • Embodiment 11-28 A compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
  • Embodiment 11-29 A compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
  • Embodiment 11-30 Use of a compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • Embodiment II-31 A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of Embodiment 11-25.
  • Embodiment 11-32 The method of Embodiment 11-31, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias,
  • neuroblastoma neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • Embodiment 11-33 A pharmaceutical composition of Embodiment 11-25 for use as a medicament.
  • Embodiment 11-34 A pharmaceutical composition of Embodiment 11-25 for use in treating or preventing a disease associated with SHP2 modulation.
  • Embodiment 11-35 Use of a pharmaceutical composition of Embodiment 11-25 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • Embodiment III As follows:
  • Embodiment III- 1. A compound of Formula IV:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment III-2 A compound of the Formula V:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12- membere
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN; R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl,
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment III-3 A compound of the Formula VI:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C 6 alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment III-4 A compound of the Formula I:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF 2 OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 ) favorOH, -C(0)NH(CH 2 ) worshipOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C 6 alkenyl, -Ci-Cscycloalkenyl, -C 2 -C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -N0 2 , and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C 6 alkenyl, -C4-C8cycloalkenyl, -C 2 -C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -N0 2 , or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C 6 alkenyl, -(CH 2 ) n -aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 ) n -aryl is optionally substituted with one or more -OH, halogen, -N0 2 , oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment III- 5 The compound of any one of Embodiment III- 1 to III-4, wherein X 1 is N.
  • Embodiment III-6 The compound of any one of of Embodiment III-l to III-4, wherein X 1 is CH.
  • Embodiment III-7 The compound of any one of of Embodiment III-l to III-6, wherein X 2 is N.
  • Embodiment III-8 The compound of any one of of Embodiment III-l to III-6, wherein X 2 is CH.
  • Embodiment III-9 The compound of any one of of Embodiment III-l to III-8, wherein X 3 is N.
  • Embodiment III- 10 The compound of any one of of Embodiment III-l to III- 8, wherein X 3 is CH.
  • Embodiment III- 1 1. The compound of any one of Embodiment III- 1 to III- 10, wherein A is monocyclic or polycyclic aryl.
  • Embodiment III- 12 The compound of any one of Embodiment III-l to III- 10, wherein A is monocyclic or polycyclic cycloalkyl.
  • Embodiment III-l 3. The compound of any one of Embodiment III-l to III- 10, wherein A is monocyclic or polycyclic heterocycloalkyl.
  • Embodiment III- 14 The compound of any one of Embodiment III-l to III- 10, wherein A is monocyclic or polycyclic heteroaryl.
  • Embodiment III-l 5. The compound of any one of Embodiment III-l to III- 14, wherein each R 1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR 5 R 6 .
  • Embodiment III- 16 The compound of Embodiment III- 14, wherein R 5 and R 6 are H.
  • Embodiment III- 17 The compound of any one of Embodiment III-l to III- 16, wherein R 4 is an optionally substituted -Ci-C6alkyl.
  • Embodiment III-l The compound of any one of Embodiment III-l to III- 17, wherein R 4 1S-CH2-OH.
  • Embodiment 111-20 The compound of Embodiment III- 19, wherein the heterocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH 2 .
  • Embodiment 111-21 The compound of any one of Embodiment III-l to III-l 8, wherein R 3 can combine with R 2 to form a 5-to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH 2 , -NHR , heteroaryl, heterocyclyl, -(CH 2 ) n NH 2 , -(CH 2 ) n OH, -COOR , -CONHR ,
  • Embodiment 111-22 The compound of Embodiment 111-21, wherein the spirocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH 2 .
  • Embodiment 111-2 The compound of any one of Embodiment III-l to III-l 8, wherein R 3 combine with R 2 to form a moiety selected from:
  • Embodiment 111-24 A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
  • Embodiment 111-25 A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
  • Embodiment 111-26 A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
  • Embodiment 111-27 A pharmaceutical composition comprising a compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
  • Embodiment 111-28 A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
  • Embodiment 111-29. The method of Embodiment 111-28, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • Embodiment 111-30. A compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
  • Embodiment III-31 A compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
  • Embodiment 111-3 Use of a compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • Embodiment 111-3 A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of Embodiment 111-27.
  • Embodiment 111-34 The method of Embodiment III-31 , wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
  • Embodiment 111-35 A pharmaceutical composition of Embodiment 111-27 for use as a medicament.
  • Embodiment 111-36 A pharmaceutical composition of Embodiment 111-27 for use in treating or preventing a disease associated with SHP2 modulation.
  • Embodiment 111-37 Use of a pharmaceutical composition of Embodiment 111-27 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
  • Embodiment IV As follows: [00293] Embodiment IV- 1. A compound of Formula IV:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12- membere
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, Cs-Cscycloalkyl, -(CH 2 )n-R , or -(CH 2 )nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH 2 )n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 ,
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment IV-2 A compound of the Formula V:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12- membere
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C 6 alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, Cs-Cscycloalkyl, -(CH 2 )n-R , or -(CH 2 )nC(0)NR 5 R 6 , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment IV-3 A compound of the Formula VI:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • X 1 , X 2 , or X 3 is N; Y 1 is -S- or a direct bond,
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , -NR 5 C(0)R 6 , or 3-to 12- member
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
  • R 4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -Ci-Cscycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 -C8cycloalkenyl, -C2-C 6 alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment IV-4 A compound of the Formula I:
  • X 1 is N or CH
  • X 2 is N or CH
  • X 3 is N or CH
  • Y 1 is -S- or a direct bond
  • A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
  • R 1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C 6 alkenyl, -C 4 - Cscycloalkenyl, -C2-C 6 alkynyl, -Cs-Cscycloalkyl, -OH, -OR 6 , halogen, -NO2, -CN, -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -NR 5 S(0) 2 R 6 , -S(0)NR 5 R 6 , -S(0)R 5 , -NR 5 S(0)NR 5 R 6 , -NR 5 S(0)R 6 , -C(0)R 5 , -CO2R 5 , -C(0)NR 5 R 6 , or -NR 5 C(0)R 6 , wherein each al
  • R 2 and R 3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH 2 )n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH 2 , -OR , -NHR , -(CH 2 )nOH, heterocyclyl, or spiroheterocyclyl; or
  • R 3 can combine with R 2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
  • R 4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR 5 , -NH-OR 5 , -0-NR 5 R 6 , -NHR 5 , -OR 5 , -NHC(0)R 5 , -NHC(0)NHR 5 , -NHS(0) 2 R 5 , -NHS(0) 2 NHR 5 , -S(0) 2 OH, -C(0)OR 5 , -NH(CH 2 )nOH, -C(0)NH(CH 2 )nOH,
  • R 5 and R 6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -Ci-Cscycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR 7 , -SR 7 , halogen, -NR 7 R 8 , -NO2, and -CN;
  • R 7 and R 8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C 2 -C6alkenyl, -C 4 -C8cycloalkenyl, -C 2 -C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH 2 , -NO2, or -CN;
  • R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C 2 -C6alkenyl, -(CH 2 )n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R 5 , -OR 5 , -NR 5 R 6 , -SR 5 , -S(0) 2 NR 5 R 6 , -S(0) 2 R 5 , -NR 5 S(0) 2 NR 5 R 6 , -NR 5 S(0) 2 R 6 , -
  • n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Embodiment IV-5 The compound of any one of Embodiments IV- 1 to IV-4, wherein X 1 is N.
  • Embodiment IV-6 The compound of any one of Embodiments IV- 1 to IV-4, wherein X 1 is CH.
  • Embodiment IV-7 The compound of any one of Embodiments IV- 1 to IV-6, wherein X 2 is N.
  • Embodiment IV-8 The compound of any one of Embodiments IV-1 to IV-6, wherein X 2 is CH.
  • Embodiment IV-9 The compound of any one of Embodiments IV-1 to IV-8, wherein X 3 is N.
  • Embodiment IV- 10 The compound of any one of Embodiments IV-1 to IV-8, wherein X 3 is CH.
  • Embodiment IV-11 The compound of any one of Embodiments IV-1 to IV- 10, wherein A is monocyclic or polycyclic aryl.
  • Embodiment IV- 12 The compound of any one of Embodiments IV-1 to IV- 10, wherein A is monocyclic or polycyclic cycloalkyl.
  • Embodiment IV-13 The compound of any one of Embodiments IV-1 to IV- 10, wherein A is monocyclic or polycyclic heterocycloalkyl.
  • Embodiment IV- 14 The compound of any one of Embodiments IV-1 to IV- 10, wherein A is monocyclic or polycyclic heteroaryl.
  • Embodiment IV-15 The compound of any one of Embodiments IV- 1 to IV- 14, wherein each R 1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR 5 R 6 .
  • Embodiment IV- 16 The compound of Embodiment IV- 15, wherein R 5 and R 6 are H.
  • Embodiment IV- 17 The compound of any one of Embodiments IV- 1 to IV- 16, wherein R 4 is an optionally substituted -Ci-C6alkyl.
  • Embodiment IV-18 The compound of any one of Embodiment IV-1 to IV- 17, wherein R 4 is-CH 2 -OH.
  • Embodiment IV- 19 The compound of any one of Embodiments IV-1 to IV- 17, wherein R 4 is -Ci-C6alkyl substituted with one or more halogen.
  • Embodiment IV-21 The compound of Embodiment IV-20, wherein the heterocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
  • Embodiment IV-22 The compound of any one of Embodiment IV-1 to IV- 19, wherein R 3 can combine with R 2 to form a 5-to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH 2 , -NHR , heteroaryl, heterocyclyl, -(CH 2 )nNH 2 , -(CH 2 )nOH, -COOR , -CONHR ,
  • Embodiment IV-23 The compound of Embodiment IV-22, wherein the spirocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
  • Embodiment IV-24 The compound of any one of Embodiment IV-1 to IV- 19, wherein R 3 combine with R 2 to form a moiety selected from: [00317] Embodiment IV-25.
  • Embodiment IV-26 A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
  • Embodiment IV-27 A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

Description

PYRIDINE, PYRAZINE, AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 62/571,760, filed October 12, 2017; U.S. Provisional Application No. 62/615,353, filed January 9, 2018; and U.S. Provisional Application No. 62/678,889, filed May 31, 2018; the contents of which are incorporated herein by reference in their entireties.
FIELD OF THE DISCLOSURE
[0002] The present disclosure relates to inhibitors of protein tyrosine phosphatase SHP2 useful in the treatment of diseases or disorders. Specifically, this disclosure is concerned with compounds and compositions inhibiting SHP2, methods of treating diseases associated with SHP2, and methods of synthesizing these compounds.
BACKGROUND OF THE DISCLOSURE
[0003] SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN77 gene that contributes to multiple cellular functions including proliferation, differentiation, cell cycle maintenance and migration. SHP2 is involved in signaling through the Ras-mitogen-activated protein kinase, the JAK-STAT or the phosphoinositol 3- kinase- AKT pathways.
[0004] SHP2 has two N-terminal Src homology 2 domains (N-SH2 and C-SH2), a catalytic domain (PTP), and a C-terminal tail. The two SH2 domains control the subcellular localization and functional regulation of SHP2. The molecule exists in an inactive, auto-inhibited conformation stabilized by a binding network involving residues from both the N-SH2 and PTP domains. Stimulation by, for example, cytokines or growth factors leads to exposure of the catalytic site resulting in enzymatic activation of SHP2.
[0005] Mutations in the the PTPN77 gene and subsequently in SHP2 have been identified in several human diseases, such as Noonan Syndrome, Leopard Syndrome, juvenile
myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. SHP2, therefore, represents a highly attractive target for the development of novel therapies for the treatment of various diseases. The compounds of the present disclosure fulfill the need for small molecules to that inhibit the activity of SHP2.
SUMMARY OF THE DISCLOSURE
[0006] The present disclosure relates to compounds capable of inhibiting the activity of SHP2. The disclosure further provides a process for the preparation of compounds disclosed herein, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
[0007] One aspect of the disclosure relates to compounds of Formula la:
Figure imgf000003_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is -H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, Cs-Cscycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0008] One aspect of the disclosure relates to compounds of Formula I:
Figure imgf000005_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0009] One aspect of the disclosure relates to compounds of Formula Ila:
Figure imgf000007_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is a direct bond;
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl; R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- Cealkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0010] One aspect of the disclosure relates to compounds of Formula lib:
Figure imgf000009_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S-;
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, Cs-Cscycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, -NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0011] One aspect of the disclosure relates to compounds of Formula III:
Figure imgf000011_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -Nth, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0012] One aspect of the disclosure relates to compounds of Formula IV:
Figure imgf000012_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein: X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
-NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -Nth, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0013] One aspect of the disclosure relates to compounds of Formula V:
Figure imgf000014_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein: X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo; R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0014] One aspect of the disclosure relates to compounds of Formula VI:
Figure imgf000016_0001
harmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond, A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -O-C(O)- NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0015] Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
[0016] Another aspect of the disclosure relates to methods of inhibiting SHP2. The method comprises administering to a patient in need thereof, an effective amount of one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
[0017] Another aspect of the disclosure is directed to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier can further comprise an excipient, diluent, or surfactant. The pharmaceutical composition can be effective for treating a disease associated with SHP2 modulation in a subject in need thereof.
[0018] Another aspect of the disclosure relates to methods of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof). [0019] Another aspect of the disclosure relates to methods of inhibiting SHP2 comprising administering to a patient in need thereof, an effective amount of a pharmaceutical composition comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof).
[0020] Another aspect of the disclosure relates to one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use in treating or preventing a disease associated with SHP2 modulation. One aspect of the disclosure relates to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier, for use in treating of preventing a disease associated with SHP2 modulation.
[0021] Another aspect of the disclosure relates to the use of one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and
pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation. Another aspect of the disclosure relates to the use of pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
[0022] Another aspect of the disclosure relates to one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament. Another aspect of the disclosure relates to pharmaceutical compositions comprising one or more compounds disclosed herein (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament. In some embodiments, the medicament is used for treating or preventing a disease associated with SHP2 modulation. [0023] The present disclosure also provides compounds and pharmaceutical compositions that are useful in inhibiting SHP2.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0024] In a first aspect, compounds of Formula la are described:
Figure imgf000020_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein A, Y1, R1, R2, R3, R4, X1, X2, X3, and n are described as above.
[0025] In a another aspect, compounds of Formula I are described:
Figure imgf000020_0002
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein A, Y1, R1, R2, R3, R4, X1, X2, X3, and n are described as above.
[0026] In another aspect, compounds of Formula Ila are described:
Figure imgf000020_0003
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein A, Y1, R1, R2, R3, R4, X1, X2, X3, and n are described as above.
[0027] In another aspect, compounds of Formula lib are described:
Figure imgf000021_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein A, Y1, R1, R2, R3, R4, X1, X2, X3, and n are described as above.
[0028] In another aspect, compounds of Formula III are described:
Figure imgf000021_0002
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein A, R1, R2, R3, R4, X1, X2, X3, and n are described as above.
[0029] In another aspect, compounds of Formula IV are described:
Figure imgf000021_0003
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein A, R1, R2, R3, R4, X1, X2, X3, and n are described as above.
[0030] In another aspect, compounds of Formula V are described:
Figure imgf000021_0004
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein A, R1, R2, R3, R4, X1, X2, X3, and n are described as above. [0031] In another aspect, compounds of Formula VI are described:
Figure imgf000022_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein A, R1, R2, R3, R4, X1, X2, X3, and n are described as above.
[0032] The details of the disclosure are set forth in the accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.
[0033] Each embodiment described herein may be taken alone or in combination with any one or more other embodiments.
Terms
[0034] The articles "a" and "an" are used in this disclosure to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0035] The term "and/or" is used in this disclosure to mean either "and" or "or" unless indicated otherwise.
[0036] By "optional" or "optionally," it is meant that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" encompasses both "aryl" and "substituted aryl" as defined herein. It will be understood by those ordinarily skilled in the art, with respect to any group containing one or more substituents, that such groups are not intended to introduce any substitution or substitution patterns that are sterically impractical, synthetically non-feasible, and/or inherently unstable.
[0037] The term "optionally substituted" is understood to mean that a given chemical moiety (e.g. an alkyl group) can (but is not required to) be bonded other substituents (e.g. heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (i.e. a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bonded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus the term "optionally substituted" means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any further functional groups.
[0038] The term "alkyl" refers to a straight or branched chain saturated hydrocarbon. Ci- C6alkyl groups contain 1 to 6 carbon atoms. Examples of a Ci-C6alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, sec-butyl and tert-butyl, isopentyl and neopentyl.
[0039] The term "alkenyl" means an aliphatic hydrocarbon group containing a carbon— carbon double bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkenyl groups have 2 to about 4 carbon atoms in the chain.
Branched means that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkenyl chain. Exemplary alkenyl groups include ethenyl, propenyl, n- butenyl, and z'-butenyl. A C2-C6 alkenyl group is an alkenyl group containing between 2 and 6 carbon atoms.
[0040] The term "alkynyl" means an aliphatic hydrocarbon group containing a carbon— carbon triple bond and which may be straight or branched having about 2 to about 6 carbon atoms in the chain. Certain alkynyl groups have 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl, or propyl are attached to a linear alkynyl chain. Exemplary alkynyl groups include ethynyl, propynyl, w-butynyl, 2-butynyl, 3-methylbutynyl, and w-pentynyl. A C2-C6 alkynyl group is an alkynyl group containing between 2 and 6 carbon atoms. [0041] The term "cycloalkyl" refers to a single saturated or partially unsaturated all carbon ring having 3 to 20 annular carbon atoms (i.e., C3-C20 cycloalkyl), for example from 3 to 12 annular atoms, for example from 3 to 10 annular atoms. The term "cycloalkyl" also includes multiple condensed, saturated and partially unsaturated all carbon ring systems (e.g., ring systems comprising 2, 3 or 4 carbocyclic rings). Accordingly, cycloalkyl includes multicyclic carbocycles such as a bicyclic carbocycles (e.g., bicyclic carbocycles having about 6 to 12 annular carbon atoms such as bicyclo[3.1.0]hexane and bicyclo[2.1.1]hexane), and poly cyclic carbocycles (e.g., tricyclic and tetracyclic carbocycles with up to about 20 annular carbon atoms). The rings of a multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. Non-limiting examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, 1- cyclopent-2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl and 1- cyclohex-3-enyl.
[0042] The term "cycloalkenyl" means monocyclic, non-aromatic unsaturated carbon rings containing 4-18 carbon atoms. Examples of cycloalkenyl groups include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and norborenyl. A C4-Cs
cycloalkenyl is a cycloalkenyl group containing between 4 and 8 carbon atoms.
[0043] The term "aryl" as used herein refers to a single all carbon aromatic ring or a multiple condensed all carbon ring system wherein at least one of the rings is aromatic. For example, in certain embodiments, an aryl group has 6 to 20 annular carbon atoms, 6 to 14 annular carbon atoms, or 6 to 12 annular carbon atoms. Aryl includes a phenyl radical. Aryl also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) having about 9 to 20 carbon atoms in which at least one ring is aromatic and wherein the other rings may be aromatic or not aromatic (i.e., carbocycle). Such multiple condensed ring systems are optionally substituted with one or more (e.g., 1, 2 or 3) oxo groups on any carbocycle portion of the multiple condensed ring system. The rings of the multiple condensed ring system can be connected to each other via fused, Spiro and bridged bonds when allowed by valency requirements. It is also to be understood that when reference is made to a certain atom-range membered aryl (e.g., 6-12 membered aryl), the atom range is for the total ring (annular) atoms of the aryl. For example, a 6-membered aryl would include phenyl and a 10-membered aryl would include naphthyl and 1, 2, 3, 4-tetrahydronaphthyl. Non-limiting examples of aryl groups include, but are not limited to, phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, anthracenyl, and the like
[0044] The aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, -H, halogen, -O-Ci-Cealkyl, -Ci-Cealkyl, -OC2-C6alkenyl, -OC2-C6alkynyl, -C2-C6alkenyl, -C2-C6alkynyl, -OH, -OP(0)(OH)2, -OC(0)Ci-C6alkyl, -C(0)Ci-C6alkyl, -OC(0)OCi- Cealkyl, -NH2, -NH(Ci-C6alkyl), -N(Ci-C6alkyl)2, -S(0)2-Ci-C6alkyl, -S(0)NHCi-C6alkyl, and -S(0)N(Ci-C6alkyl)2. The substituents can themselves be optionally substituted.
[0045] The term "heteroaryl" as used herein refers to a single aromatic ring that has at least one atom other than carbon in the ring, wherein the atom is selected from the group consisting of oxygen, nitrogen and sulfur; the term also includes multiple condensed ring systems that have at least one such aromatic ring, which multiple condensed ring systems are further described below. Thus, the term includes single aromatic rings of from about 1 to 6 annular carbon atoms and about 1-4 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the rings. The sulfur and nitrogen atoms may also be present in an oxidized form provided the ring is aromatic. Such rings include but are not limited to pyridyl, pyrimidinyl, oxazolyl or furyl. The term also includes multiple condensed ring systems (e.g., ring systems comprising 2, 3 or 4 rings) wherein a heteroaryl group, as defined above, can be condensed with one or more rings selected from heteroaryls (to form for example a naphthyridinyl such as 1,8-naphthyridinyl), heterocycloalkyls, (to form for example a 1,2,3,4-tetrahydronaphthyridinyl such as 1,2,3,4- tetrahydro- 1,8-naphthyridinyl), cycloalkyls (to form for example 5,6,7,8-tetrahydroquinolyl) and aryls (to form for example indazolyl) to form the multiple condensed ring system. Thus, a heteroaryl (a single aromatic ring or multiple condensed ring system) has about 1-20 annular carbon atoms and about 1-6 annular heteroatoms. Such multiple condensed ring systems may be optionally substituted with one or more (e.g., 1, 2, 3 or 4) oxo groups on the carbocycle or heterocycle portions of the condensed ring. The rings of the multiple condensed ring system can be connected to each other via fused, Spiro and bridged bonds when allowed by valency requirements. It is to be understood that the individual rings of the multiple condensed ring system may be connected in any order relative to one another. It is also to be understood that the point of attachment of a multiple condensed ring system (as defined above for a heteroaryl) can be at any position of the multiple condensed ring system including a heteroaryl, heterocycle, aryl or carbocycle portion of the multiple condensed ring system and at any suitable atom of the multiple condensed ring system including a carbon atom and heteroatom (e.g., a nitrogen).
Exemplary heteroaryls include but are not limited to pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrazolyl, thienyl, indolyl, imidazolyl, oxazolyl, thiazolyl, furyl, oxadiazolyl, thiadiazolyl, quinolyl, isoquinolyl, benzothiazolyl, benzoxazolyl, indazolyl, quinoxalyl, quinazolyl, 5,6,7,8-tetrahydroisoquinolinyl benzofuranyl, benzimidazolyl and thianaphthenyl.
[0046] The terms "heterocycloalkyl", "heterocycle", or "heterocyclyl" as used herein refers to a single saturated or partially unsaturated non-aromatic ring or a non-aromatic multiple ring system that has at least one heteroatom in the ring (at least one annular heteroatom selected from oxygen, nitrogen, and sulfur). Unless otherwise specified, a heterocycloalkyl group has from 3 to about 20 annular atoms, for example from 5 to 20 annular atoms, for example from 5 to 14 annular atoms, for example from 5 to 10 annular atoms, for example from 3 to 12 annular atoms. Thus, the term includes single saturated or partially unsaturated rings (e.g., 3, 4, 5, 6 or 7- membered rings) having from about 1 to 6 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The term also includes single saturated or partially unsaturated rings (e.g., 5, 6, 7, 8, 9, or 10- membered rings) having from about 4 to 9 annular carbon atoms and from about 1 to 3 annular heteroatoms selected from the group consisting of oxygen, nitrogen and sulfur in the ring. The rings of the multiple condensed ring system can be connected to each other via fused, spiro and bridged bonds when allowed by valency requirements. "Heterocyclyl" also includes radicals where heterocycle radicals are fused with a saturated, partially unsaturated ring, or aromatic carbocyclic or heterocyclic ring. Heterocycloalkyl groups include, but are not limited to, azetidine, aziridine, imidazolidine, imino-oxoimidazolidine, morpholine, oxirane (epoxide), oxetane, piperazine, piperidine, pyrazolidine, piperidine, pyrrolidine, pyrrolidinone,
tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, quinuclidine, N- bromopyrrolidine, N-chloropiperidine, and the like.
[0047] The terms "spirocycle" or "spirocyclic" means carbogenic bicyclic ring systems with both rings connected through a single atom. The ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another carbocyclic, heterocyclic, aromatic, or heteroaromatic ring. One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g., O, N, S, or P). A Cs- Ci2 spirocycle is a spirocycle containing between 5 and 12 carbon atoms. In some embodiments, a C5-C12 spirocycle is a spirocycle containing from 5 to 12 carbon atoms. One or more of the carbon atoms can be substituted with a heteroatom.
[0048] The term "spirocyclic heterocycle," "spiroheterocyclyl," or "spiroheterocycle" is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl). A spirocyclic heterocycle can contain between 5 and 12 atoms, at least one of which is a heteroatom selected from N, O, S and P. In some embodiments, a spirocyclic heterocycle can contain from 5 to 12 atoms, at least one of which is a heteroatom selected from N, O, S and P.
[0049] The term "halo" or "halogen" means a fluoro, chloro, bromo, or iodo group.
[0050] The term "carbonyl" refers to a functional group comprising a carbon atom double- bonded to an oxygen atom. It can be abbreviated herein as "oxo," as C(O), or as C=0.
[0051] The disclosure also includes pharmaceutical compositions comprising an effective amount of one or more disclosed compounds and a pharmaceutically acceptable carrier. As used herein "pharmaceutically acceptable carrier, diluent or excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surfactant, or emulsifier that has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
[0052] The disclosure includes pharmaceutically acceptable salts of the compounds described herein. Representative "pharmaceutically acceptable salts" include, but are not limited to, e.g., water-soluble and water- insoluble salts, such as the acetate, amsonate (4,4- diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, sethionate, lactate, lactobionate, laurate, magnesium, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, 3-hydroxy-2- naphthoate, oleate, oxalate, palmitate, pamoate (l,l-methene-bis-2-hydroxy-3-naphthoate, einbonate), pantothenate, phosphate/diphosphate, picrate, polygalacturonate, propionate, p- toluenesulfonate, salicylate, stearate, subacetate, succinate, sulfate, subsalicylate, suramate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate salts.
[0053] "Pharmaceutically acceptable salt" also includes both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise
undesirable, and which are formed with inorganic acids such as, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor- 10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1 ,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2- oxo-glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-l,5-disulfonic acid, naphthalene-2-sulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like.
[0054] "Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. For example, inorganic salts include, but are not limited to, ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
[0055] The term "tautomers" refers to a set of compounds that have the same number and type of atoms, but differ in bond connectivity and are in equilibrium with one another. A "tautomer" is a single member of this set of compounds. Typically a single tautomer is drawn but it is understood that this single structure is meant to represent all possible tautomers that might exist. Examples include enol-ketone tautomerism. When a ketone is drawn it is understood that both the enol and ketone forms are part of the disclosure.
[0056] The disclosure includes prodrugs of the compounds described herein. The term "prodrug," as used in this disclosure, means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound. Furthermore, as used herein a prodrug is a drug which is inactive in the body, but is transformed in the body typically either during absorption or after absorption from the gastrointestinal tract into the active compound. The conversion of the prodrug into the active compound in the body may be done chemically or biologically (i.e., using an enzyme).
[0057] The disclosure includes solvates of the compounds described herein. The term "solvate" refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the disclosure may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.
[0058] The disclosure includes isomers of the compounds described herein. The term "isomer" refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of the present disclosure may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.
[0059] The term "stereoisomers" refers to the set of compounds which have the same number and type of atoms and share the same bond connectivity between those atoms, but differ in three dimensional structure. The term "stereoisomer" refers to any member of this set of compounds. For instance, a stereoisomer may be an enantiomer or a diastereomer. The disclosure includes stereoisomers of the compounds described herein.
[0060] In addition, the present disclosure embraces all geometric and positional isomers. For example, if a compound of the present disclosure incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure. If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis or trans configuration.
[0061] The term "enantiomers" refers to a pair of stereoisomers which are non- superimposable mirror images of one another. The term "enantiomer" refers to a single member of this pair of stereoisomers. The term "racemic" refers to a 1 : 1 mixture of a pair of
enantiomers. The disclosure includes enantiomers of the compounds described herein. Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound. The compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry. In some embodiments the compounds are the (5)-enantiomer. In other embodiments the compounds are the (i?)-enantiomer. In yet other embodiments, the compounds are the (+) or (-) enantiomers
[0062] In some embodiments, compounds and compositions of the disclosure may be enriched to provide predominantly one enantiomer of a compound described herein. An enantiomerically enriched mixture may comprise, for example, at least 60 mol percent of one enantiomer, or more preferably at least 75, 80, 85, 90, 95, 96, 97, 98, 99, 99.5 or even 100 mol percent. In some embodiments, the compound described herein enriched in one enantiomer is substantially free of the other enantiomer, wherein substantially free means that the substance in question makes up less than 10%, or less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1% as compared to the amount of the other enantiomer, e.g., in the composition or compound mixture. For example, if a composition or compound mixture contains 98 grams of a first enantiomer and 2 grams of a second enantiomer, it would be said to contain 98 mol percent of the first enantiomer and only 2 mol percent of the second enantiomer.
[0063] The term "diastereomers" refers to the set of stereoisomers which cannot be made superimposable by rotation around single bonds. For example, cis- and trans- double bonds, endo- and exo- substitution on bicyclic ring systems, and compounds containing multiple stereogenic centers with different relative configurations are considered to be diastereomers. The term "diastereomer" refers to any member of this set of compounds. In some examples presented, the synthetic route may produce a single diastereomer or a mixture of diastereomers. The disclosure includes diastereomers of the compounds described herein.
[0064] In some embodiments, the compounds and compositions of the disclosure may be enriched to provide predominantly one diastereomer of a compound disclosed herein. A diastereomerically enriched mixture may comprise, for example, at least 60 mol percent of one diastereomer, or more preferably at least 75, 85, 95, 96, 97, 98, 99, or even 100 mol percent.
[0065] The compounds described herein further include all pharmaceutically acceptable isotopically labeled compounds. An "isotopically" or "radio-labeled" compound is a compound where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). For example, in some embodiments, in the compounds described herein hydrogen atoms are replaced or substituted by one or more deuterium or tritium. Certain isotopically labeled compounds of this disclosure, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e., 3H, and carbon 14, i.e., 14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. Substitution with heavier isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. Suitable isotopes that may be incorporated in compounds described herein include but are not limited to 2H (also written as D for deuterium), 3H (also written as T for tritium), nC, 13C, 14C, 13N, 15N, 150, 170, 180, 18F, 35S, 36C1 , 82Br, 75Br, 76Br, 77Br, 123I, 124I, 125I, and 131I. Substitution with positron emitting isotopes, such as nC, 18F, 150, and 13N, can be useful in Positron Emission Topography (PET) studies.
[0066] An "effective amount" when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.
[0067] The term "carrier," as used in this disclosure, encompasses excipients and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
[0068] The term "treating" with regard to a subject, refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.
[0069] The term "prevent" or "preventing" with regard to a subject refers to keeping a disease or disorder from afflicting the subject. Preventing includes prophylactic treatment. For instance, preventing can include administering to the subject one or more compounds disclosed herein before a subject is afflicted with a disease and the administration will keep the subject from being afflicted with the disease.
[0070] The term "disorder" is used in this disclosure to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
[0071] The term "administer," "administering," or "administration" as used in this disclosure refers to either directly administering one or more disclosed compounds or a pharmaceutically acceptable salt of one or more disclosed compounds or a composition comprising one or more disclosed compounds to a subject, or administering a prodrug derivative or analog of the compound or a pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.
[0072] A "patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
Compounds of the Disclosure
[0073] The present disclosure provides compounds of Formula la:
Figure imgf000033_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is -H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0074] The present disclosure provides compounds of Formula I,
Figure imgf000035_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0075] The present disclosure provides compounds of Formula Ila,
Figure imgf000037_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is a direct bond;
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0076] The present disclosure provides compounds of Formula lib,
Figure imgf000039_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S-;
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0077] The present disclosure provides compounds of Formula IV:
Figure imgf000041_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, Cs-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
-NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0078] As described above for Formula la, I, and IV, Y1 is -S- or a direct bond. In certain embodiments, Y1 is -S-. In certain embodiments, Y1 is a direct bond. [0079] As described above, X1 is N or CH. In certain embodiments, X1 is N. In certain embodiments, X1 is CH.
[0080] As described above, X2 is N or CH. In certain embodiments, X2 is N. In certain embodiments, X2 is CH.
[0081] As described above, X3 is N or CH. In certain embodiments, X3 is N. In certain embodiments, X3 is CH.
[0082] As described above, at least one of X1, X2, or X3 is N. In certain embodiments, X1 is N. In certain embodiments, X2 is N. In certain embodiments, X3 is N. In certain embodiments, X1 is N and X2 is N. In certain embodiments, X1 is N and X3 is N. In certain embodiments, X2 is N and X3 is N. In certain embodiments, X1 is N; X2 is N; and X3 is N.
[0083] As described above, A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, monocyclic or poly cyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl.
[0084] In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic cycloalkyl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic heterocycloalkyl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic aryl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic heteroaryl.
[0085] In certain embodiments, A is a monocyclic heteroaryl. In certain embodiments, A is a monocyclic aryl. In certain embodiments, A is a polycyclic heteroaryl. In certain embodiments, A is a polycyclic heterocycloalkyl.
[0086] In certain embodiments, A is selected from:
Figure imgf000043_0001
[0087] In certain embodiments, A is selected from:
Figure imgf000044_0001
[0088] As described above for formula I, Ila, and lib, R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-Cscycloalkenyl, -C2-C6alkynyl, -C3- Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6,
-S(0)NR5R6, -S(0)R5,-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl.
[0089] In certain embodiments, each R1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR5R6. In certain embodiments, R5 and R6 are H.
[0090] As described above for formula la and IV, R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12-membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl. In certain embodiments, each R1 is an optionally substituted 3-to 12-membered monocyclic or polycyclic heterocycle. In certain embodiments, each R1 is 3-to 12-membered monocyclic or polycyclic heterocycle substituted with heterocycle or -S(0)2R5. In certain embodiments, each R1 is selected from the group consisting of halogen, -Ci-Cealkyl, - OR6, -CN, -C(0)NR5R6, and -NR5R6. In certain embodiments, R5 and R6 are H. [0091] As described above, n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0092] As described above, R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-Cscycloalkenyl, -C2- C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN. In certain embodiments, R5 and R6 are H.
[0093] In certain embodiments, A (shown with R1) are selected from:
Figure imgf000045_0001
[0094] As described above for formula la, I, Ila, and lib, R4 is-Η, -D, -Ci-Cealkyl, -Ci- Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, - NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH, -C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, Cs-Cscycloalkyl, aryl, heterocyclyl containing 1-5
heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen.
[0095] In certain embodiments, R4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo. In certain embodiments, R4 is an optionally substituted -Ci-C6alkyl. In certain embodiments, R4 is -Ci-C6alkyl substituted with -OH. In certain embodiments, R4 1S-CH2-OH. In certain embodiments, R4 is -Ci-C6alkyl substituted with one or more halogen. In certain embodiments, R4 is -Ci-C6alkyl substituted with one or more fluoro. In certain embodiments, R4 is -CHF2.
[0096] As described above for formula IV, R4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci- Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5,
-NH(CH2)nOH, -C(0)NH(CH2)nOH, -C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-Cscycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen. In certain embodiments, R4 is an optionally substituted -Ci-C6alkyl. In certain embodiments, R4 is -Ci-C6alkyl substituted with -OH. In certain embodiments, R4 1S-CH2-OH. In certain embodiments, R4 is -Ci-C6alkyl substituted with one or more halogen. In certain embodiments, R4 is -Ci-C6alkyl substituted with one or more fluoro. In certain embodiments, R4 is -CHF2.
[0097] As described above, R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci-C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl. In certain embodiments, R2 or R3 is
-(CH2)nC(0)NR5R6.
[0098] As described above, R3 can combine with R2 to form a 3- to 12-membered
monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0. In certain embodiments, R3 can combine with R2 to form an optionally substituted heteroaryl or an optionally substituted heterocyclyl, wherein wherein the heteroaryl and heterocyclyl are optionally substituted with -CN.
[0099] In certain embodiments, R3 can combine with R2 to form a 3-to 12-membered optionally substituted monocyclic heterocycle. In certain embodiments, R3 can combine with R2 to form a 3-to 12-membered optionally substituted polycyclic heterocycle. In certain
embodiments, R3 can combine with R2 to form a 5-to 12-membered optionally substituted spiroheterocycle. [00100] In certain embodiments, R3 can combine with R2 to form 3-to 12-membered monocyclic or poly cyclic heterocycle, wherein the heterocycle is optionally substituted with more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2,
-(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00101] In certain embodiments, R3 can combine with R2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with -Ci- Cealkyl, -OR , or -NH2.
[00102] In certain embodiments, R3 can combine with R2 to form a 5 -to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)„COOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00103] In certain embodiments, R3 can combine with R2 to form 5-to 12-membered spiroheterocycle, wherein the spirocycle is optionally substituted with -Ci-C6alkyl, -OR , or
NH2.
[00104] In certain embodiments, R3 can combine with R2 to form a moiety selected from:
Figure imgf000047_0001
[00105] In certain embodiments, R3 can combine with R2 to form a moiety selected from:
Figure imgf000047_0002
[00106] The present disclosure provides compounds of Formula III,
Figure imgf000047_0003
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00107] The present disclosure provides compounds of Formula V:
Figure imgf000049_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl; R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
[00108] The present disclosure provides compounds of Formula VI:
Figure imgf000051_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -O-C(O)- NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00109] As described above in Formula III, V, and VI, X1 is N or CH. In certain
embodiments, X1 is N. In certain embodiments, X1 is CH. [00110] As described above in Formula III, V, and VI, X2 is N or CH. In certain embodiments, X2 is N. In certain embodiments, X2 is CH.
[00111] As described above in Formula III, V, and VI, X3 is N or CH. In certain
embodiments, X3 is N. In certain embodiments, X3 is CH.
[00112] As described above in Formula III, V, and VI, at least one of X1, X2, or X3 is N. In certain embodiments, X1 is N. In certain embodiments, X2 is N. In certain embodiments, X3 is N. In certain embodiments, X1 is N and X2 is N. In certain embodiments, X1 is N and X3 is N. In certain embodiments, X2 is N and X3 is N. In certain embodiments, X1 is N; X2 is N; and X3 is N.
[00113] As described above in Formula III, V, and VI, A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or poly cyclic
heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or poly cyclic heteroaryl.
[00114] In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic cycloalkyl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic heterocycloalkyl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic aryl. In certain embodiments, A is 5- to 12-membered monocyclic or polycyclic heteroaryl.
[00115] In certain embodiments, A is a monocyclic heteroaryl. In certain embodiments, A is a monocyclic aryl. In certain embodiments, A is a polycyclic heteroaryl. In certain embodiments, A is a polycyclic heterocycloalkyl.
[00116] In certain embodiments, A is selected from:
Figure imgf000053_0001
, and H
[00117] In certain embodiments, A is selected from:
Figure imgf000054_0001
[00118] As described above in Formula III, R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl.
[00119] In certain embodiments, each R1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR5R6. In certain embodiments, R5 and R6 are H.
[00120] As described above in Formula V and VI, R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12-membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl. In certain embodiments, each R1 is an optionally substituted 3-to 12-membered monocyclic or polycyclic heterocycle. In certain embodiments, each R1 is 3-to 12-membered monocyclic or polycyclic heterocycle substituted with heterocycle or -S(0)2R5. In certain embodiments, each R1 is selected from the group consisting of halogen, -Ci-Cealkyl, - OR6, -CN, -C(0)NR5R6, and -NR5R6. In certain embodiments, R5 and R6 are H. [00121] As described above in Formula III, V, and VI, n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00122] As described above in Formula III, V, and VI, R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN. In certain embodiments, R5 and R6 are H.
[00123] In certain embodiments, A (shown with R1) are selected from:
Figure imgf000055_0001
[00124] As described above in Formula III, R4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo. In certain embodiments, R4 is an optionally substituted -Ci-C6alkyl. In certain embodiments, R4 is -Ci-C6alkyl substituted with -OH. In certain embodiments, R4 1S-CH2-OH. In certain embodiments, R4 is -Ci-C6alkyl substituted with one or more halogen. In certain embodiments, R4 is -Ci-C6alkyl substituted with one or more fluoro. In certain embodiments, R4 is -CHF2.
[00125] As described above in Formula V and VI, R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo. In certain embodiments, R4 is -Ci-C6alkyl substituted with -OH. In certain embodiments, R4 1S-CH2-OH. In certain embodiments, R4 is -Ci-C6alkyl substituted with one or more halogen. In certain embodiments, R4 is -Ci-C6alkyl substituted with one or more fluoro. In certain embodiments, R4 is -CHF2.
[00126] As described above in Formula III and V, R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci-C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl. In certain
embodiments, R2 or R3 can be -(CH2)nC(0)NR5R6. [00127] As described above in Formula III, V, and VI, R3 can combine with R2 to form a 3- to 12-membered monocyclic or poly cyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci- Cealkyl, halogen, -OH, -OR , -Nth, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)„COOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0. In certain embodiments, R3 can combine with R2 to form an optionally substituted heteroaryl or an optionally substituted heterocyclyl, wherein wherein the heteroaryl and heterocyclyl are optionally substituted with -CN.
[00128] In certain embodiments, R3 can combine with R2 to form a 3 -to 12-membered optionally substituted monocyclic heterocycle. In certain embodiments, R3 can combine with R2 to form a 3-to 12-membered optionally substituted polycyclic heterocycle. In certain
embodiments, R3 can combine with R2 to form a 5-to 12-membered optionally substituted spiroheterocycle.
[00129] In certain embodiments, R3 can combine with R2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)„OH, -COOR , -CONHR , -CONH(CH2)„COOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00130] In certain embodiments, R3 can combine with R2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with -Ci- Cealkyl, -OR , or -NH2.
[00131] In certain embodiments, R3 can combine with R2 to form a 5-to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00132] In certain embodiments, R3 can combine with R2 to form 5-to 12-membered spiroheterocycle, wherein the spirocycle is optionally substituted with -Ci-C6alkyl, -OR , or -NH2.
[00133] In certain embodiments, R3 can combine with R2 to form a moiety selected from:
Figure imgf000057_0001
[00134] In certain embodiments, R3 can combine with R2 to form a moiety selected from:
Figure imgf000057_0002
[00135] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I having one, two, three, four, or more of the following features:
a) X1 is CH; and X2 and X3 are N;
b) A is monocyclic or polycyclic optionally substituted heteroaryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
e) R4 is -CH2-OH.
[00136] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and X2 and X3 are N;
b) A is monocyclic or polycyclic optionally substituted heteroaryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
e) R4 is -CH2-OH.
[00137] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and X2 and X3 are N;
b) A is monocyclic or polycyclic optionally substituted aryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and e) R4 is -CH2-OH.
[00138] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and X2 and X3 are N;
b) A is monocyclic or polycyclic optionally substituted aryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
e) R4 is -CH2-OH.
[00139] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and X2 and X3 are N;
b) A is monocyclic or polycyclic optionally substituted heteroaryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
e) R4 is -Ci-C6alkyl substituted with one or more halogen.
[00140] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and X2 and X3 are N;
b) A is monocyclic or polycyclic optionally substituted heteroaryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
e) R4 is -Ci-C6alkyl substituted with one or more halogen.
[00141] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and X2 and X3 are N;
b) A is monocyclic or polycyclic optionally substituted aryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
e) R4 is -Ci-C6alkyl substituted with one or more halogen.
[00142] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and X2 and X3 are N;
b) A is monocyclic or polycyclic optionally substituted aryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
e) R4 is -Ci-C6alkyl substituted with one or more halogen.
[00143] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I having one, two, three, four, or more of the following features:
a) X1 is CH; and one of X2 and X3 is N;
b) A is monocyclic or polycyclic optionally substituted heteroaryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
e) R4 is -CH2-OH or a -Ci-C6alkyl substituted with one or more halogen.
[00144] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and one of X2 and X3 is N;
b) A is monocyclic or polycyclic optionally substituted heteroaryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
e) R4 is -CH2-OH or a -Ci-C6alkyl substituted with one or more halogen.
[00145] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and I, having one, two, three, four, or more of the following features:
a) X1 is CH; and one of X2 and X3 is N; b) A is monocyclic or polycyclic optionally substituted aryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a 5 -to 12-membered optionally substituted spiroheterocycle; and
e) R4 is -CH2-OH or a -Ci-C6alkyl substituted with one or more halogen.
[00146] The present disclosure provides a compound of Formula la, I, Ila, lib, III, IV, V, and VI, having one, two, three, four, or more of the following features:
a) X1 is CH; and one of X2 and X3 is N;
b) A is monocyclic or polycyclic optionally substituted aryl;
c) R1 is independently, at each occurrence, -H,-Ci-C6alkyl, halogen, or -NH2; d) R3 can combine with R2 to form a form 3 -to 12-membered monocyclic or polycyclic optionally substituted heterocycle; and
e) R4 is -CH2-OH or a -Ci-C6alkyl substituted with one or more halogen. [00147] The present disclosure provides a compound selected from:
Figure imgf000060_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[00148] The present disclosure provides a compound selected from:
Figure imgf000061_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof.
[00149] The present disclosure provides a compound selected from:
Figure imgf000061_0002
Figure imgf000062_0001
Figure imgf000063_0001
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof.
[00150] The present disclosure provides a compound selected from
Figure imgf000063_0002
and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, and isomers thereof. Methods of Synthesizing the Disclosed Compounds
[00151] The compounds of the present disclosure may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the schemes given below.
[00152] The compounds of any of the formulae described herein may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes and examples. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of Formula I.
[00153] Those skilled in the art will recognize if a stereocenter exists in any of the compounds of the present disclosure. Accordingly, the present disclosure includes both possible
stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, "Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley- lnterscience, 1994).
Preparation of Compounds
[00154] The compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
[00155] The compounds of the present disclosure can be prepared in a number of ways well known to those skilled in the art of organic synthesis. By way of example, compounds of the disclosure can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. These methods include but are not limited to those methods described below.
Scheme 1. General synthesis of (3-amino-6-phenylpyrazin-2-yl)methanol
Figure imgf000065_0001
[00156] A general synthesis of (3-amino-6-phenylpyrazin-2-yl)methanol is outlined in Scheme 1. 3-Chloro-6-phenylpyrazine-2-ethylcarboxylate can be coupled to a substituted aryl- or heteroaryl boronic acid in the presence of a palladium catalyst (e.g., Pd(dppf)Ci2). The resulting biaryl intermediate can then be coupled to a substituted primary or secondary amine under SNAr conditions, followed by reduction to give a (3-amino-6-phenylpyrazin-2- yl)methanol. Additional deprotection and/or functionalization steps can be required to produce the final compound.
A general synthesis of (3-(amino)-6-(phenylthio)pyrazin-2-yl)methanol is outlined in Scheme 2. Scheme 2. General synthesis of (3-(amino)-6-(phenylthio)pyrazin-2-yl)methanol
Figure imgf000065_0002
[00157] 3-Chloro-6-phenylpyrazine-2-carboxylate can be coupled to a primary or secondary amines under SNAr conditions. The resulting aminopyrazine ester can then be reduced to produce amino pyrazin-2-yl-methanol, following coupling to an appropriately substituted potassium (or sodium) salt of arylthiol or heteroarylthiol. Additional deprotection and/or functionalization steps can be required to produce the final compound.
Methods of Using the Disclosed Compounds and Compositions
Methods and Uses of the Disclosure
[00158] Another aspect of the disclosure relates to a method of treating a disease associated with SHP2 modulation in a subject in need thereof. The method involves administering to a patient in need of treatment for diseases or disorders associated with SHP2 modulation an effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or of one or more pharmaceutical
compositions of the present disclosure. In some embodiments, the disease can be, but is not limited to Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R). SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer. Knock-down of SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers. SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
[00159] In addition, SHP2 plays a role in transducing signals originating from immune checkpoint molecules, including but not limited to programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). In this context, modulation of SHP2 function can lead to immune activation, specifically anti-cancer immune responses.
[00160] Another aspect of the disclosure is directed to a method of inhibiting SHP2. The method involves administering to a patient in need thereof an effective amount of one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or of one or more pharmaceutical compositions of the present disclosure.
[00161] The present disclosure relates to compounds or compositions disclosed herein that are capable of modulating the activity of (e.g., inhibiting) SHP2. The present disclosure also relates to the therapeutic use of such compounds and compositions.
[00162] One or more disclosed compounds or compositions can be administered in effective amounts to treat or prevent a disorder and/or prevent the development thereof in subjects. In some embodiments, SHP2 is inhibited after treatment with less than 1000 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with about 10 nM to about 100 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with 10 nM to 100 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with less than 10 nM of a compound of the disclosure.
[00163] Another aspect of the present disclosure relates to one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and
pharmaceutically acceptable salts, co-crystals, prodrugs, solvates, hydrates, tautomers, or isomers thereof), or one or more compositions of the present disclosure for use in treating or preventing a disease associated with SHP2 modulation. In some embodiments, the disease is Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. SHP2 is an important downstream signaling molecule for a variety of receptor tyrosine kinases, including the receptors of platelet-derived growth factor (PDGF-R), fibroblast growth factor (FGF-R) and epidermal growth factor (EGF-R). SHP2 is also an important downstream signaling molecule for the activation of the mitogen activated protein (MAP) kinase pathway which can lead to cell transformation, a prerequisite for the development of cancer. Knock-down of SHP2 significantly inhibited cell growth of lung cancer cell lines with SHP2 mutation or EML4/ALK translocations as well as EGFR amplified breast cancers and esophageal cancers. SHP2 is also activated downstream of oncogenes in gastric carcinoma, anaplastic large-cell lymphoma and
glioblastoma.
[00164] In another aspect, the present disclosure relates to the use of one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, co-crystals, prodrugs, solvates, hydrates, tautomers, or isomers thereof), in the manufacture of a medicament for treating or preventing a disease. In some embodiments, the disease is associated with SHP2 modulation.
[00165] In another aspect, the present disclosure relates to one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and
pharmaceutically acceptable salts, co-crystals, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament. In some embodiments, the medicament is used for treating or preventing a disease associated with SHP2 modulation. [00166] In one aspect, the present disclosure relates to one or more compositions comprising one or more compounds of the present disclosure (e.g., compounds of Formula la, I, Ila, lib, III, IV, V, or VI, and pharmaceutically acceptable salts, prodrugs, solvates, hydrates, tautomers, or isomers thereof), for use as a medicament. In some embodiments, the medicament is used for treating or preventing a disease associated with SHP2 modulation.
Pharmaceutical Compositions and Modes of Administration of the Disclosure
[00167] Another aspect of the present disclosure relates to pharmaceutical compositions comprising one or more compounds of the present disclosure and a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers can further include excipients such as diluent, surfactant, lipid, solvent. In certain embodiments, there are one or more pharmaceutically acceptable carriers or excipients in a pharmaceutical composition.
[00168] Compositions can be prepared according to conventional preparation methods of the dosage forms that are applicable for different route of adminstration, respectively. The present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume.
[00169] Administration of the disclosed compounds and pharmaceutical compositions can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, intravenous, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
[00170] Depending on the intended mode of administration, the disclosed compounds or pharmaceutical compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, capsules, tablets, pellets, suppositories, pills, modified-release dosage forms, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, patches, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular, transdermal form, and all using forms well known to those skilled in the pharmaceutical arts.
[00171] Illustrative pharmaceutical compositions are liquid and solid dosage forms, such as tablets and capsules, comprising one or more compounds of the present disclosure and a pharmaceutically acceptable carrier, such as, but not limited to, a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, corn oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also; c) a binder, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, magnesium carbonate, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, waxes and/or polyvinylpyrrolidone, if desired; d) a disintegrant, e.g., starches, agar, methyl cellulose, bentonite, xanthan gum, alginic acid or its sodium salt, or effervescent mixtures; e) absorbent, colorant, flavorant and sweetener; f) an emulsifier or dispersing agent, such as Tween 80, Labrasol, HPMC, DOSS, caproyl 909, labrafac, labrafil, peceol, transcutol, capmul MCM, capmul PG-12, captex 355, gelucire, vitamin E TGPS or other acceptable emulsifier; and/or g) an agent that enhances absorption of the compound such as cyclodextrin, hydroxypropyl-cyclodextrin, PEG400, PEG200. In certain embodiments, pharmaceutical compositions comprise HPMC. In certain embodiments, pharmaceutical compositions comprise vegetarian (Vegi) type of capsules.
[00172] Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, lyophilization etc. For example, one or more disclosed compounds are dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, buffer, glycerol, ethanol, cyclodextrin, cremophor EL and the like, to thereby form an injectable isotonic solution or suspension or lyophilized cake for re-constitution. Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
[00173] One or more disclosed compounds or compositions can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier. [00174] One or more disclosed compounds or compositions can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines. In some embodiments, a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described for instance in U.S. Pat. No. 5,262,564, the contents of which are hereby incorporated by reference.
[00175] One or more disclosed compounds or compositions can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled. The disclosed compounds can also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy
propylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxide polylysine substituted with palmitoyl residues. Furthermore, the one or more disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels. In some embodiments, one or more disclosed compounds are not covalently bound to a polymer, e.g., a polycarboxylic acid polymer, or a polyacrylate.
[00176] One or more disclosed compounds or compositions can be delivered by parental administration. Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Injectables can be prepared in
conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving or dispersing in liquid prior to injection.
Dosage Regimens of the Disclosure
[00177] The dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed. A physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
[00178] Effective dosage amounts of the disclosed compounds, when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses. In some embodiments, the compositions are in the form of a tablet that can be scored.
[00179] If desired, the effective daily dose of one or more compounds or compositions of this disclosure may be administered as one, two, three, four, five, six, or more sub-doses
administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In some embodiments of this disclosure, the one or more compounds or compositions of this disclosure, or mixtures thereof, may be administered two or three times daily. In some embodiments, the one or more compounds or compositions of this disclosure will be
administered once daily.
[00180] In some embodiments, one or more compounds or compositions described herein may be used alone or together or conjointly administered, or used in combination, with another type of therapeutic agent. Conjoint administration or used in combination refers to any form of administration of two or more different therapeutic compounds or compositions such that the second compound or composition is administered while the previously administered therapeutic compound or composition is still effective in the body. For example, the different therapeutic compounds or compositions can be administered either in the same formulation or in a separate formulation, either simultaneously, sequentially, or by separate dosing of the individual components of the treatment. In some embodiments, the different therapeutic compounds or compositions can be administered within one hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or a week of one another. Thus, an individual who receives such treatment can benefit from a combined effect of different therapeutic compounds or compositions.
Kits
[00181] In some embodiments, this disclosure also provides a pharmaceutical package or kit comprising one or more containers filled with at least one compound or composition of this disclosure. Optionally associated with such a container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects (a) approval by the agency of manufacture, use or sale for human administration, (b) directions for use, or both. In some embodiments, the kit comprises at least two containers, at least one of which contains at least one compound or composition of this disclosure. In some embodiments, the kit contains at least two containers, and each of the at least two containers contains at least one compound or composition of this disclosure.
[00182] In some embodiments, the kit includes additional materials to facilitate delivery of the subject compounds and compositions. For example, the kit may include one or more of a catheter, tubing, infusion bag, syringe, and the like. In some embodiments, the compounds and compositions are packaged in a lyophilized form, and the kit includes at least two containers: a container comprising the lyophilized compounds or compositions and a container comprising a suitable amount of water, buffer, or other liquid suitable for reconstituting the lyophilized material.
[00183] The foregoing applies to any of the compounds, compositions, methods, and uses described herein. This disclosure specifically contemplates any combination of the features of such compounds, compositions, methods, and uses (alone or in combination) with the features described for the various kits described in this section.
Exemplary Embodiments
[00184] Some embodiments of this disclosure are Embodiment I, as follows:
[00185] Embodiment 1-1. A compound of the Formula I:
Figure imgf000072_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH; X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 is-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00186] Embodiment 1-2. A compound of the Formula II:
Figure imgf000074_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N; Y1 is a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 is-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen; R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00187] Embodiment 1-3. A compound of the Formula III:
Figure imgf000076_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer,
thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N; A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00188] Embodiment 1-4. The compound of any one of Embodiments 1-1 to 1-3, wherein X1 is N.
[00189] Embodiment 1-5. The compound of any one of Embodiments 1-1 to 1-3, wherein X1 is CH.
[00190] Embodiment 1-6. The compound of any one of Embodiments 1-1 to 1-5, wherein X2 is N.
[00191] Embodiment 1-7. The compound of any one of Embodiments 1-1 to 1-5, wherein X2 is CH.
[00192] Embodiment 1-8. The compound of any one of Embodiments 1-1 to 1-7, wherein X3 is N.
[00193] Embodiment 1-9. The compound of any one of Embodiments 1-1 to 1-7, wherein X3 is CH.
[00194] Embodiment 1-10. The compound of any one of Embodiments 1-1 to 1-9, wherein A is monocyclic or polycyclic aryl.
[00195] Embodiment 1-11. The compound of any one of Embodiments 1-1 to 1-9, wherein A is monocyclic or polycyclic cycloalkyl.
[00196] Embodiment 1-12. The compound of any one of Embodiments 1-1 to 1-9, wherein A is monocyclic or polycyclic heterocycloalkyl. [00197] Embodiment 1-13. The compound of any one of Embodiments I-l to 1-9, wherein A is monocyclic or polycyclic heteroaryl.
[00198] Embodiment 1-14. The compound of any one of Embodiments I-l to 1-13, wherein each R1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR5R6.
[00199] Embodiment 1-15. The compound of Embodiment 1-14, wherein R5 and R6 are H.
[00200] Embodiment 1-16. The compound of any one of Embodiments I-l to 1-15, wherein R4 is an optionally substituted -Ci-C6alkyl.
[00201] Embodiment 1-17. The compound of any one of Embodiments I-l to 1-16, wherein R4 is-CH2-OH.
[00202] Embodiment 1-18. The compound of any one of Embodiments I-l to 1-17, wherein R3 can combine with R2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR ,
-CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00203] Embodiment 1-19. The compound of Embodiment 1-18, wherein the heterocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
[00204] Embodiment 1-20. The compound of any one of Embodiments I-l to 1-17, wherein R3 can combine with R2 to form a 5-to 12-membered spiroheterocycle, wherein the
spiroheterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR ,
-CONH(CH2)„COOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00205] Embodiment 1-21. The compound of Embodiment 1-20, wherein the spirocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
[00206] Embodiment 1-22. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000080_0001
[00207] Embodiment 1-23. A pharmaceutical composition comprising a compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
[00208] Embodiment 1-24. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
[00209] Embodiment 1-25. The method of Embodiment 1-24, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias,
neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00210] Embodiment 1-26. A compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
[00211] Embodiment 1-27. A compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
[00212] Embodiment 1-28. Use of a compound of any one of Embodiments 1-1 to 1-22, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation. [00213] Embodiment 1-29. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of Embodiment I- 23.
[00214] Embodiment 1-30. The method of Embodiment 1-29, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00215] Embodiment 1-31. A pharmaceutical composition of Embodiment 1-23 for use as a medicament.
[00216] Embodiment 1-32. A pharmaceutical composition of Embodiment 1-23 for use in treating or preventing a disease associated with SHP2 modulation.
[00217] Embodiment 1-33. Use of a pharmaceutical composition of Embodiment 1-23 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
[00218] Some embodiments of this disclosure are Embodiment II, as follows:
[00219] Embodiment II- 1. A compound of the Formula I:
Figure imgf000081_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl; R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN; R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00220] Embodiment II-2. A compound of the Formula Ila:
Figure imgf000083_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is a direct bond;
A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00221] Embodiment II-3. A compound of the Formula lib:
Figure imgf000085_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S-;
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, Cs-Cscycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00222] Embodiment II-4. A compound of the Formula III:
Figure imgf000087_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 is -H, -D, or -Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. [00223] Embodiment II-5. The compound of any one of Embodiments II- 1 to II-4, wherein X1 is N.
[00224] Embodiment II-6. The compound of any one of Embodiments II- 1 to II-4, wherein X1 is CH.
[00225] Embodiment II-7. The compound of any one of Embodiments II- 1 to II-6, wherein X2 is N.
[00226] Embodiment II-8. The compound of any one of Embodiments II- 1 to II-6, wherein X2 is CH.
[00227] Embodiment II-9. The compound of any one of Embodiments II- 1 to II-8, wherein X3 is N.
[00228] Embodiment 11-10. The compound of any one of Embodiments II- 1 to II- 8, wherein X3 is CH.
[00229] Embodiment II- 11. The compound of any one of Embodiments II- 1 to 11-10, wherein A is monocyclic or poly cyclic aryl.
[00230] Embodiment 11-12. The compound of any one of Embodiments II- 1 to 11-10, wherein A is monocyclic or poly cyclic cycloalkyl.
[00231] Embodiment 11-13. The compound of any one of Embodiments II- 1 to 11-10, wherein A is monocyclic or polycyclic heterocycloalkyl.
[00232] Embodiment 11-14. The compound of any one of Embodiments II- 1 to 11-10, wherein A is monocyclic or polycyclic heteroaryl.
[00233] Embodiment 11-15. The compound of any one of Embodiments II- 1 to 11-14, wherein each R1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR5R6.
[00234] Embodiment II- 16. The compound of claim 14, wherein R5 and R6 are H.
[00235] Embodiment 11-17. The compound of any one of Embodiments II- 1 to 11-16, wherein R4 is an optionally substituted -Ci-C6alkyl.
[00236] Embodiment 11-18. The compound of any one of Embodiments II- 1 to 11-17, wherein R4 is -CH2-OH [00237] Embodiment 11-19. The compound of any one of Embodiments II- 1 to 11-18, wherein R3 can combine with R2 to form 3-to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH,
-OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00238] Embodiment 11-20. The compound of Embodiment 11-19, wherein the heterocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
[00239] Embodiment 11-21. The compound of any one of Embodiments II- 1 to 11-18, wherein R3 can combine with R2 to form a 5-to 12-membered spiroheterocycle, wherein the
spiroheterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00240] Embodiment 11-22. The compound of Embodiment 11-21, wherein the spirocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
[00241] Embodiment 11-23. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000090_0001
[00242] Embodiment 11-24. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000091_0001
(5) and (5a).
[00243] Embodiment 11-25. A pharmaceutical composition comprising a compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
[00244] Embodiment 11-26. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
[00245] Embodiment 11-27. The method of Embodiment 11-26, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias,
neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00246] Embodiment 11-28. A compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
[00247] Embodiment 11-29. A compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
[00248] Embodiment 11-30. Use of a compound of any one of Embodiments II- 1 to 11-24, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation. [00249] Embodiment II-31. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of Embodiment 11-25.
[00250] Embodiment 11-32. The method of Embodiment 11-31, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias,
neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00251] Embodiment 11-33. A pharmaceutical composition of Embodiment 11-25 for use as a medicament.
[00252] Embodiment 11-34. A pharmaceutical composition of Embodiment 11-25 for use in treating or preventing a disease associated with SHP2 modulation.
[00253] Embodiment 11-35. Use of a pharmaceutical composition of Embodiment 11-25 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
[00254] Some embodiments of this disclosure are Embodiment III, as follows:
[00255] Embodiment III- 1. A compound of Formula IV:
Figure imgf000092_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl; R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
-NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen; R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00256] Embodiment III-2. A compound of the Formula V:
Figure imgf000094_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond, A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN; R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00257] Embodiment III-3. A compound of the Formula VI:
Figure imgf000096_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or polycyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-
Cscycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3 -to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00258] Embodiment III-4. A compound of the Formula I:
Figure imgf000098_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)„OH, -C(0)NH(CH2)„OH,
-C(0)NH(CH2)„R , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -N02, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -N02, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -N02, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00259] Embodiment III- 5. The compound of any one of Embodiment III- 1 to III-4, wherein X1 is N. [00260] Embodiment III-6. The compound of any one of of Embodiment III-l to III-4, wherein X1 is CH.
[00261] Embodiment III-7. The compound of any one of of Embodiment III-l to III-6, wherein X2 is N.
[00262] Embodiment III-8. The compound of any one of of Embodiment III-l to III-6, wherein X2 is CH.
[00263] Embodiment III-9. The compound of any one of of Embodiment III-l to III-8, wherein X3 is N.
[00264] Embodiment III- 10. The compound of any one of of Embodiment III-l to III- 8, wherein X3 is CH.
[00265] Embodiment III- 1 1. The compound of any one of Embodiment III- 1 to III- 10, wherein A is monocyclic or polycyclic aryl.
[00266] Embodiment III- 12. The compound of any one of Embodiment III-l to III- 10, wherein A is monocyclic or polycyclic cycloalkyl.
[00267] Embodiment III-l 3. The compound of any one of Embodiment III-l to III- 10, wherein A is monocyclic or polycyclic heterocycloalkyl.
[00268] Embodiment III- 14. The compound of any one of Embodiment III-l to III- 10, wherein A is monocyclic or polycyclic heteroaryl.
[00269] Embodiment III-l 5. The compound of any one of Embodiment III-l to III- 14, wherein each R1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR5R6.
[00270] Embodiment III- 16. The compound of Embodiment III- 14, wherein R5 and R6 are H.
[00271] Embodiment III- 17. The compound of any one of Embodiment III-l to III- 16, wherein R4 is an optionally substituted -Ci-C6alkyl.
[00272] Embodiment III-l 8. The compound of any one of Embodiment III-l to III- 17, wherein R4 1S-CH2-OH.
[00273] Embodiment III-l 9. The compound of any one of Embodiment III-l to III-l 8, wherein R3 can combine with R2 to form 3 -to 12-membered monocyclic or polycyclic heterocycle, wherein the heterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00274] Embodiment 111-20. The compound of Embodiment III- 19, wherein the heterocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
[00275] Embodiment 111-21. The compound of any one of Embodiment III-l to III-l 8, wherein R3 can combine with R2 to form a 5-to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR ,
-CONH(CH2)„COOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00276] Embodiment 111-22. The compound of Embodiment 111-21, wherein the spirocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
[00277] Embodiment 111-23. The compound of any one of Embodiment III-l to III-l 8, wherein R3 combine with R2 to form a moiety selected from:
Figure imgf000101_0001
[00278] Embodiment 111-24. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000101_0002
[00279] Embodiment 111-25. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000102_0001
(5) and (5a).
[00280] Embodiment 111-26. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000102_0002
Figure imgf000103_0001
Figure imgf000104_0001
[00281] Embodiment 111-27. A pharmaceutical composition comprising a compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
[00282] Embodiment 111-28. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
[00283] Embodiment 111-29. The method of Embodiment 111-28, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon. [00284] Embodiment 111-30. A compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
[00285] Embodiment III-31. A compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
[00286] Embodiment 111-32. Use of a compound of any one of Embodiment III-l to 111-26, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
[00287] Embodiment 111-33. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of Embodiment 111-27.
[00288] Embodiment 111-34. The method of Embodiment III-31 , wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00289] Embodiment 111-35. A pharmaceutical composition of Embodiment 111-27 for use as a medicament.
[00290] Embodiment 111-36. A pharmaceutical composition of Embodiment 111-27 for use in treating or preventing a disease associated with SHP2 modulation.
[00291] Embodiment 111-37. Use of a pharmaceutical composition of Embodiment 111-27 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
[00292] Some embodiments of this disclosure are Embodiment IV, as follows: [00293] Embodiment IV- 1. A compound of Formula IV:
Figure imgf000105_0001
(IV) or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, Cs-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN; R4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
-NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, Cs-Cscycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00294] Embodiment IV-2. A compound of the Formula V:
Figure imgf000107_0001
(V) or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, Cs-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN; R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00295] Embodiment IV-3. A compound of the Formula VI:
Figure imgf000109_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer,
thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N; Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN; R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00296] Embodiment IV-4. A compound of the Formula I:
Figure imgf000111_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or poly cyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 ls-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[00297] Embodiment IV-5. The compound of any one of Embodiments IV- 1 to IV-4, wherein X1 is N.
[00298] Embodiment IV-6. The compound of any one of Embodiments IV- 1 to IV-4, wherein X1 is CH.
[00299] Embodiment IV-7. The compound of any one of Embodiments IV- 1 to IV-6, wherein X2 is N.
[00300] Embodiment IV-8. The compound of any one of Embodiments IV-1 to IV-6, wherein X2 is CH.
[00301] Embodiment IV-9. The compound of any one of Embodiments IV-1 to IV-8, wherein X3 is N.
[00302] Embodiment IV- 10. The compound of any one of Embodiments IV-1 to IV-8, wherein X3 is CH.
[00303] Embodiment IV-11. The compound of any one of Embodiments IV-1 to IV- 10, wherein A is monocyclic or polycyclic aryl.
[00304] Embodiment IV- 12. The compound of any one of Embodiments IV-1 to IV- 10, wherein A is monocyclic or polycyclic cycloalkyl.
[00305] Embodiment IV-13. The compound of any one of Embodiments IV-1 to IV- 10, wherein A is monocyclic or polycyclic heterocycloalkyl.
[00306] Embodiment IV- 14. The compound of any one of Embodiments IV-1 to IV- 10, wherein A is monocyclic or polycyclic heteroaryl. [00307] Embodiment IV-15. The compound of any one of Embodiments IV- 1 to IV- 14, wherein each R1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR5R6.
[00308] Embodiment IV- 16. The compound of Embodiment IV- 15, wherein R5 and R6 are H.
[00309] Embodiment IV- 17. The compound of any one of Embodiments IV- 1 to IV- 16, wherein R4 is an optionally substituted -Ci-C6alkyl.
[00310] Embodiment IV-18. The compound of any one of Embodiment IV-1 to IV- 17, wherein R4 is-CH2-OH.
[00311] Embodiment IV- 19. The compound of any one of Embodiments IV-1 to IV- 17, wherein R4 is -Ci-C6alkyl substituted with one or more halogen.
[00312] Embodiment IV-20. The compound of any one of Embodiment IV-1 to IV- 19, wherein R3 can combine with R2 to form 3 -to 12-membered monocyclic or poly cyclic heterocycle, wherein the heterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00313] Embodiment IV-21. The compound of Embodiment IV-20, wherein the heterocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
[00314] Embodiment IV-22. The compound of any one of Embodiment IV-1 to IV- 19, wherein R3 can combine with R2 to form a 5-to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR ,
-CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
[00315] Embodiment IV-23. The compound of Embodiment IV-22, wherein the spirocycle is unsubstituted or substituted with -Ci-C6alkyl, -OR , or -NH2.
[00316] Embodiment IV-24. The compound of any one of Embodiment IV-1 to IV- 19, wherein R3 combine with R2 to form a moiety selected from:
Figure imgf000114_0001
[00317] Embodiment IV-25. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000115_0001
[00318] Embodiment IV-26. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000115_0002
(5) and (5a).
[00319] Embodiment IV-27. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000115_0003
Figure imgf000116_0001
Figure imgf000117_0001
[00320] Embodiment IV-28. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000118_0001
[00321] Embodiment IV-29. A pharmaceutical composition comprising a compound of any one of Embodiments IV- 1 to IV-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
[00322] Embodiment IV-30. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of Embodiment IV- 1 to IV-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
[00323] Embodiment IV-31. The method of Embodiment IV-30, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00324] Embodiment IV-32. A compound of any one of Embodiment IV- 1 to IV-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
[00325] Embodiment IV-33. A compound of any one of Embodiments IV- 1 to IV-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
[00326] Embodiment IV-34. Use of a compound of any one of Embodiments IV- 1 to IV-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation. [00327] Embodiment IV-35. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of Embodiment IV-29.
[00328] Embodiment IV-36. The method of Embodiment IV-35, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
[00329] Embodiment IV-37. A pharmaceutical composition of Embodiment IV-29 for use as a medicament.
[00330] Embodiment IV-38. A pharmaceutical composition of Embodiment IV-29 for use in treating or preventing a disease associated with SHP2 modulation.
[00331] Embodiment IV-39. Use of a pharmaceutical composition of Embodiment IV-29 in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
Examples
[00332] The disclosure is further illustrated by the following examples and synthesis examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and/or scope of the appended claims.
[00333] Definitions used in the following examples and elsewhere herein are:
CH2CI2, DCM Methylene chloride, Dichloromethane
CH3CN, MeCN Acetonitrile
Cul Copper (I) iodide
DIPEA Diisopropylethyl amine
DMF N,N-Dimethylformamide
EtOAc Ethyl acetate
Hr hour
H2O Water
HC1 Hydrochloric acid
K3PO4 Potassium phosphate (tribasic) MeOH Methanol
Na2S04 Sodium sulfate
NMP N-methyl pyrrolidone
Pd(dppf)Cl2 [l,l'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
Example 1 - Synthesis of (3-[(li?)-l-amino-8-azaspiro[4.5]decan-8-yl]-6-(2,3- dichloropyridin-4-yl)pyrazin-2-yl)methanol (Compound 1)
Figure imgf000120_0001
Step-1: Synthesis of 3-chloro-6-(2,3-dichloropyridin-4-yl)pyrazine-2-ethylcarboxylate
[00334] A mixture of 6-bromo-3-chloropyrazine-2-ethylcarboxylate (1 g, 3.97 mmol), (2,3- dichloropyridin-4-yl)boronic acid (0.93 g, 4.76 mmol), and potassium carbonate (2.18g, 15.8 mmol) in 40mL of acetonitrile was degassed, and Pd(dppf)ChCH2Cl2 (648 mg, 0.79 mmol) was added. The resulting mixture was allowed to stir under an inert atmosphere at 95°C for lh. Concentration under reduced pressure, and purification by column chromatography (40% EtO Ac/60% Heptane) resulted in 3-chloro-6-(2,3-dichloropyridin-4-yl)pyrazine-2- ethylcarboxylate (350 mg, 27% yield).
Step-2: Synthesis of 6-(2,3 -dichloropyridin-4-yl)-3-((i?)- 1 -((R)- 1 , 1 -dimethylethylsulfinamido)-8- azaspiro[4.5]decan-8-yl)pyrazine-2-ethylcarboxylate
[00335] To a solution of 3-chloro-6-(2,3-dichloropyridin-4-yl)pyrazine-2-ethylcarboxylate (350 mg, 1.35 mmol) and (i?)-2-methyl-N-((i?)-8-azaspiro[4.5]decan-l-yl)propane-2-sulfinamide (450 mg, 1.4 mmol) in DMA (2.5 mL) under an inert atmosphere was added DIPEA (233 uL, 1.4 mmol). The resulting mixture was allowed to stir at 50°C for 30 min. Ethyl acetate (20 mL) was added to the reaction mixture, and the resulting slurry was washed with water (20 mL), brine (10 mL), and dried over anhydrous magnesium sulfate. Filtration, and concentration under reduced pressure resulted in 6-(2,3-dichloropyridin-4-yl)-3-((i?)-l-((i?)-l,l -dimethylethylsulfinamido)-8- azaspiro[4.5]decan-8-yl)pyrazine-2-ethylcarboxylate (150 mg). The product was submitted to the next step without further purification.
Step-3: Synthesis of (3-[(li?)-l-amino-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichloropyridin-4- yl)pyrazin-2-yl)methanol
[00336] To a solution of 6-(2,3-dichloropyridin-4-yl)-3-((R)-l -((R)-l,l- dimethylethylsulfinamido)-8-azaspiro[4.5]decan-8-yl)pyrazine-2-ethylcarboxylate (150 mg, 0.28 mmol) in DCM (3 mL) at -78°C was added dropwise 1M solution of DIBAL-H in DCM (1.1 mL, 1. lmmol). The resulting mixture was allowed to stir at -78°C for 30 min, then warmed up to 0 °C and allowed to stir for an additional 5 min. The reaction mixture was subsequently cooled down to -78°C, followed by addition of saturated Rochelle's salt solution (6 mL). The resulting slurry was allowed to warm up to RT under vigorous stirring for a period of lh, followed by addition of DCM (20 mL) and water ( 15 mL). Layers were separated and the aqueous phase was extracted with DCM (20 mL). The combined organic layers were dried over anhydrous magnesium sulfate. Filtration and concentration under reduced pressure resulted in the yellow oil. The resulting sample was dissolved in MeOH (2 mL), and HQ/ MeOH (4 M, 0.5 mL) was added. The resulting mixture was stirred at 50 °C for 1 hr, and concentrated under reduced pressure. Purification by preparative HPLC chromatography, followed by liophilisation resulted in (i?)-(3-(l-amino-8-azaspiro[4.5]decan-8-yl)-6-(2,3-dichloropyridin-4-yl)pyrazin-2- yl)methanol (11 mg, 9.7 % yield) as a white solid. ¾ NMR (500 MHz, Methanol-d4) δ 8.62 (s, 1H), 8.56 (s, 1H), 8.40 (d, J = 5.0 Hz, 1H), 7.76 (d, J = 5.0 Hz, 1H), 4.75 (s, 2H), 3.95 - 3.88 (m, 1H), 3.88 - 3.80 (m, 1H), 3.30 - 3.15 (m, 3H), 2.30 -2.20 (m, 1H), 1.99 - 1.71 (m, 5H), 1.66 - 1.54 (m, 2H). LC-MS (ESI): m/z [M + H] C19H25CI2N5O calculated 408.13; found 408.30.
Example 2 - Synthesis of (3-[(li?)-l-amino-8-azaspiro[4.5]decan-8-yl]-6-(2,3- dichlorophenyl)pyrazin-2-yl)methanol (Compound 2)
Figure imgf000122_0001
[00337] (3-[(li?)-l -amino-8-azaspiro [4.5] decan- 8-yl] -6-(2,3 -dichlorophenyl)pyrazin-2- yl)methanol was synthesized in the manner similar to Example 1, except (2,3-dichloropyridin-4- yl)boronic acid was substituted with (2,3-dichlorophenyl)boronic acid. ¾ NMR (500 MHz, Methanol-d4) δ 8.57 (s, 1H), 8.44 (d, J = 0.5 Hz, 1H), 7.64 (dd, J = 8.0, 1.6 Hz, 1H), 7.61 (dd, J = 7.8, 1.6 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 4.75 (d, J = 0.5 Hz, 2H), 3.74 (dd, J = 26.9, 13.3 Hz, 2H), 3.22 - 3.11 (m, 3H), 2.27 - 2.14 (m, 1H), 2.01 - 1.75 (m, 6H), 1.74 - 1.63 (m, 1H), 1.56 (dd, J = 20.9, 13.0 Hz, 2H). LC-MS (ESI): m/z [M + H] C20H25CI2N4O calculated 407.13; found 407.31.
Example 3 - Synthesis of [3-(4-amino-4-methylpiperidin-l-yl)-6-(2,3- dichlorophenyl)pyrazin-2-yl] methanol (Compound 3)
Figure imgf000122_0002
[00338] [3-(4-amino-4-methylpiperidin-l-yl)-6-(2,3-dichlorophenyl)pyrazin-2-yl]methanol can be synthesized in the manner similar to Example 1, except (i?)-2-methyl-N-((i?)-8- azaspiro[4.5]decan-l-yl)propane-2-sulfinamide was substituted with tert-butyl N-(4- methylpiperidin-4-yl)carbamate. ¾ NMR (500 MHz, Methanol-d4) δ 8.55 (s, 1 H) 8.45 (s, 1 H) 7.60 (ddd, J=14.36, 8.00, 1.75 Hz, 2 H) 7.39 - 7.46 (m, 1 H) 4.73 (s, 2 H) 3.72 (dt, J=14.03, 4.17 Hz, 2 H) 3.32 - 3.39 (m, 2 H) 1.96 - 2.06 (m, 2 H) 1.86 - 1.95 (m, 2 H) 1.50 (s, 3 H). LC- MS (ESI): m/z [M + H] C17H21CI2N4O calculated 367.1; found 366.9. Example 4 - Synthesis of (6-((2-amino-3-chloropyridin-4-yl)thio)-3-(4- methylpiperidin-l-yl)pyrazin-2-yl)methanol (Compound 4)
Figure imgf000123_0001
[00339] Step-1: Synthesis of methyl 6-bromo-3-(4-((tert-butoxycarbonyl)amino)-4- methylpiperidin- 1 -yl)pyrazine-2-carboxy late
[00340] A mixture of 6-bromo-3-chloropyrazine-2-methylcarboxylate (2 g, 7.95 mmol), tert- butyl N-(4-methylpiperidin-4-yl)carbamate (1.87 g, 8.74 mmol), N,N-Diisopropylethylamine (6.57 mL, 39.7 mmol), and 40 mL of acetonitrile was allowed to stir in a sealed tube at 35° C for 2 hrs, followed by concentration under reduced pressure. The residue was extracted with EtO Ac/water, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting product was submitted to the next step without further purification. XH NMR (500 MHz, Methanol-d4) δ 8.27 (s, 1H), 3.95 (s, 3H), 3.68 - 3.59 (m, 2H), 3.32 - 3.27 (m, 2H), 2.14 (d, J = 13.9 Hz, 2H), 1.59 (ddd, J = 14.1, 10.8, 4.1 Hz, 2H), 1.46 (s, 12H), 1.35 (s, 3H). LC-MS (ESI): m/z [M + H] Ci7H26BrN404 calculated 429.12, found 429.3
Step-2: Synthesis of (3-(4-amino-4-methylpiperidin-l-yl)-6-bromopyrazin-2-yl)methanol
[00341] Methyl 6-bromo-3-(4-((tert-butoxycarbonyl)amino)-4-methylpiperidin-l-yl)pyrazine- 2-carboxylate (3.5 g, 8.15 mmol) was dissolved in DCM (81.5 mL) . The resulting yellow solution was cooled to -78 °C and DIBAL-H (4.63 g, 32.6 mmol) was added dropwise, and the resulting mixture was allowed to stir for 1 hr at -78 °C, warmed up to 0 °C for 30 minutes, and cooled back to -78 °C, followed by addition of saturated aqueous Rochelle's salt solution (800 mL) at -78 °C. To the resulting slurry was added 400 ml of DCM and the reaction was allowed to warm to RT while stirring vigorously. To the resulting slurry was allowed to stir for 18 h at RT, and the aqueous phase was extracted with DCM (2 x 400 mL). The combined organic extracts were dried over magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in 20 mL of MeOH, and 2.0 ml of 4NHCl/dioxane was added. The resulting mixture was allowed to stir at 50°C for 18h. Purification by preparative HPLC chromatography, followed by liophilisation resulted in (3-(4-amino-4-methylpiperidin-l-yl)-6- bromopyrazin-2-yl)methanol. ¾ NMR (500 MHz, Methanol-d4) δ 8.55 (s, 1H), 8.29 - 8.25 (m, 1H), 4.64 (d, J = 0.5 Hz, 2H), 3.62 (dt, J = 14.0, 4.1 Hz, 2H), 3.27 (ddd, J = 13.5, 10.1, 3.2 Hz, 3H), 1.98 (ddd, J = 13.8, 10.0, 4.1 Hz, 2H), 1.93 - 1.85 (m, 2H), 1.49 (s, 3H). LC-MS (ESI): m/z [M + H] CiiHivBrN40 calculated 301.06, found 301.2
Step-3: Synthesis of (6-((2-amino-3-chloropyridin-4-yl)thio)-3-(4-amino-4-methylpiperidin-l- yl)pyrazin-2-yl)methanol
[00342] A solution of (3-(4-amino-4-methylpiperidin-l-yl)-6-bromopyrazin-2-yl)methanol (50 mg, 0.1660 mmol), 3-chloro-4-(potassiosulfanyl)pyridin-2-amine (49.4 mg, 0.2490 mmol), Pd2dba3 (15.2 mg, 0.01660 mmol), and Xantphos (19.2 mg, 0.03320 mmol) in dioxane (1.66 mL) was degassed, and N,N-Diisopropylethylamine (57.8 uL,0.332 mmol) was added. The resulting mixture was heated to 120 °C under a microwave conditions for 2 h, allowed to cool to RT, filtered over celite, and concentrated under reduced pressure. Purification by preparative HPLC followed by liophilization resulted in 7.60 mg (6-((2-amino-3-chloropyridin-4-yl)thio)-3- (4-amino-4-methylpiperidin-l-yl)pyrazin-2-yl)methanol (12.0% Yield). ¾ NMR (400 MHz, Methanol-d4) δ 8.43 (s, 2H), 8.32 (s, 1H), 7.62 (dd, J = 5.6, 0.7 Hz, 1H), 6.07 (dd, J = 5.6, 0.7 Hz, 1H), 4.68 (s, 2H), 3.83 (dt, J = 14.2, 4.5 Hz, 2H), 3.37 (ddd, J = 13.7, 10.2, 3.2 Hz, 2H), 1.98 (ddd, J = 14.0, 10.1, 4.1 Hz, 2H), 1.90 (dt, J = 13.4, 3.9 Hz, 2H), 1.50 (s, 3H). LC-MS (ESI): m/z [M + H] C ieH21 CINeOS calculated 381.1, found 381.3.
Example 5. Synthesis of [6-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-3-[(5S,4S)-4-amino-3- methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-2-pyridyl]methanol. (Compound 5)
Figure imgf000124_0001
Step 1. [00343] To a solution of methyl 3-fluoropyridine-2-carboxylate (319mg, 2.06 mmol) and (35', )S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (454 mg, 1.87 mmol, 2HC1 salt) in DMF (3.8 mL) was added CS2CO3 (1.83 g, 5.61 mmol). The mixture was stirred at 100 °C for 4 hrs. The reaction mixture was quenched by addition H2O (3 mL) at 25 °C and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na2S04, filtered and concentrated under reduced pressure to afford methyl 3-[(3S,4S)- 4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyridine-2-carboxylate (2 g, crude) as a white oil. LCMS (ESI): m/z [M +H] calculated for C16H24N3O3: 306.2; found 306.3.
Step 2.
[00344] To a solution of methyl 3-[(3<S,, )S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl]pyridine-2-carboxylate (2 g, 6.55 mmol) in THF (20 mL) was added B0C2O (4.3 g, 19.65 mmol, 4.5 mL). The reaction mixture was stirred at 25 °C for 12 hrs. The reaction mixture was quenched by the addition of H2O (3 mL) at 25 °C. The reaction mixture was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2S04, filtered and concentrated under reduced pressure. The remaining residue was purified by column
chromatography to afford methyl 3-[(3<S,, )S)-4-(ieri-butoxycarbonylamino)-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]pyridine-2-carboxylate (300 mg, 11 % yield) as a white solid. 'H NMR (400MHz, Chloroform-^ δ ppm 8.27 (d, J = 3.7 Hz, 1H), 7.44 - 7.38 (m, 1H), 7.36 - 7.30 (m, 1H), 5.31 (s, 2H), 4.59 ( d, J=10.8 Hz, 1H), 4.18 ( d, J = 4.6 Hz, 1H), 4.02 (d, J = 4.4 Hz, 1H), 3.99 (s, 1H), 3.98 (s, 2H), 3.73 - 3.62 (m, 2H), 3.26 - 2.84 (m, 5H), 1.99 - 1.77 (m, 3H), 1.71 ( d, J = 4.4 Hz, 1H), 1.51 (s, 1H), 1.46 (s, 6H), 1.24 - 1.18 (m, 3H). LCMS (ESI): m/z: [M +H] calculated for C21H32N3O5: 406.2; found 406.3.
Step 3.
[00345] To a solution of methyl 3-[(3<S,, )S)-4-(/er/-butoxycarbonylamino)-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]pyridine-2-carboxylate (250 mg, 616 umol) in CH3CN (5 mL) was added NBS (165 mg, 925 umol). The mixture was stirred at 0 °C for 5 min. The reaction mixture was quenched by the addition of H2O (3 mL) at 25 °C. The reaction mixture was extracted with EtOAc and the combined organic layers were washed with brine, dried over Na2S04, filtered and concentrated under reduced pressure. The residue was purified by column chromatography to afford methyl 6-bromo-3-[(3<S,, )S)-4-(/er/-butoxycarbonylamino)-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl]pyridine-2-carboxylate (200 mg, 67 % yield) as a white solid. XH NMR (400MHz, Chloroform-i/) δ ppm 7.47 (d, J = 8.7 Hz, 1H), 7.29 (s, 1H), 4.59 (d, J = 11.0 Hz, 1H), 4.18 - 4.14 (m, 1H), 4.01 (s, 1H), 4.00 - 3.96 (m, 1H), 3.95 (s, 3H), 3.71 - 3.61 (m, 2H), 3.22 - 2.87 (m, 4H), 3.22 - 2.87 (m, 1H), 1.96 - 1.75 (m, 3H), 1.72 - 1.63 (m, 1H), 1.50 (s, 1H), 1.46 (s, 9H), 1.20 (d, J = 6.2 Hz, 3H). LCMS (ESI): m/z: [M+H] calculated for
C2iH3iBrN305:484.1, 486.1 ; found 484.1, 486.2.
Step 4.
[00346] To a solution of methyl 6-bromo-3-[(3<S,, )S)-4-(ieri-butoxycarbonylamino)-3-methyl- 2-oxa-8-azaspiro[4.5]decan-8-yl]pyridine-2-carboxylate (184 mg, 380 umol) in 1,4-dioxane (2 mL) was added 2-amino-3-chloro-pyridine-4-thiol (73 mg, 456 umol), 1 , 10-Phenanthroline (14 mg, 76 umol), Cul (7 mg, 38 umol) and K3PO4 (161 mg, 760 umol) at 20 °C, and the mixture was degassed with N2. The reaction mixture was heated to 140 °C for 1 hr under N2. The reaction mixture was filtered and concentrated under reduced pressure. The resulting residue was purified by prep-HPLC to afford methyl 6-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-3-[(3,S', )S -4-(fert- butoxycarbonylamino)-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyridine-2-carboxylate (140 mg, 65 % yield) as a white solid. LCMS (ESI): m/z: [M +H] calculated for C26H35CIN5O5S: 564.2; found 564.3.
Step 5.
[00347] To a solution of methyl 6-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-3-[(3,S', )S)-4-(/er/- butoxycarbonylamino)-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyridine-2-carboxylate (90 mg, 159 umol) in THF (1 mL) was added L1BH4 (10 mg, 479 umol). The mixture was stirred at 50 °C for 30 min. To the mixture was added 0.2 mL of HC1 and the mixture was stirred at 25°C for 30 min. The mixture was adjusted to pH = 7 with NaHCC , filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC to afford [6-[(2- amino-3-chloro-4-pyridyl)sulfanyl]-3-[(3<S',- )S -4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl]-2-pyridyl]methanol (6 mg, 9 % yield) as a yellow solid. ¾ NMR (400MHz, Methanol-^) δ ppm 8.49 (s, 1H), 7.69 - 7.56 (m, 2H), 7.53 - 7.47 (m, 1H), 6.16 (d, J = 5.5 Hz, 1H), 4.73 (s, 2H), 4.32 - 4.22 (m, 1H), 3.93 (d, J = 9.2 Hz, 1H), 3.82 (d, J = 9.0 Hz, 1H), 3.41 (d, J = 4.2 Hz, 1H), 3.25 - 3.11 (m, 2H), 2.91 - 2.75 (m, 2H), 2.05 - 1.95 (m, 2H), 1.94 - 1.85 (m, 1H), 1.74 (d, J = 12.7 Hz, 1H), 1.30 (d, J= 6.5 Hz, 3H). LCMS (ESI): m/z [M +H] calculated for C20H27CIN5O2S: 436.1; found 436.3.
Example 6. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (5,6-dichloro-2H-l,3-benzodioxol-4-yl)pyrazin-2-yl}methanol. (Compound 6)
Figure imgf000127_0001
Step 1
[00348] To a solution of 1,3-benzodioxole (500 mg, 4.09 mmol, 1.0 eq) in MeCN (5 mL) was added TMSC1 (44.48 mg, 409.43 umol) and NCS (1.20 g, 9.01 mmol). The mixture was stirred at 20 °C for 2 hr and then quenched by addition aqueous Na2S203 (10 ml). After extraction with EtOAc the combined organic layers were washed with brine, dried over Na2S04, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography to give 5,6-dichloro- 1,3-benzodioxole (620 mg, 3.25 mmol, 79% yield) as a white solid. ¾ NMR (400 MHz, METHANOL-^) δ ppm 6.98 (s, 2 H) 6.02 (s, 2 H).
Step 2
[00349] ft-BuLi (2.5 M, 500 uL) was added drop wise to a mixture of 5,6-dichloro- 1,3- benzodioxole (200 mg, 1.1 mmol) in THF (5 mL) at -78 °C. After 30 min, B(OMe)3 (163 mg, 1.6 mmol) was added at -78 °C. The reaction was allowed to warm to 20 °C for over 2 hr and IN HCl was added. After extraction with EtOAc the combined organic layers were washed with brine, dried over Na2S04, filtered and concentrated under reduced pressure to give (5,6-dichloro- l,3-benzodioxol-4-yl)boronic acid (200 mg, 684 umol, 80% purity) as a light yellow solid.
LCMS (ESI): m/z: [M -H] calculated for C7H4BCI2C : 232.9; found 233.0.
Step 3
[00350] To a solution of [3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- bromo- pyrazin-2-yl]methanol (for synthesis see example 1, 100 mg, 280 μπιοΐ) in DME (2 mL) and H2O (0.4 mL) was added (5,6-dichloro-l,3-benzodioxol-4-yl)boronic acid (79 mg, 336 μπιοι), Na2CC (59 mg, 560 μπιοΐ) and Pd(PPh3)4 (32 mg, 28 μπιοΐ, 0.1 eq). The mixture was heated at 110 °C for 24 hr under N2. After cooling to rt, the reaction mixture was concentrated under reduced pressure to give a crude residue, which was purified by prep-HPLC to give {3- [(3<S',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(5,6-dichloro-2H-l,3- benzodioxol-4-yl)pyrazin-2-yl} methanol (6.5 mg, 13.3 umol, 5 % yield) as a white solid. LCMS (ESI): m/z: [M +H] calculated for C21H24CI2N4O4: 467.1; found 467.2; ¾ NMR (400 MHz, DMSO-i e) δ ppm 8.23 (s, 1 H) 7.28 (d, J=1.71 Hz, 1 H) 6.11 (s, 2 H) 4.94 (br s, 1 H) 4.60 (br s, 2 H) 3.73 (br d, J=8.31 Hz, 1 H) 3.63 (br d, J=13.20 Hz, 3 H) 3.56 (br d, J=9.17 Hz, 1 H) 3.11 - 3.30 (m, 3 H) 1.89 (br d, J=8.44 Hz, 1 H) 1.75 - 1.84 (m, 1 H) 1.81 (br d, J=14.18 Hz, 2 H) 1.56 - 1.69 (m, 3 H) 1.14 (br d, J=6.48 Hz, 3 H).
Example 7. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (2,3-dichloro-6-methoxyphenyl)pyrazin-2-yl} methanol. (Compound 7)
Figure imgf000128_0001
Step 1
[00351] To a solution of 3,4-dichlorophenol (4 g, 24.5 mmol) in DMF (40 mL) was added NBS (4.4 g, 24.5 mmol) at 0 °C. After stirring for 30 min at 0 °C the solvent was removed under reduced pressure and the crude residue was purified by column chromatography to give 2- bromo-3,4-dichloro-phenol (0.95 g, 4.0 mmol, 16 % yield) as a white solid. ¾ NMR (400 MHz, DMSO-d6) δ ppm 11.00 (s, 1 H) 7.46 (d, J=9.04 Hz, 1 H) 6.95 (d, J=8.82 Hz, 1 H).
Step 2
[00352] To a solution of 2-bromo-3,4-dichloro-phenol (0.35 g, 1.5 mmol) in DMF (2 mL) was added K2CO3 (540 mg, 3.9 mmol) and CH3I (0.4 ml, 6.5 mmol) at 20 °C. After 3 hr the reaction was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over magnesium sulfate. The solvent was removed under reduced pressure and the crude residue was purified by column chromatography to give 3-bromo-l,2-dichloro-4-methoxy-benzene (0.3 g, 1.2 mmol, 81 % yield) as a white solid. ¾ NMR (400 MHz, METHANOL-d4) δ ppm 7.49 (d, J=9.04 Hz, 1 H) 7.00 (d, J=9.04 Hz, 1 H) 3.90 (s, 3 H).
Step 3
[00353] To a solution of 3-bromo-l,2-dichloro-4-methoxy-benzene (0.25 g, 0.98 mmol) in dioxane (6 mL) was added 4,4,5, 5-tetramethyl-2-(4,4,5,5-tetramethyl- 1,3, 2-dioxaborolan-2-yl)- 1,3,2-dioxaborolane (372 mg, 1.5 mmol), KOAc (192 mg, 1.9 mmol) and Pd(dppf)Cl2-CH2Cb (80 mg, 97.7 μπιοΐ). The reaction mixture was stirred at 85 °C for 5hr under N2. Upon cooling to rt, the reaction was diluted with water and extracted with ethyl acetate. The combined organic layers were dried over Na2S04, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography to give 2-(2,3-dichloro-6-methoxy-phenyl)- 4,4,5, 5-tetramethyl-l,3,2-dioxaborolane (0.19 g, 0.63 mmol, 64% yield) as a yellow solid. XH NMR (400 MHz, METHANOL-d4) δ ppm 7.44 (d, J=8.93 Hz, 1 H) 6.89 (d, J=8.80 Hz, 1 H) 3.78 (s, 3 H) 1.37 (s, 12 H).
Step 4
[00354] To a solution of [3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- bromo-pyrazin-2-yl]methanol (for synthesis see example 1, 79 mg, 220 μπιοΐ) in DME (2 mL) was added 2-(2,3-dichloro-6-methoxy-phenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (0.1 g, 330 μιηοΐ), Na2C03 (47 mg, 440 μιηοΐ), H20 (0.4 mL) and Pd(PPh3)4 (25 mg, 22 μιηοΐ). The reaction was stirred at 85 °C for 5hr under N2. After cooling to rt the mixture was filtrated and the solvent was removed under reduced pressure and the crude residue was purified by prep- HPLC to give {3-[(3<S,,4<S -4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichloro- 6-methoxyphenyl)pyrazin-2-yl}methanol (2.9 mg, 6 umol, 3% yield) as a white solid. LCMS (ESI): m/z: [M+H] calculated for C2iH27Cl2N403: 453.1 ; found 453.3; ¾ NMR (400 MHz, METHANOL- d4) δ ppm 8.49 (br s, 1 H) 8.10 - 8.07 (m, 1 H) 7.58 (d, J=9.04 Hz, 1 H) 7.10 (d, J=9.04 Hz, 1 H) 4.71 (s, 2 H) 4.29 (dd, J=6.51, 4.30 Hz, 1 H) 3.95 (d, J=9.04 Hz, 1 H) 3.84 (d, J=9.04 Hz, 1 H) 3.75 (s, 3 H) 3.71-3.65 (m, 1 H) 3.39 (d, J=4.19 Hz, 1 H) 3.16 - 3.01 (m, 2 H) 2.04 - 1.86 (m, 3 H) 1.74 (d, J= 12.57 Hz, 1 H) 1.30 (d, J=6.62 Hz, 3 H).
Example 8. Synthesis of 2-{5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]- 6-(hydroxymethyl)pyrazin-2-yl}-3,4-dichlorophenol (Compound 8)
Figure imgf000130_0001
Step 1
[00355] To a solution of methyl 3,6-dibromopyrazine-2-carboxylate (8.4 g, 28.3 mmol) in MeCN (142 mL) was added (3<S,,4<S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine bis- hydrochloride (7.59 g, 31.2 mmol), DIEA (24.7 ml, 142 mmol). The reaction mixture was stirred at rt for 16 hr. The solvent was removed under reduced pressure and the residue was partitioned between water NH4OH (10: 1) and EtOAc. The phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were dried over anhydrous Na2S04, filtered and concentrated to give methyl 3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-6-bromo-pyrazine-2-carboxyte (12 g, crude), which was used without further purification. LCMS (ESI): m/z: [M +H] calculated for Ci5H22BrN403: 385.1; found 385.1.
Step 2
[00356] To a solution of ethyl 3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl]-6-bromo-5-methyl-pyrazine-2-carboxylate (12 g, 29.0 mmol) in DCM (240 mL) at -78 °C was added DIBAL-H (1 M, 116 mL) over 10 min. The reaction mixture was stirred at -78 °C for 1 hr and then warmed to 0 °C for 1 hr. The reaction was quenched by pouring it into saturated aqueous Rochelle's salt solution. EtOAc was added and the reaction was allowed to warm to rt overnight while stirring vigorously. The biphasic mixture was then separated, and the aqueous phase was extracted with EtOAc. The combined organic extracts were dried over Na2S04, filtered and concentrated. The yellow residue was triturated with EtOAc to give [3-[(3 ,45)-4- amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-bromo-5-methyl-pyrazin-2-yl]methanol (4.86 g, 45 % yield). ¾ NMR (400 MHz, DMSO-i e) δ ppm 8.27 (s, 1 H) 5.51 (s, 1 H) 4.43 (s, 1 H) 4.05 - 4.02 (m, 1 H) 3.62 (d, J= 8.38 Hz, 1 H) 3.44 (d, J= 8.60 Hz, 1 H) 3.34 - 3.26 (m, 2 H) 3.13 - 2.95 (m, 2 H) 2.86 (d, J=4.85 Hz, 1 H) 1.84 - 1.61 (m, 2 H) 1.60 - 1.42 (m, 2 H) 1.32 ( s, 2 H) 1.05 (d, J= 6.39 Hz, 2 H).
Step 3
[00357] To a solution of 3,4-dichlorophenol (4 g, 24.54 mmol) in DMF (40 mL) was added NBS (4.37 g, 24.54 mmol) at 0 °C and the reaction was stirred for 0.5 hr. The solvent was evaporated under reduced pressure and the crude residue was purified by column
chromatography to give 2-bromo-3,4-dichloro-phenol (0.95 g, 3.93 mmol, 16 % yield) as a white solid. ¾ NMR (400 MHz, DMSO-i/e) δ ppm 11.00 (s, 1 H) 7.46 (d, J=9.04 Hz, 1 H) 6.95 (d, J=8.82 Hz, 1 H).
Step 4
[00358] To a solution of 2-bromo-3,4-dichloro-phenol (0.3 g, 1.24 mmol) in dioxane (6 mL) was added [3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-bromo-pyrazin-2- yl]methanol (443.1 mg, 1.24 mmol), KOAc (243.4 mg, 2.48 mmol), 4,4,5, 5-tetramethyl-2- (4,4,5, 5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,3,2-dioxaborolane (472.4 mg, 1.86 mmol) and Pd(dppf)Cl2-CH2Ch (101.3 mg, 124.0 μιηοΐ) at 20 °C under N2, the mixture was heated to 105 °C for 2 hr. After cooling to rt and filtration the solvent was removed under reduced pressure and the crude residue was purified by prep-HPLC to give 2-{5-[(3<S,,4<S)-4-amino-3-methyl-2- oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyrazin-2-yl}-3,4-dichlorophenol (3 mg, 7 umol, 51% yield) as a white solid. LCMS (ESI): m/z: [M +H] calculated for C20H25CI2N4O3 : 439.1; found 439.1. ¾ NMR (400 MHz, METHANOL-^) δ ppm 8.52 (br s, 1 H) 8.22 (s, 1 H) 7.40 (d, J=8.82 Hz, 1 H) 6.88 (d, J=9.04 Hz, 1 H) 4.72 (s, 2 H) 4.25 - 4.32 (m, 1 H) 3.93 (d, J=9.04 Hz, 1 H) 3.82 (d, J=9.48 Hz, 1 H) 3.62 - 3.74 (m, 3 H) 3.01 - 3.16 (m, 3 H) 1.93 - 2.02 (m, 2 H) 1.86 (br d, J=13.23 Hz, 1 H) 1.73 (br d, J=13.45 Hz, 1 H) 1.29 (d, J=6.39 Hz, 3 H).
Example 9. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (5-chloroquinoxalin-6-yl)pyrazin-2-yl} methanol. (Compound 9)
[00359] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(5- chloroquinoxalin-6-yl)pyrazin-2-yl} methanol was synthesized in a manner similar to 2- {5- [(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyrazin-2-yl}- 3,4-dichlorophenol except 2-bromo-3,4-dichloro-phenol was substituted with 6-bromo-5-chloro- quinoxaline. LCMS (ESI): m/z: [M +H] calculated for C22H26CIN6O2: 441.2; found 440.9; ¾ NMR (400 MHz, METHANOL-d4) δ ppm 9.01 (br d, J=13.23 Hz, 2 H) 8.71 (s, 1 H) 8.49 (br s, 1 H) 8.25 - 8.20 (m, 1 H) 8.18 - 8.13 (m, 1 H) 4.78 (s, 2 H) 4.34 - 4.26 (m, 1 H) 3.97 (d, J=9.26 Hz, 1 H) 3.88 - 3.73 (m, 3 H) 3.40 (br d, J=3.75 Hz, 1 H) 3.23 - 3.06 (m, 2 H) 2.05 - 1.95 (m, 2 H) 1.94 - 1.87 (m, 1 H) 1.76 (br d, J=13.45 Hz, 1 H) 1.31 (d, J=6.39 Hz, 3 H).
Example 10. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin-2-yl}methanol. (Compound 10)
Figure imgf000132_0001
[00360] To a microwave vial was added {3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-6-bromopyrazin-2-yl}methanol (for synthesis see example 1, 30 mg, 84 μιηοΐ), (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid (25 mg, 125
μιηοΐ), tetrakis(triphenylphosphine) palladium (10 mg, 8.4 μηιοΐ), and potassium carbonate (35 mg, 250 μηιοΐ). The reaction vial was evacuated and purged with N2 three times before stirring under microwave conditions at 120 °C for 1.5 hr. The resulting reaction mixture was filtered through a pad of celite, washing with DCM and MeOH. The filtrate was concentrated under reduced pressure and the residue was subjected to column chromatography, followed by reverse phase HPLC to yield the desired product, {3-[(3<S,,4<S -4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin-2- yljmethanol (10.0 mg, 23.2 μηιοΐ, 28 %). LCMS (ESI): m/z: [M + H] calcd for C21H26CIN7OS: 431.2; found 431.4. ¾ NMR (500 MHz, Methanol-i/4) δ 8.38 (s, 1H), 7.22 (dt, J= 7.6, 1.1 Hz, 1H), 7.10 (d, J= 7.6 Hz, 1H), 4.68 (t, J= 8.8 Hz, 4H), 4.33 - 4.24 (m, 1H), 3.94 (d, J= 9.1 Hz, 1H), 3.83 (d, J= 9.1 Hz, 1H), 3.74 - 3.58 (m, 2H), 3.40 (d, J= 4.2 Hz, 1H), 3.35 (td, J= 8.8, 1.1 Hz, 2H), 3.14 - 2.98 (m, 2H), 2.04 - 1.92 (m, 2H), 1.88 (d, J= 13.5 Hz, 1H), 1.77 - 1.69 (m, 1H), 1.30 (d, J= 6.6 Hz, 3H).
Example 11. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (lH-indol-7-yl)pyrazin-2-yl}methanol. (Compound 11) [00361] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(lH-indol-7- yl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino-3-methyl- 2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin-2- yljmethanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with (lH-indol-7-yl)boromc acid. LCMS (ESI): m/z: [M +Η] calculated for C22H27N5O2: 394.2; found 394.5; ¾ NMR (500 MHz, Methanol-d4) δ 8.50 (s, 1H), 8.48 (s, 1H), 7.53 (dt, J = 7.9, 1.0 Hz, 1H), 7.39 (dd, J = 8.3, 1.0 Hz, 1H), 7.18 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.14 (S, 1H) 7.03 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H), 6.80 (d, J = 0.8 Hz, 1H), 4.72 (s, 2H), 4.30 - 4.18 (m, 1H), 3.88 (d, J = 9.0 Hz, 1H), 3.77 (d, J = 8.9 Hz, 1H), 3.65 - 3.52 (m, 2H), 3.29 (d, J = 1.6 Hz, 1H), 3.13 - 2.95 (m, 2H), 1.98 - 1.87 (m, 2H), 1.82 (d, J =13.5 Hz, 1H), 1.69 (d, J = 13.1 Hz, 1H), 1.25 (d, J = 6.5 Hz, 4H).
Example 12. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (quinoxalin-6-yl)pyrazin-2-yl}methanol. (Compound 12)
[00362] { 3 - [(3<S',4)S)-4-amino-3 -methyl-2-oxa-8-azaspiro[4.5 ] decan- 8-yl] -6-(quinoxalin-6- yl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino-3-methyl-
2- oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin-2- yljmethanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with 6- quinoxalinyl-boronic acid. LCMS (ESI): m/z: [M +H] calculated for C22H26N6O2: 407.2; found 407.5. ¾ NMR (500 MHz, Methanol-i/4) δ 8.90 (dd, J= 18.4, 1.9 Hz, 2H), 8.82 (s, 1H), 8.71 (d, J= 1.9 Hz, 1H), 8.59 (dd, J= 8.9, 2.0 Hz, 1H), 8.16 (d, J= 8.9 Hz, 1H), 4.79 (s, 2H), 3.99 (d, J= 9.1 Hz, 1H), 3.88 (d, J= 9.1 Hz, 1H), 3.50 (d, J= 4.1 Hz, 1H), 3.37 (s, 1H), 2.68 (s, 3H), 1.35 (d, J= 6.5 Hz, 3H).
Example 13. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (4-chloro-2H-indazol-6-yl)pyrazin-2-yl}methanol. (Compound 13)
[00363] { 3 - [(35 45)-4^ιηιηο-3 -methyl-2-oxa-8-azaspiro[4.5 ] decan- 8-yl] -6-(4-chloro-2H- indazol-6-yl)pyrazin-2-yl}methanol was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino-
3- methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin- 2-yl}methanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with (4-chloro-lH-indazol-6-yl)boronic acid. LCMS (ESI): m/z: [M +H] calculated for
C21H25CIN6O2: 429.2; found 429.0; ¾ NMR (400 MHz, METHANOL-^) δ ppm 8.67 (s, 1 H) 8.12 (d, J=12.79 Hz, 2 H) 7.93 (s, 1 H) 4.76 (s, 2 H) 4.19 - 4.30 (m, 1 H) 3.86 (d, J=8.38 Hz, 1 H) 3.72 (d, J=8.60 Hz, 1 H) 3.56 (br dd, J=11.69, 5.95 Hz, 2 H) 3.16 (br t, J=10.69 Hz, 1 H) 3.06 - 3.11 (m, 1 H) 3.04 (d, J=4.85 Hz, 1 H) 1.85 - 2.01 (m, 2 H) 1.67 - 1.80 (m, 2 H) 1.23 (d, J=6.39 Hz, 3 H) .
Example 14. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (5-chloro-2H-indazol-6-yl)pyrazin-2-yl}methanol. (Compound 14)
[00364] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(5-chloro-2H- indazol-6-yl)pyrazin-2-yl}methanol was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino- 3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin- 2-yl}methanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with 5-chloro-6-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-lH-indazole. LCMS (ESI): m/z: [M +H] calculated for C21H26CIN6O2: 429.2; found 429.0; ¾ NMR (400 MHz, DMSO-d6) δ ppm 8.44 (s, 1 H) 8.23 (br s, 1 H) 8.13 (s, 1 H) 8.01 (s, 1 H) 7.79 (s, 1 H) 4.59 (s, 2 H) 4.08 - 4.16 (m, 1 H) 3.75 (br d, j=8.38 Hz, 1 H) 3.54 - 3.67 (m, 3 H) 3.03 - 3.19 (m, 3 H) 1.76 - 1.93 (m, 2 H) 1.55 - 1.70 (m, 2 H) 1.14 (d, J=6.39 Hz, 3 H).
Example 15. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (l-methyl-lH-indol-2-yl)pyrazin-2-yl}methanol. (Compound 15)
[00365] { 3 - [(35',4)S)-4-amino-3 -methyl-2-oxa-8-azaspiro[4.5 ] decan- 8-yl] -6-( 1 -methyl- 1 H- indol-2-yl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3-[(3<S,,4<S -4-amino-3- methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin-2- yljmethanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with (l-methyl-lH-indol-2-yl)boronic acid. LCMS (ESI): m/z: [M + H] calcd for C21H26CIN7OS: 408.2; found 408.1. ¾ NMR (500 MHz, Methanol-d4) δ 8.50 (s, 1H), 8.48 (s, 1H), 7.53 (dt, J = 7.9, 1.0 Hz, 1H), 7.39 (dd, J = 8.3, 1.0 Hz, 1H), 7.18 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H), 7.03 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H), 6.80 (d, J = 0.8 Hz, 1H), 4.72 (s, 2H), 4.30 - 4.18 (m, 1H), 4.00 (s, 3H), 3.88 (d, J = 9.0 Hz, 1H), 3.77 (d, J = 8.9 Hz, 1H), 3.65 - 3.52 (m, 2H), 3.29 (d, J = 1.6 Hz, 1H), 3.13 - 2.95 (m, 2H), 1.98 - 1.87 (m, 2H), 1.82 (d, j = 13.5 Hz, 1H), 1.69 (d, j = 13.1 Hz, 1H), 1.25 (d, J = 6.5 Hz, 3H). Example 16. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (8-chloro-3,4-dihydro-2H-l-benzopyran-7-yl)pyrazin-2-yl}methanol (Compound 16)
[00366] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(8-chloro-3,4- dihydro-2H-l-benzopyran-7-yl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l- benzofuran-6-yl)pyrazin-2-yl} methanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with (8-chloro-3,4-dihydro-2H-l-benzopyran-7-yl)boronic acid. LCMS (ESI): m/z: [M + H] calcd for C21H26CIN7OS: 445.2; found 445.4; ¾ NMR (500 MHz,
Methanol-i 4) δ 8.36 (s, 1H), 7.12 - 7.01 (m, 2H), 4.69 (s, 2H), 4.29 - 4.26 (m, 3H), 3.93 (d, J = 9.2 Hz, 1H), 3.82 (d, J= 9.2 Hz, 1H), 3.72 - 3.59 (m, 1H), 3.41 (d, J= 4.1 Hz, 1H), 3.03 (dddd, J= 31.9, 13.5, 11.1, 2.8 Hz, 2H), 2.85 (t, J = 6.5 Hz, 2H), 2.63 (s, 2H), 2.05 - 1.91 (m, 3H), 1.87 (d, J= 13.4 Hz, 1H), 1.75 - 1.67 (m, 1H), 1.28 (d, J = 6.5 Hz, 3H).
Example 17. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (2-chloro-6-fluoro-3-methoxyphenyl)pyrazin-2-yl}methanol. (Compound 17)
[00367] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2-chloro-6- fluoro-3-methoxyphenyl)pyrazin-2-yl}methanol was synthesized in a manner similar to {3- [(3<S,,4<S)-4-amino-3 -methyl-2-oxa-8-azaspiro [4.5] decan- 8-yl] -6-(7-chloro-2,3 -dihydro- 1 - benzofuran-6-yl)pyrazin-2-yl} methanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with (2-chloro-6-fluoro-3-methoxyphenyl)boronic acid. LCMS (ESI): m/z: [M + H] calcd for C21H26CIN7OS: 437.2; found 437.2; ¾ NMR (500 MHz, Methanol-i/4) δ 8.20 (d, J= 0.7 Hz, 1H), 7.23 - 7.18 (m, 2H), 4.74 (s, 2H), 4.35 - 4.26 (m, 1H), 3.97 (d, J= 9.0 Hz, 1H), 3.94 (s, 3H), 3.86 (d, J = 9.1 Hz, 1H), 3.82 - 3.69 (m, 2H), 3.39 (d, J = 4.3 Hz, 1H), 3.22 - 3.05 (m, 2H), 2.07 - 1.96 (m, 2H), 1.90 (d, J= 13.8 Hz, 1H), 1.76 (d, J = 12.5 Hz, 1H), 1.32 (d, J = 6.5 Hz, 3H).
Example 18. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (2,3,6-trichlorophenyl)pyrazin-2-yl}methanol. (Compound 18)
[00368] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3,6- trichlorophenyl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3-[(3<S,,4<S)-4- amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6- yl)pyrazin-2-yl} methanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with (2,3,6-trichlorophenyl)boronic acid. LCMS (ESI): m/z: [M + H] calcd for C20H23CI3N4O2: 457.1 ; found 457.2; ¾ NMR (500 MHz, Methanol-i 4) δ 8.69 - 8.50 (m, 1H), 8.50 (s, 1H), 7.72 (d, J= 2.5 Hz, 1H), 7.70 (d, J= 2.5 Hz, 1H), 4.75 (s, 2H), 4.33 (qd, J= 6.5, 4.2 Hz, 1H), 3.99 (dd, J= 9.1, 0.8 Hz, 1H), 3.88 (dd, J= 9.2, 0.8 Hz, 1H), 3.82 (dtd, J= 13.4, 4.1, 1.6 Hz, 1H), 3.78 - 3.73 (m, 1H), 3.47 (d, J= 4.2 Hz, 1H), 3.16 (ddd, J= 13.8, 11.1, 2.9 Hz, 1H), 3.09 (ddd, J= 13.6, 11.2, 2.7 Hz, 1H), 2.01 (ddd, J= 13.6, 8.4, 3.5 Hz, 2H), 1.95 - 1.89 (m, 1H), 1.82 - 1.71 (m, 1H), 1.35 (d, J = 6.5 Hz, 3H).
Example 19. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (2H-indazol-5-yl)pyrazin-2-yl} methanol. (Compound 19)
[00369] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2H-indazol-5- yl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino-3-methyl- 2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin-2- yljmethanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with (lH-indazol-6-yl)boromc acid. LCMS (ESI): m/z: [M + Η] calcd for C21H26N6O2: 395.2; found 395.4; ¾ NMR (500 MHz, Methanol-i/4) δ 8.67 (s, 1H), 8.47 (dd, J= 1.7, 0.8 Hz, 1H), 8.18 - 8.12 (m, 2H), 7.65 (d, J= 8.8 Hz, 1H), 4.77 (s, 2H), 3.96 (d, J= 9.1 Hz, 1H), 3.85 (d, J= 9.1 Hz, 1H), 3.48 (d, J= 4.1 Hz, 1H), 3.37 (s, 3H), 2.68 (s, OH), 2.00 (s, 1H), 1.34 (d, J= 6.5 Hz, 3H).
Example 20. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (2H-indazol-5-yl)pyrazin-2-yl}methanol (Compound 20)
[00370] {3-[(35',4)S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2H-indazol-5- yl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino-3-methyl- 2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6-yl)pyrazin-2- yljmethanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with m-indazol-6-ylboronic acid. LCMS (ESI): m/z: [M +Η] calculated for C21H27N6O2: 395.2; found 395.4; ¾ NMR (400 MHz, DMSO-i/e) δ ppm 13.20 ( s, 1 H) 8.78 (s, 1 H) 8.21 (s, 1 H) 8.10 (s, 1 H) 7.84 (s, 2 H) 5.39 ( s, 1 H) 4.61 (s, 2 H) 4.12 - 4.06 (m, 1 H) 3.69 (d, J= 8.38 Hz, 1 H) 3.52 (d, J= 8.60 Hz, 2 H) 3.20 - 3.02 (m, 3 H) 2.96 (d, J = 5.29 Hz, 1 H) 1.76 - 1.74 (m, 2 H) 1.68 - 1.52 (m, 2 H) 1.10 (d, J= 6.62 Hz, 3 H). Example 21. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (2,3-dichlorophenyl)pyrazin-2-yl}methanol. (Compound 21)
[00371] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3- dichlorophenyl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3-[(3<S,,4<S -4- amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(7-chloro-2,3-dihydro-l-benzofuran-6- yl)pyrazin-2-yl} methanol except (7-chloro-2,3-dihydro-l-benzofuran-6-yl)boronic acid was substituted with 2,3 dichlorobenzoic acid. LCMS (ESI): m/z: [M +H] calculated for
C20H24CI2N4O2: 423.1 ; found 423.4; ¾ NMR (500 MHz, Methanol- d4) δ 8.55 (s, 1H), 8.44 (d, J = 0.6 Hz, 1H), 7.66 - 7.57 (m, 2H), 7.43 (t, J = 7.9 Hz, 1H), 4.75 (d, J = 0.5 Hz, 2H), 4.31 (qd, J = 6.5, 4.3 Hz, 1H), 3.97 (dd, J = 9.0, 0.8 Hz, 1H), 3.85 (dd, J = 9.0, 0.8 Hz, 1H), 3.73 (ddtd, J = 26.7, 13.4, 4.2, 1.6 Hz, 2H), 3.40 - 3.35 (m, 1H), 3.16 (ddd, J = 13.6, 10.9, 2.9 Hz, 1H), 3.09 (ddd, J = 13.5, 11.0, 2.8 Hz, 2H), 2.68 (s, OH), 2.05 - 1.95 (m, 3H), 1.93 - 1.86 (m, 2H), 1.80 - 1.73 (m, 1H), 1.32 (d, J = 6.5 Hz, 3H).
Example 22. Synthesis of 3-({5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl] -6-(hydroxymethyl)pyrazin-2-yl} sulfanyl)-2-chlorobenzonitrile. (Compound 22)
Figure imgf000137_0001
Step 1
[00372] To a mixture of 3-bromo-2-chloro-benzonitrile (0.5 g, 2.3 mmol) and 2-ethylhexyl 3- sulfanylpropanoate (656 mg, 3.0 mmol) in dioxane (4 mL) was added Xantphos (27 mg, 46 μιηοΐ), DIEA (0.8 ml, 4.6 mmol) and Pd2(dba)3 (11 mg, 12 μηιοΐ). The mixture was stirred at 100 °C for under N2 for 5 hr and then cooled to rt, poured into water (2 mL) and extracted with EtOAc. The combined organic phases were dried over anhydrous Na2S04, filtered and the solvent was removed under reduced pressure. The residue was purified by column chromatography to give 2-ethylhexyl 3-(2-chloro-3-methanimidoyl-phenyl)sulfanylpropanoate (720 mg, 88 % yield) as a brown solid. ¾ NMR (400MHz, METHANOL-d4) δ = 7.69 (dd, J=1.3, 8.2 Hz, 1H), 7.61 (dd, J=1.3, 7.7 Hz, 1H), 7.48 - 7.43 (m, 1H), 4.03 (d, J=5.7 Hz, 2H), 3.33 (s, 2H), 2.72 (t, J=6.8 Hz, 2H), 1.60 - 1.51 (m, 1H), 1.41 - 1.24 (m, 8H), 0.93 - 0.86 (m, 6H)
Step 2
[00373] To a mixture of 2-ethylhexyl 3-(2-chloro-3-cyano-phenyl)sulfanylpropanoate (720 mg, 2.0 mmol) in THF (4 mL) was added i-BuOK (1 M in THF, 3.1 mmol, 3.1 mL) at -78 °C under N2. The mixture was stirred at -78 °C for 1 hr and then concentrated under reduced pressure. The crude residue was purified by column chromatography to give 2-chloro-3- mercaptobenzonitrile (260 mg, 63% yield) as a brown solid. ¾ NMR (400MHz, METHANOL- d4) δ = 7.75 (dd, J=l. l, 7.9 Hz, 1H), 7.56 (dd, J=l. l, 7.7 Hz, 1H), 7.32 (t, J=7.9 Hz, 1H).
Step 3
[00374] To a solution of 2-chloro-3-mercaptobenzonitrile (116 mg, 560 umol) and [3- [(3<S',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-bromo-pyrazin-2-yl]methanol (100 mg, 280 umol) in 1,4-dioxane (2 mL) was added K3P04 (119 mg, 560 umol) 1,10- phenanthroline (10 mg, 56 umol) and Cul (5 mg, 27 umol). The mixture was degassed and then heated to 130 °C for 12 hr. After cooling to rt and filtration, the solvent was removed under reduced pressure. The crude residue was purified by prep-HPLC to give 3-({5-[(3<S,,4<S)-4-amino- 3 -methyl-2-oxa-8-azaspiro [4.5] decan- 8-yl] -6-(hydroxymethyl)pyrazin-2-yl} sulfany l)-2- chlorobenzonitrile (14.3 mg, 32 umol, 11% yield) as a white solid. LCMS (ESI): m/z: [M -H] calculated for C21H23CIN5O2S : 444.1 ; found 444.1; ¾ NMR (400MHz, METHANOL-d4) δ = 8.51 (br s, 1H), 8.20 (s, 1H), 7.72 - 7.69 (m, 1H), 7.50 (dd, J=1.5, 8.1 Hz, 1H), 7.42 - 7.36 (m, 1H), 4.63 (s, 2H), 4.31 - 4.24 (m, 1H), 3.92 (d, J=9.2 Hz, 1H), 3.84 - 3.66 (m, 3H), 3.34 - 3.32 (m, 1H), 3.19 - 3.02 (m, 2H), 1.99 - 1.80 (m, 3H), 1.71 (br d, J=13.2 Hz, 1H), 1.29 (d, J=6.6 Hz, 3H).
Example 23. Synthesis of 4-({5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl] -6-(hydroxymethyl)pyrazin-2-yl} sulfanyl)-3-chloropyridine-2-carbonitrile. (Compound 23) [00375] 4-({5-[(35',4)S -4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (hydroxymethyl)pyrazin-2-yl}sulfanyl)-3-chloropyridine-2-carbonitrile was synthesized in a manner similar to 3-({5-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (hydroxymethyl)pyrazin-2-yl} sulfanyl)-2-chlorobenzonitrile except 2-chloro-3- mercaptobenzonitrile was substituted with 3-chloro-4-sulfanyl-pyridine-2-carbonitrile. LCMS (ESI): m/z: [M +H] calculated for C20H24CIN6O2S: 447.1 ; found 447.2; ¾ NMR (400MHz, METHANOL- d4) δ = 8.48 (br s, 1H), 8.36 (s, 1H), 8.30 (d, J=5.3 Hz, 1H), 7.13 (d, J=5.3 Hz, 1H), 4.68 (s, 2H), 4.34 - 4.21 (m, 1H), 3.98 - 3.93 (m, 1H), 3.87 (br s, 1H), 3.84 (br d, J=8.8 Hz, 1H), 3.36 (br d, J=4.0 Hz, 1H), 3.27 - 3.09 (m, 3H), 2.01 - 1.81 (m, 3H), 1.73 (br d, J=12.8 Hz, 1H), 1.30 (d, J=6.6 Hz, 3H).
Example 24. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- [(3-chloro-2-methoxypyridin-4-yl)sulfanyl]pyrazin-2-yl}methanol. (Compound 24)
[00376] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-[(3-chloro-2- methoxypyridin-4-yl)sulfanyl]pyrazin-2-yl}methanol was synthesized in a manner similar to 3- ({5-[(3<S,,4<S -4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyrazin-2- yl}sulfanyl)-2-chlorobenzonitrile except 2-chloro-3-mercaptobenzonitrile was substituted with 3- chloro-2-methoxy-4-pyndinethiol. LCMS (ESI): m/z: [M +H] calculated for C20H27CIN5O3S: 452.1; found 452.2; ¾ NMR (400MHz, METHANOL-d4) δ = 8.49 (s, 1H), 8.32 (s, 1H), 7.80 (d, J=5.5 Hz, 1H), 6.40 (d, J=5.5 Hz, 1H), 4.67 (s, 2H), 4.32 - 4.25 (m, 1H), 3.99 - 3.93 (m, 4H), 3.91 - 3.78 (m, 3H), 3.38 (d, J=4.2 Hz, 1H), 3.39 - 3.36 (m, 1H), 3.23 - 3.08 (m, 2H), 2.00 - 1.84 (m, 3H), 1.73 (br d, J=12.6 Hz, 1H), 1.30 (d, J=6.4 Hz, 3H).
Example 25. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- [(2-chloro-3-methoxyphenyl)sulfanyl]pyrazin-2-yl}methanol (Compound 25)
[00377] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-[(2-chloro-3- methoxyphenyl)sulfanyl]pyrazin-2-yl}methanol was synthesized in a manner similar to 3-({5- [(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(hydroxymethyl)pyrazin-2- yl}sulfanyl)-2-chlorobenzonitrile except 2-chloro-3-mercaptobenzonitrile was substituted with 2- chloro-3-methoxy-benzenethiol. LCMS (ESI): m/z: [M +H] calculated for C21H28N4SO3CI: 451.1; found 451.2; XH NMR (400MHz, METHANOLS) δ = 8.49 (br s, 1 H), 7.97 (s, 2 H), 7.25 - 7.17 (m, 2 H), 7.04 (dd, J=1.2, 8.3 Hz, 2 H), 6.86 (dd, J=1.3, 7.9 Hz, 2 H), 4.63 (s, 4 H), 4.30 - 4.24 (m, 2 H), 3.95 - 3.88 (m, 8 H), 3.81 (d, J= 9.2 Hz, 2 H), 3.72 - 3.58 (m, 4 H), 3.37 (d, J= 4.2 Hz, 2 H), 3.11 - 2.96 (m, 4 H), 1.98 - 1.82 (m, 6 H), 1.72 - 1.64 (m, 2 H), 1.29 (d, J= 6.5 Hz, 7 H).
Example 26. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- {[3-chloro-2-(3-methanesulfonylazetidin-l-yl)pyridin-4-yl]sulfanyl}pyrazin-2-yl}methanol. (Compound 26)
Figure imgf000140_0001
[00378] Dioxane (1.4 ml) was added to a mixture of {3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-6-bromopyrazin-2-yl}methanol (50 mg, 139 μηιοΐ), 3-chloro-2-(3- methanesulfonylazetidin-l-yl)pyridine-4-thiol (56 mg, 201 μηιοΐ), Xantphos (16 mg, 28 μηιοΐ), tris(dibenzylideneacetone) dipalladium (13 mg, 14 μηιοΐ). DIPEA (48 μΐ^, 278 μηιοΐ) was added. And the heterogeneous mixture was heated to 120 °C under N2 for 1 hr. After cooling to rt and filtration the solvent was removed under reduced pressure and the crude residue was purified by prep HPLC to give {3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- {[3- chloro-2-(3-methanesulfonylazetidin- 1 -yl)pyridin-4-yl] sulfanyl} pyrazin-2-yl} methanol (20.3 mg, 25% yield). LCMS (ESI): m/z [M +H] calculated for C23H32CIN6O4S2: 555.2; found 555.3; ¾ NMR (500 MHz, Methanol-i/4) δ 8.55 (s, 1H), 8.32 (s, 1H), 7.81 (d, J= 5.5 Hz, 1H), 6.24 (d, J= 5.4 Hz, 1H), 4.69 (d, J= 0.4 Hz, 2H), 4.60 - 4.48 (m, 4H), 4.36 - 4.26 (m, 2H), 3.95 (d, J = 8.9 Hz, 1H), 3.91 - 3.77 (m, 3H), 3.32 (d, J= 4.5 Hz, 1H), 3.23 (ddd, J= 13.7, 10.8, 3.1 Hz, 1H), 3.15 (ddd, J= 13.6, 10.9, 2.8 Hz, 1H), 3.03 (s, 3H), 2.01 - 1.91 (m, 2H), 1.90 - 1.83 (m, 1H), 1.78 - 1.70 (m, 1H), 1.31 (d, J= 6.5 Hz, 3H).
Example 27. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- ({3-chloro-2-[(oxan-4-yl)amino]pyridin-4-yl}sulfanyl)pyrazin-2-yl}methanol. (Compound
27)
[00379] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-({3-chloro-2- [(oxan-4-yl)amino]pyridin-4-yl}sulfanyl)pyrazin-2-yl} methanol was synthesized in a manner similar to {3 - [(3<S,,4<S)-4-amino-3 -methyl-2-oxa- 8-azaspiro[4.5 ] decan- 8-y 1] -6- { [3 -chloro-2-(3 - methanesulfonylazetidin- 1 -y l)pyridin-4-yl] sulfany 1 } pyrazin-2-yl } methanol except 3 -chloro-2-(3 - methanesulfonylazetidin- 1 -yl)pyridine-4-thiol was substituted with 3-chloro-2-[(tetrahydro-2H- pyran-4-yl)amino]-4-pyndinethiol. LCMS (ESI): m/z [M +H] calculated for C24H33CIN6O3S: 521.2; found 521.4; ¾ NMR (500 MHz, Methanol- d4) δ 8.56 (s, OH), 8.30 (s, 1H), 7.72 (d, J = 5.5 Hz, 1H), 6.05 (d, J = 5.6 Hz, 1H), 4.69 (s, 2H), 4.32 - 4.25 (m, 1H), 4.13 (tt, J = 11.0, 4.2 Hz, 1H), 4.04 - 3.97 (m, 2H), 3.92 (d, J = 8.8 Hz, 1H), 3.85 - 3.72 (m, 3H), 3.56 (td, J = 11.8, 2.1 Hz, 2H), 3.29 - 3.12 (m, 4H), 2.01 - 1.89 (m, 4H), 1.82 (d, J = 13.4 Hz, 1H), 1.78 - 1.71 (m, 1H), 1.71 - 1.61 (m, 2H), 1.28 (d, J = 6.5 Hz, 3H).
Example 28. Synthesis of 3-({5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl]-6-(hydroxymethyl)pyrazin-2-yl}sulfanyl)-2-chloro-N,N-dimethylbenzamide.
(Compound 28)
[00380] 3-({5-[(35',4)S -4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- (hydroxymethyl)pyrazin-2-yl}sulfanyl)-2-chloro-N,N-dimethylbenzamide was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-{[3-chloro- 2-(3 -methanesulfonylazetidin- 1 -yl)pyridin-4-y 1] sulfany 1} pyrazin-2-yl } methanol except 3 -chloro-
2- (3 -methanesulfonylazetidin- 1 -yl)pyridine-4-thiol was substituted with 2-chloro-N,N-dimethyl-
3- sulfanylbenzamide. LCMS (ESI): m/z [M +H] calculated for C23H30CIN5O3S: 492.2; found 492.3; ¾ NMR (500 MHz, Methanol-d4) δ 8.45 (s, 1H), 8.13 (s, 1H), 7.43 - 7.34 (m, 2H), 7.30 (dd, J = 6.9, 2.3 Hz, 1H), 4.65 (s, 2H), 4.31 (qd, J = 6.5, 4.1 Hz, 1H), 3.96 (d, J = 9.1 Hz, 1H), 3.90 - 3.81 (m, 1H), 3.76 (d, J = 13.6 Hz, 1H), 3.72 - 3.65 (m, 1H), 3.44 (d, J = 4.2 Hz, 1H), 3.14 (s, 3H), 3.12 - 3.01 (m, 1H), 2.91 (s, 3H), 1.97 (td, J = 12.2, 11.3, 4.0 Hz, 2H), 1.89 (d, J = 13.5 Hz, 1H), 1.78 - 1.69 (m, 1H), 1.33 (d, J= 6.5 Hz, 3H).
Example 29. Synthesis of l-[4-({5-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl] -6-(hydroxymethyl)pyrazin-2-yl} sulfanyl)-3-chloropyridin-2-yl] azetidin-3-ol.
(Compound 29)
[00381] ^^-({S-tiS^^^^-amino-S-methyl^-oxa-S-azaspiro^^ldecan-S-yll-e- (hydroxymethyl)pyrazin-2-yl}sulfanyl)-3-chloropyridin-2-yl]azetidin-3-ol was synthesized in a manner similar to {3-[(3<S,,4<S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-{[3-chloro- 2-(3 -methanesulfonylazetidin- 1 -yl)pyridin-4-y 1] sulfany 1} pyrazin-2-yl } methanol except 3 -chloro- 2-(3 -methanesulfonylazetidin- 1 -yl)pyridine-4-thiol was substituted with l-(2-chloro-3- sulfanylphenyl)azetidin-3-ol. LCMS (ESI): m/z [M +H] calculated for C22H30CIN6O3S: 493.2; found 493.3; ¾ NMR (500 MHz, Methanol-i/4) δ 8.31 (s, 1H), 7.75 (d, J= 5.5 Hz, 1H), 6.15 (d, J= 5.5 Hz, 1H), 4.69 (s, 2H), 4.62 (tt, J= 6.6, 4.7 Hz, 1H), 4.52 - 4.46 (m, 2H), 4.32 - 4.24 (m, 1H), 4.01 (ddd, J= 9.1, 4.7, 1.2 Hz, 2H), 3.92 (d, J= 8.8 Hz, 1H), 3.84 - 3.73 (m, 3H), 3.26 (ddd, J= 13.5, 10.5, 3.1 Hz, 1H), 3.21 - 3.14 (m, 2H), 1.94 (dddd, J= 20.4, 14.0, 10.5, 3.8 Hz, 2H), 1.85 - 1.78 (m, 1H), 1.77 - 1.70 (m, 1H), 1.27 (d, J= 6.5 Hz, 3H).
Example 30. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- [(2,3-dichlorophenyl)sulfanyl]pyrazin-2-yl}methanol. (Compound 30)
[00382] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-[(2,3- dichlorophenyl)sulfanyl]pyrazin-2-yl} methanol was synthesized in a manner similar to {3- [(3<S',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-{[3-chloro-2-(3- methanesulfonylazetidin- 1 -y l)pyridin-4-yl] sulfanyl } pyrazin-2-yl } methanol except 3 -chloro-2-(3 - methanesulfonylazetidin-l-yl)pyridine-4-thiol was substituted with 2,3-dichlorobenzenethiol. LCMS (ESI): m/z [M +H] calculated for C20H24CI2N4O2S: 455.1; found 455.3; ¾ NMR (500 MHz, Methanol-d4) δ 8.49 (s, 1H), 8.12 (d, J = 0.5 Hz, 1H), 7.45 (ddd, J = 7.9, 1.6, 0.5 Hz, 1H), 7.21 (td, J = 7.9, 0.5 Hz, 1H), 7.15 (ddd, J = 8.0, 1.6, 0.5 Hz, 1H), 4.64 (d, J = 0.5 Hz, 2H), 4.28 (qd, J = 6.5, 4.2 Hz, 1H), 3.94 (d, J = 9.1 Hz, 1H), 3.83 (dd, J = 9.1, 0.8 Hz, 1H), 3.79 - 3.64 (m, 2H), 3.41 (d, J = 4.2 Hz, 1H), 3.10 (ddd, J = 13.8, 11.1, 2.9 Hz, 1H), 3.03 (ddd, J = 13.7, 11.2, 2.7 Hz, 1H), 2.66 (d, J = 0.5 Hz, 3H), 1.95 (ddt, J= 15.1, 11.1, 4.0 Hz, 2H), 1.86 (ddt, J = 13.3, 4.7, 2.7 Hz, 1H), 1.72 (dt, J = 12.8, 2.3 Hz, 1H), 1.31 (d, J = 6.5 Hz, 3H).
Example 31. Synthesis of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3- methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrazin-2-yl}methanol. (Compound 31)
[00383] {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3,S',4)S -4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]pyrazin-2-yl} methanol was synthesized in a manner similar to {3- [(3<S',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-{[3-chloro-2-(3- methanesulfonylazetidin- 1 -yl)pyridin-4-yl] sulfanyl } pyrazin-2-yl } methanol except 3 -chloro-2-(3 - methanesulfonylazetidin-l-yl)pyridine-4-thiol was substituted with 2-amino-3-chloro-4- pyndinethiol. LCMS (ESI): m/z [M +H] calculated for C19H25CIN6O2S: 437.1; found 437.4; ¾ NMR (500 MHz, Methanol-d4) δ 8.50 (s, 2H), 8.31 (d, J = 2.1 Hz, 1H), 7.62 (dd, J = 5.7, 2.1 Hz, 1H), 6.07 (dd, J = 5.7, 2.1 Hz, 1H), 4.68 (d, J = 2.1 Hz, 2H), 4.33 - 4.26 (m, 1H), 3.96 (d, J = 9.3 Hz, 1H), 3.91 - 3.77 (m, 4H), 3.40 - 3.34 (m, 1H), 3.24 - 3.09 (m, 2H), 1.95 (d, J = 12.5 Hz, 2H), 1.88 (d, J = 13.3 Hz, 1H), 1.74 (d, J = 13.2 Hz, 1H), 1.31 (dd, J = 6.5, 2.1 Hz, 3H).
Example 32. Synthesis of {3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6- [(2-amino-5-chloropyridin-4-yl)sulfanyl] pyrazin-2-yl} methanol. (Compound 32)
[00384] {3-[(35',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-[(2-amino-5- chloropyridin-4-yl)sulfanyl]pyrazin-2-yl} methanol was synthesized in a manner similar to {3- [(3<S',4)S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-{[3-chloro-2-(3- methanesulfonylazetidin- 1 -y l)pyridin-4-yl] sulfanyl } pyrazin-2-yl } methanol except 3 -chloro-2-(3 - methanesulfonylazetidin-l-yl)pyridine-4-thiol was substituted with 2-amino-5-chloro-4- pyndinethiol. LCMS (ESI): m/z [M +H] calculated for C19H25CIN6O2S : 437.1; found 437.5; ¾ NMR (500 MHz, Methanol-d4) δ 8.39 (s, 1H), 8.33 (s, 1H), 7.81 (s, 1H), 6.07 (s, 1H), 4.71 (s, 2H), 4.42 - 4.26 (m, 1H), 3.98 (d, J = 9.1 Hz, 1H), 3.94 - 3.76 (m, 3H), 3.46 (d, J = 4.1 Hz, 1H), 3.21 - 3.08 (m, 2H), 2.07 - 1.86 (m, 3H), 1.80 - 1.61 (m, 1H), 1.34 (d, J = 6.5 Hz, 3H).
Example 33. Synthesis of [2-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-5-[(3S,4S)-4-amino-3- methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrimidin-4-yl] methanol.
Figure imgf000143_0001
Step 1
[00385] To a solution of 2,4-dichloro-5-fluoro-pyrimidine (5 g, 30 mmol) in 1,4-dioxane (70 mL) was added tributyl(l-ethoxyvinyl)tin (9.73 g, 30 mmol, 9.10 mL), LiCl (3.8 g, 90 mmol, 1.84 mL) and Pd(PPh3)4 (1.73 g, 1.5 mmol). The mixture was stirred at 85 °C for 1.5 hrs. The reaction mixture was concentrated under reduced pressure and the resulting residue was purified by column chromatography to afford 2-chloro-4-(l-ethoxyvinyl)-5-fluoro-pyrimidine (3.9 g, 19.2 mmol, 64 % yield) as a white solid. ¾ NMR (400MHz, Chloroform-d) δ = 8.47 (d, J=2.9 Hz, 1H), 5.31 (d, J=3.1 Hz, 1H), 4.72 (d, J=2.9 Hz, 1H), 3.96 (q, J=7.0 Hz, 2H), 1.43 (t, J=6.9 Hz, 3H).
Step 2
[00386] To a solution of 2-chloro-4-(l -ethoxyvinyl)-5-fluoro-pyrimidine (3.7 g, 18.4 mmol) in 1,4-dioxane (260 rriL) was added a solution of NaI04 (7.90 g, 37 mmol) in H2O (130 rriL). Solid KMn04 (438 mg, 2.77 mmol) was then added to this solution. The mixture was stirred at 25 °C for 1 hr. The reaction mixture was filtered and the resulting filtrate was diluted with EtOAc (50 mL), aqueous sodium bicarbonate (30 rriL) and aqueous NaCl (30 rriL). The resulting mixture was stirred for 5 min. The aqueous layer was extracted with EtOAc (50 mL x 2) and the combined organic layers were dried over sodium sulfate, filtrated and concentrated under reduced pressure. The resulting residue was purified by column chromatography to afford ethyl 2-chloro-5-fluoro-pyrimidine-4-carboxylate (2.7 g, 13 mmol, 72 % yield) as a colorless oil. XH NMR (400MHz, Chloroform-d) δ = 8.70 (d, J=1.8 Hz, 1H), 4.51 (q, J=7.2 Hz, 2H), 1.44 (t, J=7.2 Hz, 3H).
Step 3
[00387] To a solution of ethyl 2-chloro-5-fluoro-pyrimidine-4-carboxylate (547 mg, 2.7 mmol) and (3<S,,4<S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (650 mg, 2.7 mmol) in i- PrOH (10 mL) was added DIPEA (6.91 g, 53.5 mmol, 9.3 mL). The mixture was stirred at 0 °C for 12 hrs. The reaction mixture was used for next step without purification. LCMS (ESI): m/z: [M +H] calculated for Ci6H24ClN403: 355.2; found 355.1.
Step 4
[00388] To a solution of ethyl 5-[(3<S,,4<S -4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8- yl]-2-chloro-pyrimidine-4-carboxylate (949 mg, 2.7 mmol) in i-PrOH (5 mL) was added B0C2O (2.92 g, 13.4 mmol, 3.1 mL) and DIPEA (6.9 g, 53.5 mmol, 9.3 mL). The mixture was stirred at 0 °C for 1 hr. The reaction mixture was concentrated under reduced pressure and the resulting residue was purified by prep-HPLC to afford ethyl 5-[(3<S,,4<S)-4-(/er/-butoxycarbonylamino)-3- methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-2-chloro-pyrimidine-4-carboxylate (600 mg, 1.3 mmol, 49 % yield) as a yellow solid. LCMS (ESI): m/z: [M +H] calculated for C21H32CIN4O5: 455.20; found 455.4.
Step 5
[00389] To a solution of 2-amino-3-chloro-pyridine-4-thiol (159 mg, 0.99 mmol) and ethyl 5- [(3<S,,4<S)-4-(/er/-butoxycarbonylamino)-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-2-chloro- pyrimidine-4-carboxylate (300 mg, 659 umol) in 1,4-dioxane (5 mL) was added 1,10- Phenanthroline (24 mg, 132 umol), Cul (13 mg, 66 umol) and K3PO4 (420 mg, 2 mmol) under N2. The mixture was stirred at 130 °C for 3 hrs. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting residue was purified by prep-HPLC to afford ethyl 2-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-5-[(3<S',4)S -4-(/er/-butoxycarbonylamino)- 3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrimidine-4-carboxylate (180 mg, 311 umol, 47 % yield) as a yellow oil. LCMS (ESI): m/z: [M +H] calculated for C26H36CIN6O5S: 579.2; found 579.3.
Step 6
[00390] To a solution of ethyl 2-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-5-[(3,S',4)S)-4-(tert- butoxycarbonylamino)-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]pyrimidine-4-carboxylate (80 mg, 138 umol) in THF (1 mL) was added DIBAL-H (1 M in toluene, 414.43 uL). The mixture was stirred at -78 °C for 1 hr, and NaBH4 (26 mg, 691 umol) in MeOH (1 mL) was then added to the reaction mixture. The reaction mixture was stirred at 25 °C for 1 hr. The mixture was quenched by the addition of H2O (2 mL). The mixture was filtered and the resulting filtrate was concentrated under reduced pressure. The remaining residue was purified by prep-HPLC to afford feri-butyl N-[(35',4)S)-8-[2-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-4- (hydroxymethyl)pyrimidin-5-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (40 mg, 75 umol, 54 % yield) as a white solid. LCMS (ESI): m/z: [M +H] calculated for C24H34CIN6O4S: 537.2; found 537.3.
Step 7
[00391] A solution of feri-butyl N-[(35',4)S)-8-[2-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-4- (hydroxymethyl)pyrimidin-5-yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-yl]carbamate (27 mg, 50 umol) in HCl/MeOH (4M, 10 niL) was stirred at 0 °C for 3 hr. The reaction mixture was concentrated under reduced pressure. The resulting residue was purified by prep-HPLC to afford [2-[(2-amino-3-chloro-4-pyridyl)sulfanyl]-5-[(3)S',4)S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]pyrimidin-4-yl]methanol (2 mg, 4.6 umol, 9 % yield) as a white solid. ¾ NMR (400MHz, Methanol-d4) δ = 8.55 (d, J=19.8 Hz, 1H), 8.35 (s, 1H), 7.83 (d, J=5.4 Hz, 1H), 6.93 (d, J=5.4 Hz, 1H), 4.68 (s, 2H), 4.33 - 4.22 (m, 1H), 3.92 (d, J=9.2 Hz, 1H), 3.81 (d, J=9.2 Hz, 1H), 3.40 (d, J=4.2 Hz, 1H), 3.23 - 3.05 (m, 2H), 2.96 - 2.77 (m, 2H), 2.04 - 1.83 (m, 3H), 1.73 (d, J=12.7 Hz, 1H), 1.30 (d, J=6.5 Hz, 3H). LCMS (ESI): m/z: [M +H] calculated for C19H26CIN6O2S: 437.1 ; found 437.1.
Example 34. Synthesis of (li?)-8-[5-(2,3-dichlorophenyl)-3-(difluoromethyl)pyrazin-2-yl]-8- azaspiro[4.5]decan-l-amine
Figure imgf000146_0001
Step 1.
[00392] To a solution of methyl 3,6-dibromopyrazine-2-carboxylate (583 mg, 1.97 mmol), and (2,3-dichlorophenyl)boronic acid (375 mg, 1.97 mmol) in dioxane (40 ml) was added CS2CO3 (1.93 g, 5.91 mmol) in H2O (10 mL) and PdCkdppf (144 mg, 0.2 mmol). The reaction was refluxed for 20 min, allowed to cool to rt, and extracted with EtOAc. The combined organic layers were washed with brine and dried over MgS04. The mixture was concentrated under reduced pressure. Purification by flash chromatography resulted in 370 mg (52%) of the desired product. ¾ NMR (500 MHz, CDCh) δ 8.58 - 8.53 (m, 1H), 7.38 - 7.32 (m, 1H), 7.29 - 7.22 (m, 1H), 7.14 - 7.08 (m, 1H), 3.82 - 3.76 (m, 3H).
Step 2. [00393] To a solution of methyl 3-bromo-6-(2,3-dichlorophenyl)pyrazine-2-carboxylate (270 mg, 0.75 mmol) in THF (5 mL) at -78 °C was added DIBAL-H (2.23 mL, 1 M, 2.23 mmol). The reaction was warmed to rt and stirred for 2 h. The reaction mixture cooled back to 0 °C and quenched with methanol and Rochelle's salt. Extraction with EtOAc, followed by drying over MgS04 gave (3-bromo-6-(2,3-dichlorophenyl)pyrazin-2-yl)methanol (108 mg, 43%) which was used without further purification in the next step.
Step 3.
[00394] To a solution of (3-bromo-6-(2,3-dichlorophenyl)pyrazin-2-yl)methanol (224 mg, 0.67 mmol) in CH2CI2 (5 mL) was added the Dess-Martin reagent (222 mg, 1.0 mmol). The reaction was stirred at rt for 1 h and quenched by addition of aqueous NaHSC . The mixture was extracted with EtOAc, organic layer was concentrated under reduced pressure, and the combined organic fractions were dried over MgS04. The resulting solution was filtered through a pad of silica gel to give 3-bromo-6-(2,3-dichlorophenyl)pyrazine-2-carbaldehyde (158 mg, 71%).
Step 4.
[00395] To a solution of 3-bromo-6-(2,3-dichlorophenyl)pyrazine-2-carbaldehyde (70 mg, 0.21 mmol) in CH2CI2 (5 mL) was added DAST (101 mg, 0.63 mmol). The reaction was stirred at rt for 1 h, concentrated under reduced pressure, and the resulting residue was purified by filtration through a plug of silica to give the desired 2-bromo-5-(2,3-dichlorophenyl)-3- (difluoromethyl)pyrazine (53 mg, 76%).
Step 5.
[00396] To a solution of 2-bromo-5-(2,3-dichlorophenyl)-3-(difluoromethyl)pyrazine (50 mg, 0.14 mmol) in DMA (5 mL) was added (5)-2-methyl-N-((i?)-8-azaspiro[4.5]decan-l-yl)propane- 2-sulfinamide (72.8 mg, 0.28 mmol) and DIPEA (1 mL). The resulting solution was stirred under microwave conditions at 120 °C for 2 h. After cooling to rt the solvent was removed under reduced pressure and the crude residue was purified by flash chromatography to give (S)-N-((R)- 8-(5 -(2,3 -dichlorophenyl)-3 -(difluoromethyl)pyrazin-2-y 1)- 8-azaspiro [4.5] decan- 1 -yl)-2- methylpropane-2-sulfinamide (44 mg, 59%).
Step 6. [00397] To a solution of (5)-N-((i?)-8-(5-(2,3-dichlorophenyl)-3-(difluoromethyl)pyrazin-2- yl)-8-azaspiro[4.5]decan-l-yl)-2-methylpropane-2-sulfinamide (35 mg, 0.066 mmol) in methanol (5 mL) was added 1 mL of HC1 in dioxane. The resulting solution was stirred at rt for 10 min. After removal of all volatiles under reduced pressure the crude residue was purified by prep- HPLC to give (li?)-8-[5-(2,3-dichlorophenyl)-3-(difluoromethyl)pyrazin-2-yl]-8- azaspiro[4.5]decan-l-amineas the formic acid salt (22 mg, 70%). 1H NMR (500 MHz,
Methanol-d4) δ 8.82 (t, J = 4.3 Hz, 1H), 8.06 - 7.50 (m, 3H), 7.44 - 6.82 (m, 1H), 4.36 - 3.70 (m, 5H), 2.79 - 1.06 (m, 10H). LC-MS (ESI): m/z [M + H] C20H22CI2F2N4 calculated 427.1; found 427.3.
Example 35. Synthesis of (3S,4S)-8-[5-(2,3-dichlorophenyl)-3-(difluoromethyl)pyrazin-2- yl]-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine
Figure imgf000148_0001
[00398] To a solution of 2-bromo-5-(2,3-dichlorophenyl)-3-(difluoromethyl)pyrazine (123 mg, 0.347 mmol, Example 34) in DMA (5 mL) was added (li?,2i?)-2-methyl-8-azaspiro[4.5]decan-l- amine hydrochloride (168 mg, 0.694 mmol) and DIPEA (1 mL). The resulting solution was stirred under microwave conditions at 120 °C for 2 h. After cooling to rt the resulting mixture was concentrated under reduced pressure and the residue was purified by prep-HPLC to provide (3<S',4)S)-8-[5-(2,3-dichlorophenyl)-3-(difluoromethyl)pyrazin-2-yl]-3-methyl-2-oxa-8- azaspiro[4.5]decan-4-amine as the formate salt (30 mg, 18%). ¾ NMR (500 MHz, Methanol-i/4) 8.63 (s, 1H), 7.65-7.42 (m, 3H), 6.93 (t, J = 50 Hz, 1H, CF2H), 4.34 (m, 1H), 4.02-3.19 (m, 7H), 2.68-1.94 (4H), 1.36 (d, J= 5.0 Hz, 3H); LC-MS (ESI): m/z [M + H] C20H22CI2F2N4O calculated 443.1; found 443.3.
Biological Examples - SHP2 Allosteric Inhibition Assay
[00399] Without wishing to be bound by theory, SHP is allosterically activated through binding of bis-tyrosyl-phosphorylated peptides to its Src Homology 2 (SH2) domains. The latter activation step leads to the release of the auto-inhibitory interface of SHP2, which in turn renders the SHP2 protein tyrosine phosphatase (PTP) active and available for substrate recognition and reaction catalysis. The catalytic activity of SHP2 was monitored using the surrogate substrate DiFMUP in a prompt fluorescence assay format.
[00400] The phosphatase reactions were performed at room temperature in 96-well black polystyrene plate, flat bottom, non-binding surface (Corning, Cat # 3650) using a final reaction volume of 100 μL· and the following assay buffer conditions: 50 mM HEPES, pH 7.2, 100 mM NaCl, 0.5 mM EDTA, 0.05% P-20, 1 mM DTT.
[00401] The inhibition of SHP2 by compounds of the present disclosure (concentrations varying from 0.00005-10 μΜ) was monitored using an assay in which 0.2 nM of SHP2 was incubated with 0.5 μΜ of Activating Peptide 1 (sequence: H2N-
LN(pY)IDLDLV(dPEG8)LST(pY)ASINFQK-amide) or Activating Peptide 2 (sequence: H2N- LN(pY)AQLWHA(dPEG8)LTI(pY)ATIRRF-amide). After 30-60- minutes incubation at 25 °C, the surrogate substrate DiFMUP (Invitrogen, Cat # D6567) was added to the reaction and activity was determined by a kinetic read using a microplate reader (Envision, Perkin-Elmer or Spectramax M5, Molecular Devices). The excitation and emission wavelengths were 340 nm and 450 nm, respectively. Initial rates were determined from a linear fit of the data, and the inhibitor dose response curves were analyzed using normalized IC50 regression curve fitting with control based normalization.
[00402] Using the above- protocol, SHP2 inhibition measured as set forth in Table 1.
Table- 1 : SHP2 Inhibition of Tested Compounds
Figure imgf000149_0001
[00403] Using the above-protocol, SHP2 inhibition measured as set forth in Table 2. In the table below: "+++" refers to <=50nM; "++' refers to >50nM to <=500nM; and "+" refers to >500nM. Table-2: SHP2 Inhibition of Tested Compounds
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
[00404] In some embodiments, compounds of the disclosure tested in the assay described above demonstrated an activity of less than 1000 nM. In some embodiments, compounds of the disclosure tested in the assay described above demonstrated an activity of about 10 nM to about 100 nM. In some embodiments, compounds of the disclosure tested in the assay described above demonstrated an activity of 10 nM to 100 nM. In some embodiments, compounds of the disclosure tested in the assay described above demonstrated an activity of less than 10 nM.
[00405] One or more disclosed compounds or compositions can be administered in effective amounts to treat or prevent a disorder and/or prevent the development thereof in subjects. In some embodiments, SHP2 is inhibited after treatment with less than 1000 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with about 1 nM to about 10 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with about 10 nM to about 100 nM of a compound of the disclosure. In some embodiments, SHP2 is inhibited after treatment with about 100 nM to about 10 μΜ of a compound of the disclosure.
Equivalents
[00406] While the present disclosure has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present disclosure.

Claims

CLAIMS:
1. A compound of Formula IV:
Figure imgf000157_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -C3-C8cycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -Nth, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH,
-NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, Cs-Cscycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
2. A compound of the Formula V:
Figure imgf000159_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3-to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, Cs-Cscycloalkyl, -(CH2)n-R , or -(CH2)nC(0)NR5R6, wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-C6alkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR ,
-0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo;
R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
3. A compound of the Formula VI:
Figure imgf000161_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond,
A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, -NR5C(0)R6, or 3-to 12- membered monocyclic or polycyclic heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl or heterocycle is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or spiroheterocycle is optionally substituted with one or more -Ci-Cealkyl, halogen, -OH, -OR , -NH2, -NHR , optionally substituted heteroaryl, optionally substituted heterocyclyl,
-(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -0-C(0)-NR5R6, -CF3, -CHF2, -CH2F, or =0; wherein the heteroaryl and heterocyclyl are optionally substituted with -CN;
R4 is-Ci-C6alkyl, wherein each alkyl is optionally substituted with one or more -OH, -NH2, halogen, or oxo; R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
4. A compound of the Formula I:
Figure imgf000162_0001
or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, wherein:
X1 is N or CH;
X2 is N or CH;
X3 is N or CH;
wherein at least one of X1, X2, or X3 is N;
Y1 is -S- or a direct bond, A is selected from the group consisting of 5- to 12-membered monocyclic or poly cyclic cycloalkyl, monocyclic or polycyclic heterocycloalkyl, monocyclic or polycyclic aryl, or monocyclic or polycyclic heteroaryl;
R1 is independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4- Cscycloalkenyl, -C2-C6alkynyl, -Cs-Cscycloalkyl, -OH, -OR6, halogen, -NO2, -CN, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, -C(0)R5, -CO2R5, -C(0)NR5R6, or -NR5C(0)R6, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, or cycloalkyl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5,
-NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5, -NR5S(0)NR5R6, -NR5S(0)R6, heterocycle, aryl, or heteroaryl;
R2 and R3 are independently selected from the group consisting of -H, -D, -OH, -Ci- C6alkyl, a 3 -to 12-membered monocyclic or polycyclic heterocycle, a 5- to 12-membered spiroheterocycle, C3-Cscycloalkyl, or -(CH2)n-R , wherein each alkyl, heterocycle, or cycloalkyl is optionally substituted with one or more -Ci-Cealkyl, -OH, -NH2, -OR , -NHR , -(CH2)nOH, heterocyclyl, or spiroheterocyclyl; or
R3 can combine with R2 to form a 3- to 12-membered monocyclic or polycyclic heterocycle, or a 5- to 12-membered spiroheterocycle, wherein each heterocycle or
spiroheterocycle is optionally substituted with one or more -Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0;
R4 is-H, -D, -Ci-Cealkyl, -Ci-Cehaloalkyl, -Ci-Cehydroxyalkyl -CF2OH, -CHFOH, -NH-NHR5, -NH-OR5, -0-NR5R6, -NHR5, -OR5, -NHC(0)R5, -NHC(0)NHR5, -NHS(0)2R5, -NHS(0)2NHR5, -S(0)2OH, -C(0)OR5, -NH(CH2)nOH, -C(0)NH(CH2)nOH,
-C(0)NH(CH2)nR , -C(0)R , -NH2, -OH, -CN, -C(0)NR5R6, -S(0)2NR5R6, C3-C8cycloalkyl, aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, or heteroaryl containing 1-5 heteroatoms selected from the group consisting of N, S, P, and O, wherein each alkyl, cycloalkyl, or heterocyclyl is optionally substituted with one or more -OH, -NH2, -OR , halogen, or oxo; wherein each aryl or heteroaryl is optionally substituted with one or more -OH, -NH2, or halogen; R5 and R6 are each independently, at each occurrence, selected from the group consisting of -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -Ci-Cscycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or poly cyclic 3 -to 12-membered heterocycle, -OR7, -SR7, halogen, -NR7R8, -NO2, and -CN;
R7 and R8 are independently, at each occurrence, -H, -D, -Ci-C6alkyl, -C2-C6alkenyl, -C4-C8cycloalkenyl, -C2-C6alkynyl, -C3-Cscycloalkyl, a monocyclic or polycyclic 3-to 12- membered heterocycle, wherein each alkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkyl, or heterocycle is optionally substituted with one or more -OH, -SH, -NH2, -NO2, or -CN;
R is independently -H, -D,-Ci-C6alkyl, -Ci-C6cycloalkyl, -C2-C6alkenyl, -(CH2)n-aryl, heterocyclyl containing 1-5 heteroatoms selected from the group consisting of N, S, P, or O, or heteroaryl containing 1 -5 heteroatoms selected from the group consisting of N, S, P, and O; wherein each alkyl, cycloalkyl, alkenyl, heterocycle, heteroaryl, or -(CH2)n-aryl is optionally substituted with one or more -OH, halogen, -NO2, oxo, -CN, -R5, -OR5, -NR5R6, -SR5, -S(0)2NR5R6, -S(0)2R5, -NR5S(0)2NR5R6, -NR5S(0)2R6, -S(0)NR5R6, -S(0)R5,
-NR5S(0)NR5R6, -NR5S(0)R6, -C(0)NR5R6-, - NR5R6C(0)-, heterocycle, aryl, heteroaryl, -(CH2)nOH, -Ci-Cealkyl, CF3, CHF2, or CH2F; and
n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
5. The compound of any one of claims 1 -4, wherein X1 is N.
6. The compound of any one of claims 1 -4, wherein X1 is CH.
7. The compound of any one of claims 1 -6, wherein X2 is N.
8. The compound of any one of claims 1 -6, wherein X2 is CH.
9. The compound of any one of claims 1 -8, wherein X3 is N.
10. The compound of any one of claims 1 -8, wherein X3 is CH.
11. The compound of any one of claims 1 -10, wherein A is monocyclic or polycyclic aryl.
12. The compound of any one of claims 1 -10, wherein A is monocyclic or polycyclic cycloalkyl.
13. The compound of any one of claims 1-10, wherein A is monocyclic or poly cyclic heterocycloalkyl.
14. The compound of any one of claims 1-10, wherein A is monocyclic or poly cyclic heteroaryl.
15. The compound of any one of claims 1-14, wherein each R1 is selected from the group consisting of -H, halogen, -Ci-C6alkyl, and -NR5R6.
16. The compound of claim 15, wherein R5 and R6 are H.
17. The compound of any one of claims 1-16, wherein R4 is an optionally substituted -Ci- Cealkyl.
18. The compound of any one of claims 1-17, wherein R4 is-CH2-OH
19. The compound of any one of claims 1-17, wherein R4 is -Ci-C6alkyl substituted with one or more halogen.
20. The compound of any one of claims 1-19, wherein R3 can combine with R2 to form 3 -to 12-membered monocyclic or poly cyclic heterocycle, wherein the heterocycle is optionally substituted with-Ci-C6alkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
21. The compound of claim 20, wherein the heterocycle is unsubstituted or substituted with -Ci-Cealkyl, -OR , or -NH2.
22. The compound of any one of claims 1-19, wherein R3 can combine with R2 to form a 5 -to 12-membered spiroheterocycle, wherein the spiroheterocycle is optionally substituted with-Ci- Cealkyl, halogen, -OH, -OR , -NH2, -NHR , heteroaryl, heterocyclyl, -(CH2)nNH2, -(CH2)nOH, -COOR , -CONHR , -CONH(CH2)nCOOR , -NHCOOR , -CF3, -CHF2, -CH2F, or =0.
23. The compound of claim 22, wherein the spirocycle is unsubstituted or substituted with -Ci-Cealkyl, -OR , or -NH2.
24. The compound of any one of claims 1-19, wherein R3 combine with R2 to form a moiety selected from:
Figure imgf000166_0001
, 1 , and
25. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000166_0002
26. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000166_0003
(5) and (5a).
27. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
28. A compound, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, selected from the group consisting of
Figure imgf000169_0002
29. A pharmaceutical composition comprising a compound of any one of claims 1-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, and a pharmaceutically acceptable carrier.
30. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof.
31. The method of claim 30, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
32. A compound of any one of claims 1-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use as a medicament.
33. A compound of any one of claims 1-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, for use in treating or preventing a disease associated with SHP2 modulation.
34. Use of a compound of any one of claims 1-28, or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, tautomer, or isomer thereof, in the manufacture of a medicament for treating or preventing a disease associated with SHP2 modulation.
35. A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition of claim 29.
36. The method of claim 35, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
37. A pharmaceutical composition of claim 29 for use as a medicament.
38. A pharmaceutical composition of claim 29 for use in treating or preventing a disease associated with SHP2 modulation.
Use of a pharmaceutical composition of claim 29 in the manufacture of a medicament for g or preventing a disease associated with SHP2 modulation.
PCT/US2018/055502 2017-10-12 2018-10-11 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors WO2019075265A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CN201880066291.0A CN111212834B (en) 2017-10-12 2018-10-11 Pyridine, pyrazine and triazine compounds as allosteric SHP2 inhibitors
AU2018347516A AU2018347516A1 (en) 2017-10-12 2018-10-11 Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
JP2020519790A JP2020536881A (en) 2017-10-12 2018-10-11 Pyridine, pyrazine and triazine compounds as allosteric SHP2 inhibitors
KR1020207013076A KR20200070295A (en) 2017-10-12 2018-10-11 Pyridine, pyrazine and triazine compounds as allosteric SHP2 inhibitors
EP18795913.5A EP3694848A1 (en) 2017-10-12 2018-10-11 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
BR112020007058-0A BR112020007058A2 (en) 2017-10-12 2018-10-11 pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
MX2020003579A MX2020003579A (en) 2017-10-12 2018-10-11 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors.
RU2020115095A RU2020115095A (en) 2017-10-12 2018-10-11 PYRIDINE, PYRAZINE AND TRIAZINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS
CA3078565A CA3078565A1 (en) 2017-10-12 2018-10-11 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
SG11202002941WA SG11202002941WA (en) 2017-10-12 2018-10-11 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CONC2020/0003714A CO2020003714A2 (en) 2017-10-12 2020-03-27 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
PH12020550216A PH12020550216A1 (en) 2017-10-12 2020-03-31 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
IL273756A IL273756A (en) 2017-10-12 2020-04-01 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
US16/845,539 US11702411B2 (en) 2017-10-12 2020-04-10 Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
US18/131,226 US20240067636A1 (en) 2017-10-12 2023-04-05 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762571760P 2017-10-12 2017-10-12
US62/571,760 2017-10-12
US201862615353P 2018-01-09 2018-01-09
US62/615,353 2018-01-09
US201862678889P 2018-05-31 2018-05-31
US62/678,889 2018-05-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/845,539 Continuation US11702411B2 (en) 2017-10-12 2020-04-10 Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors

Publications (1)

Publication Number Publication Date
WO2019075265A1 true WO2019075265A1 (en) 2019-04-18

Family

ID=64049755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/055502 WO2019075265A1 (en) 2017-10-12 2018-10-11 Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors

Country Status (16)

Country Link
US (2) US11702411B2 (en)
EP (1) EP3694848A1 (en)
JP (1) JP2020536881A (en)
KR (1) KR20200070295A (en)
CN (1) CN111212834B (en)
AU (1) AU2018347516A1 (en)
BR (1) BR112020007058A2 (en)
CA (1) CA3078565A1 (en)
CO (1) CO2020003714A2 (en)
IL (1) IL273756A (en)
MX (1) MX2020003579A (en)
PH (1) PH12020550216A1 (en)
RU (1) RU2020115095A (en)
SG (1) SG11202002941WA (en)
TW (1) TW201930292A (en)
WO (1) WO2019075265A1 (en)

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10561655B2 (en) 2018-03-21 2020-02-18 Synblia Therapeutics, Inc. SHP2 inhibitors and uses thereof
US10590090B2 (en) 2016-07-12 2020-03-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
WO2020065452A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
US10844079B2 (en) 2018-11-06 2020-11-24 Etern Biopharma (Shanghai) Co., Ltd. Spiro aromatic ring compound and application thereof
US10851110B2 (en) 2016-05-31 2020-12-01 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
US10858359B2 (en) 2016-06-07 2020-12-08 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic ring derivatives useful as SHP2 inhibitors
WO2020261156A1 (en) 2019-06-28 2020-12-30 Array Biopharma Inc. Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
WO2021018287A1 (en) * 2019-08-01 2021-02-04 上海奕拓医药科技有限责任公司 Spiroaromatic compound, preparation and application thereof
EP3772513A1 (en) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10934302B1 (en) 2018-03-21 2021-03-02 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
WO2021043077A1 (en) * 2019-09-06 2021-03-11 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compound and preparation method therefor and use thereof
US10954243B2 (en) 2018-05-02 2021-03-23 Navire Pharma, Inc. Substituted heterocyclic inhibitors of PTPN11
WO2021073439A1 (en) * 2019-10-14 2021-04-22 杭州雷索药业有限公司 Pyrazine derivative for inhibiting shp2 activity
US10988466B2 (en) 2017-03-23 2021-04-27 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic derivatives useful as SHP2 inhibitors
US11008572B2 (en) 2017-08-04 2021-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2021143680A1 (en) 2020-01-16 2021-07-22 浙江海正药业股份有限公司 Heteroaryl derivative, preparation method therefor, and use thereof
US11104675B2 (en) 2018-08-10 2021-08-31 Navire Pharma, Inc. PTPN11 inhibitors
WO2021171261A1 (en) 2020-02-28 2021-09-02 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
US11208399B2 (en) 2019-05-17 2021-12-28 Novartis Ag NLRP3 inflammasome inhibitors
WO2021259077A1 (en) 2020-06-22 2021-12-30 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compound, pharmaceutical composition comprising same, and use thereof
WO2022093856A1 (en) 2020-10-27 2022-05-05 Amgen Inc. Heterocyclic spiro compounds and methods of use
CN114761394A (en) * 2020-01-16 2022-07-15 浙江海正药业股份有限公司 Pyridine or pyrimidine derivative and preparation method and application thereof
WO2022161222A1 (en) * 2021-01-29 2022-08-04 四川科伦博泰生物医药股份有限公司 Heterocyclic shp2 inhibitor, preparation method therefor, and use thereof
EP4039685A1 (en) 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors
EP4067358A1 (en) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
WO2022208391A1 (en) 2021-03-31 2022-10-06 Pfizer Inc, 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
WO2022232332A1 (en) 2021-04-29 2022-11-03 Amgen Inc. 2-aminobenzothiazole compounds and methods of use thereof
WO2022237367A1 (en) * 2021-05-13 2022-11-17 中国科学院上海药物研究所 Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof
WO2022258612A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
WO2022258600A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
WO2022269525A1 (en) 2021-06-23 2022-12-29 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
US11596633B2 (en) 2017-09-07 2023-03-07 Revolution Medicines, Inc. SHP2 inhibitor compositions and methods for treating cancer
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
US11629145B2 (en) 2016-10-24 2023-04-18 D. E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
US11634417B2 (en) 2019-04-02 2023-04-25 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
WO2023078881A1 (en) 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
US11673901B2 (en) 2017-12-15 2023-06-13 Revolution Medicines, Inc. Polycyclic compounds as allosteric SHP2 inhibitors
US11673896B2 (en) 2017-01-23 2023-06-13 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
WO2023122938A1 (en) * 2021-12-28 2023-07-06 Js Innomed Holdings Ltd. Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
US11702411B2 (en) 2017-10-12 2023-07-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
US11701354B2 (en) 2017-09-29 2023-07-18 D. E. Shaw Research, Llc Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
WO2023159086A1 (en) 2022-02-16 2023-08-24 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
WO2023159087A1 (en) 2022-02-16 2023-08-24 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
US11739093B2 (en) 2017-01-23 2023-08-29 Revolution Medicines, Inc. Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
US11827644B2 (en) 2019-03-04 2023-11-28 Suzhou Genhouse Pharmaceutical Co., Ltd Pyrazine derivative and application thereof in inhibiting SHP2
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US11845744B2 (en) 2019-02-05 2023-12-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11890281B2 (en) 2019-09-24 2024-02-06 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of making and using the same
EP4345101A1 (en) 2022-09-29 2024-04-03 Irbm S.P.A. Azole derivatives as shp2 inhibitors
US11952386B2 (en) 2014-01-17 2024-04-09 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US11964971B2 (en) 2019-02-06 2024-04-23 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
US12029739B2 (en) 2021-07-09 2024-07-09 Kanaph Therapeutics Inc. SHP2 inhibitor and use thereof
RU2826735C2 (en) * 2019-05-17 2024-09-16 Новартис Аг Nlrp3 inflammasome inhibitors
US12097203B2 (en) 2021-05-05 2024-09-24 Huyabio International, Llc Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022007869A1 (en) * 2020-07-10 2022-01-13 浙江海正药业股份有限公司 Pyridine or pyrimidine derivative and preparation method therefor and use thereof
WO2024022244A1 (en) * 2022-07-26 2024-02-01 首药控股(北京)股份有限公司 Heterocyclic compound having biological activity
KR20240110741A (en) * 2023-01-05 2024-07-16 주식회사 카나프테라퓨틱스 Shp2 inhibitors and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
WO2015107494A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
WO2016203406A1 (en) * 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2017216706A1 (en) * 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2018013597A1 (en) * 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018130928A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
WO2018136264A1 (en) * 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2572728A (en) 1949-01-07 1951-10-23 American Cyanamid Co Hydroxybenzenesulfonamidopyra-zines and preparation of same
US2636882A (en) 1950-08-11 1953-04-28 Quaker Oats Co Preparation of 3-pyridols from 2-acylfurans
BE758503A (en) 1969-11-07 1971-05-05 Shell Int Research PESTICIDE COMPOSITIONS
GB1459571A (en) 1974-09-12 1976-12-22 Pfizer Ltd Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus
JPS5762269A (en) 1980-10-03 1982-04-15 Ogawa Koryo Kk 2,3,5-trisubstituted pyrazine derivative
US4513135A (en) 1982-03-05 1985-04-23 Eli Lilly And Company Diaryl-pyrazine derivatives affecting GABA binding
DE3242195A1 (en) 1982-11-15 1984-05-17 Basf Ag, 6700 Ludwigshafen NEW 2-AMINOPYRAZINE AND METHOD FOR PRODUCING 2-AMINOPYRAZINE AND PYRAZINE
JPH0249775A (en) 1988-05-19 1990-02-20 Nippon Soda Co Ltd Heterocyclic compound having 6-membered or 7-membered ring and production thereof
JPH04112877A (en) 1990-09-04 1992-04-14 Nippon Soda Co Ltd New cyanopyrazine derivative and production thereof
WO1993009664A1 (en) 1991-11-12 1993-05-27 Nippon Soda Co., Ltd. Wavelength conversion material for agriculture
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
NZ330119A (en) 1996-02-07 2000-02-28 Janssen Pharmaceutica Nv Pyrazolopyrimidines as crf receptor antagonists
JP2002512628A (en) 1997-06-13 2002-04-23 スージェン・インコーポレーテッド Novel heteroaryl compounds for regulating protein tyrosine enzyme-related cell signaling
CA2382789A1 (en) 1999-08-27 2001-03-08 Sugen, Inc. Phosphate mimics and methods of treatment using phosphatase inhibitors
EE200200453A (en) 2000-02-16 2003-12-15 Neurogen Corporation Substituted arylpyrazines
WO2003029422A2 (en) 2001-10-01 2003-04-10 Mount Sinai School Of Medicine Noonan syndrome gene
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
BR0214309A (en) 2001-11-21 2004-10-13 Upjohn Co Substituted aryl-1,4-pyrazine derivatives
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
MXPA05002418A (en) 2002-09-12 2005-05-27 Pharmacia & Upjohn Co Llc Substituted 1,4-pyrazine derivatives.
ATE514713T1 (en) 2002-12-23 2011-07-15 Wyeth Llc ANTIBODIES TO PD-1 AND THEIR USE
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
CA2524519A1 (en) 2003-05-09 2004-11-18 Pharmacia & Upjohn Company Llc Compounds as crf1 receptor antagonists
GB0314057D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2856684B1 (en) 2003-06-26 2008-04-11 Sanofi Synthelabo DIPHENYLPYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
AU2004274403A1 (en) 2003-09-03 2005-03-31 Aventis Pharmaceuticals Inc. 5-aryl-Pyrazolo(4,3-d)pyrimidines, pyridines, and pyrazines and related compounds
ATE369370T1 (en) 2003-10-10 2007-08-15 Pfizer Prod Inc SUBSTITUTED 2H-(1,2,4)TRIAZOLO(4,3-A)PYRAZINE AS GSK-3 INHIBITORS
BRPI0415863A (en) 2003-10-27 2007-01-09 Astellas Pharma Inc pyrazine derivatives and their pharmaceutical uses
DE102004015954A1 (en) 2004-04-01 2005-11-10 Ina-Schaeffler Kg belt drive
CN1938296A (en) 2004-04-01 2007-03-28 安斯泰来制药有限公司 Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
ATE522510T1 (en) 2004-12-23 2011-09-15 Mallinckrodt Inc FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USE THEREOF IN CHECKING KIDNEY FUNCTION
TW200716594A (en) 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
EP1948827B1 (en) 2005-10-21 2016-03-23 The Regents of The University of California C-kit oncogene mutations in melanoma
US9283288B2 (en) 2006-02-24 2016-03-15 Medibeacon, Inc. Methods of using optical agents
JP2007277097A (en) 2006-04-03 2007-10-25 Mie Univ Luminous compound, method for emitting light, and method for producing luminous compound
WO2007117699A2 (en) 2006-04-07 2007-10-18 University Of South Florida Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs
WO2007127375A2 (en) * 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
NZ573015A (en) 2006-05-31 2010-11-26 Galapagos Nv Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
WO2007145921A1 (en) 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP2131861A2 (en) 2007-03-01 2009-12-16 Mallinckrodt Inc. Integrated photoactive small molecules and uses thereof
CA2682340A1 (en) 2007-04-06 2008-10-16 Novartis Ag [2 , 6] naphthyridines useful as protein kinase inhibitors
US8133895B2 (en) 2007-05-10 2012-03-13 Janssen Pharmaceutica N.V. Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
JPWO2008156174A1 (en) 2007-06-21 2010-08-26 大正製薬株式会社 Pyrazineamide compound
JP2010535769A (en) 2007-08-09 2010-11-25 メルク・シャープ・エンド・ドーム・コーポレイション Pyridine carboxamide orexin receptor antagonist
WO2009025823A1 (en) * 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US9174969B2 (en) 2008-07-21 2015-11-03 University Of South Florida Indoline scaffold SHP-2 inhibitors and cancer treatment method
EP2349267B1 (en) 2008-10-30 2014-06-25 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
SG172885A1 (en) 2009-01-23 2011-08-29 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the jak pathway
WO2010121212A2 (en) 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
US20120065205A1 (en) * 2009-06-01 2012-03-15 Mercer Swati P Pyrazine carboxamide orexin receptor antagonists
US9567318B2 (en) 2009-08-17 2017-02-14 Memorial Sloan-Kettering Cancer Center Substituted pyrimidine compounds and uses thereof
CA2780713A1 (en) 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
US8673913B2 (en) 2009-11-13 2014-03-18 Case Western Reserve University SHP-2 phosphatase inhibitor
KR101647871B1 (en) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 Antibodies against human csf-1r and uses thereof
TW201200518A (en) * 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
JP5833105B2 (en) * 2010-05-11 2015-12-16 サノフイ Substituted N-heteroaryl spirolactam bipyrrolidines, their preparation and therapeutic use
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
SI2593452T1 (en) 2010-07-14 2017-06-30 Novartis Ag Ip receptor agonist heterocyclic compounds
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
JP5808826B2 (en) 2011-02-23 2015-11-10 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
US20120330012A1 (en) 2011-04-29 2012-12-27 Abbott Laboratories Novel Tricyclic Compounds
CN103181918B (en) 2011-05-04 2014-10-29 厦门大学 Application of fatty acid compound in preparation of medicines for preventing and treating liver cancer
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2882746B1 (en) 2012-08-07 2016-12-07 Merck Patent GmbH Pyridopyrimidine derivatives as protein kinase inhibitors
EP3323821A1 (en) 2012-11-08 2018-05-23 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CN105189484B (en) 2012-11-29 2018-05-04 凯莫森特里克斯股份有限公司 Cxcr7 antagonists
WO2014113584A1 (en) 2013-01-16 2014-07-24 Rhode Island Hospital Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
US20150374687A1 (en) 2013-02-07 2015-12-31 Merck Patent Gmbh Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
RU2708032C2 (en) 2013-02-20 2019-12-03 Новартис Аг CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
CN103554038B (en) 2013-06-19 2015-10-14 云南大学 Phenyl polyhalide nitrile quinazolinones and its production and use
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
WO2015164862A1 (en) 2014-04-25 2015-10-29 Memorial Sloan-Kettering Cancer Center Treatment of h-ras-driven tumors
TWI687419B (en) 2014-07-10 2020-03-11 美商英塞特公司 Imidazopyridines and imidazopyrazines as LSD1 inhibitors
ES2896400T3 (en) * 2014-08-01 2022-02-24 Nuevolution As Active compounds against bromdomains
EP3220910B1 (en) 2014-11-18 2020-01-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
US20170362305A1 (en) 2014-12-17 2017-12-21 Siemens Healthcare Diagnostics Inc. Sandwich assay design for small molecules
SI3237418T1 (en) 2014-12-23 2019-06-28 Novartis Ag Triazolopyrimidine compounds and uses thereof
EP4289950A3 (en) 2015-01-09 2024-01-24 Revolution Medicines, Inc. Macrocyclic compounds that participate in cooperative binding and medical uses thereof
KR20170109589A (en) 2015-02-05 2017-09-29 티르노보 리미티드 Combination of IRS / STAT3 dual modulators and anticancer drugs for cancer treatment
EA201792205A1 (en) 2015-04-03 2018-02-28 Инсайт Корпорейшн HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
WO2016203405A1 (en) 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US10426842B2 (en) 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
AU2016329064B2 (en) 2015-10-01 2023-10-19 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
WO2017156397A1 (en) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
GB201604970D0 (en) * 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
KR20210141778A (en) 2016-06-07 2021-11-23 자코바이오 파마슈티칼스 컴퍼니 리미티드 Novel heterocyclic derivatives useful as shp2 inhibitors
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TWI848901B (en) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2 phosphatase inhibitors and methods of use thereof
CN117327075A (en) 2017-01-23 2024-01-02 锐新医药公司 Bicyclic compounds as allosteric SHP2 inhibitors
KR20220113545A (en) 2017-03-23 2022-08-12 자코바이오 파마슈티칼스 컴퍼니 리미티드 Novel heterocyclic derivatives useful as shp2 inhibitors
WO2018187423A1 (en) 2017-04-05 2018-10-11 Warp Drive Bio, Inc. Methods and reagents for analyzing protein-protein interfaces
CA3058953A1 (en) 2017-04-05 2018-10-11 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
EP3630770B1 (en) 2017-05-26 2024-08-28 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
BR112020004246A2 (en) 2017-09-07 2020-09-01 Revolution Medicines, Inc. shp2 inhibitory compositions and methods for the treatment of cancer
WO2019075265A1 (en) 2017-10-12 2019-04-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
BR112020009757A2 (en) 2017-12-15 2020-11-03 Revolution Medicines, Inc. polycyclic compounds as allosteric inhibitors of shp2
CN110156786B (en) 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 Pyrimido-cyclic compounds, process for their preparation and their use
SG11202007740TA (en) 2018-02-13 2020-09-29 Shanghai Blueray Biopharma Co Ltd Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
US10561655B2 (en) * 2018-03-21 2020-02-18 Synblia Therapeutics, Inc. SHP2 inhibitors and uses thereof
JP2021521155A (en) 2018-04-10 2021-08-26 レヴォリューション・メディスンズ，インコーポレイテッド SHP2 inhibitor compositions, methods for treating cancer, and methods for identifying subjects with SHP mutations.
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
CA3111980A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
EP3853234A1 (en) * 2018-09-18 2021-07-28 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
CN113473990A (en) 2018-10-08 2021-10-01 锐新医药公司 SHP2 inhibitor composition for treating cancer
CN114751903B (en) 2018-11-07 2023-09-15 上海凌达生物医药有限公司 Nitrogen-containing fused heterocycle SHP2 inhibitor compound, preparation method and application
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
BR112021009880A2 (en) 2018-11-30 2021-08-17 Tuojie Biotech (Shanghai) Co., Ltd. pyrimidine and derivative of five-membered nitrogen heterocycle, method of preparation thereof and medical uses thereof
US20220073521A1 (en) 2018-11-30 2022-03-10 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
EP3897644A4 (en) 2018-12-21 2022-09-07 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
WO2021091967A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
WO2015107494A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
WO2016203406A1 (en) * 2015-06-19 2016-12-22 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2017216706A1 (en) * 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2018013597A1 (en) * 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018130928A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
WO2018136264A1 (en) * 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 November 1984 (1984-11-16), XP002787395, retrieved from stn Database accession no. 86663-20-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 November 1984 (1984-11-16), XP002787397, retrieved from stn Database accession no. 68559-45-5 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 18 December 1984 (1984-12-18), XP002787396, retrieved from stn Database accession no. 93034-72-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 January 2015 (2015-01-22), XP002787394, retrieved from stn Database accession no. 1643677-14-8 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 23 November 2004 (2004-11-23), XP002787398, retrieved from stn Database accession no. 786652-86-6 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 23 November 2004 (2004-11-23), XP002787399, retrieved from stn Database accession no. 786652-83-3 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 April 2011 (2011-04-27), XP002787392, retrieved from STN Database accession no. 1286273-60-6 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 August 2010 (2010-08-27), XP002787406, retrieved from stn Database accession no. 1239320-06-9 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 31 May 2006 (2006-05-31), XP002787401, retrieved from stn Database accession no. 886208-65-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 6 April 1990 (1990-04-06), XP002787400, Database accession no. 126317-60-0 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 9 November 2007 (2007-11-09), XP002787393, retrieved from stn Database accession no. 952723-55-6 *
E. L. ELIEL; S. H. WILEN; L. N. MANDER: "Stereochemistry of Organic Compounds", 1994, WILEY-LNTERSCIENCE
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
US11952386B2 (en) 2014-01-17 2024-04-09 Novartis Ag N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
US10851110B2 (en) 2016-05-31 2020-12-01 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
US11840536B2 (en) 2016-05-31 2023-12-12 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
US10858359B2 (en) 2016-06-07 2020-12-08 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic ring derivatives useful as SHP2 inhibitors
US10934285B2 (en) 2016-06-14 2021-03-02 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US11905283B2 (en) 2016-06-14 2024-02-20 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
US10590090B2 (en) 2016-07-12 2020-03-17 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
US11661401B2 (en) 2016-07-12 2023-05-30 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
US11629145B2 (en) 2016-10-24 2023-04-18 D. E. Shaw Research, Llc SHP2 phosphatase inhibitors and methods of use thereof
US11673896B2 (en) 2017-01-23 2023-06-13 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
US11739093B2 (en) 2017-01-23 2023-08-29 Revolution Medicines, Inc. Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors
US10988466B2 (en) 2017-03-23 2021-04-27 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic derivatives useful as SHP2 inhibitors
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
US11326165B1 (en) 2017-08-04 2022-05-10 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11091475B2 (en) 2017-08-04 2021-08-17 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11434489B1 (en) 2017-08-04 2022-09-06 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11008572B2 (en) 2017-08-04 2021-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11021708B2 (en) 2017-08-04 2021-06-01 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11162101B2 (en) 2017-08-04 2021-11-02 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11603531B1 (en) 2017-08-04 2023-03-14 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11596633B2 (en) 2017-09-07 2023-03-07 Revolution Medicines, Inc. SHP2 inhibitor compositions and methods for treating cancer
US11701354B2 (en) 2017-09-29 2023-07-18 D. E. Shaw Research, Llc Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors
US11702411B2 (en) 2017-10-12 2023-07-18 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
US11673901B2 (en) 2017-12-15 2023-06-13 Revolution Medicines, Inc. Polycyclic compounds as allosteric SHP2 inhibitors
US10561655B2 (en) 2018-03-21 2020-02-18 Synblia Therapeutics, Inc. SHP2 inhibitors and uses thereof
US10934302B1 (en) 2018-03-21 2021-03-02 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
US12084447B2 (en) 2018-03-21 2024-09-10 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
US10954243B2 (en) 2018-05-02 2021-03-23 Navire Pharma, Inc. Substituted heterocyclic inhibitors of PTPN11
US11932643B2 (en) 2018-05-02 2024-03-19 Navire Pharma, Inc. Substituted heterocyclic inhibitors of PTPN11
US11104675B2 (en) 2018-08-10 2021-08-31 Navire Pharma, Inc. PTPN11 inhibitors
US11945815B2 (en) 2018-08-10 2024-04-02 Navire Pharma, Inc. PTPN11 inhibitors
US10894797B2 (en) 2018-09-18 2021-01-19 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors
US11518772B2 (en) 2018-09-18 2022-12-06 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11034705B2 (en) 2018-09-18 2021-06-15 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as Src homology-2 phosphate inhibitors
US11459340B2 (en) 2018-09-18 2022-10-04 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors
WO2020065452A1 (en) * 2018-09-29 2020-04-02 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2
US11873307B2 (en) 2018-09-29 2024-01-16 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of SHP2
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
US11685748B2 (en) 2018-11-06 2023-06-27 Etern Biopharma (Shanghai) Co., Ltd. Spiro aromatic ring compound and application thereof
US10844079B2 (en) 2018-11-06 2020-11-24 Etern Biopharma (Shanghai) Co., Ltd. Spiro aromatic ring compound and application thereof
US11845744B2 (en) 2019-02-05 2023-12-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11964971B2 (en) 2019-02-06 2024-04-23 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11827644B2 (en) 2019-03-04 2023-11-28 Suzhou Genhouse Pharmaceutical Co., Ltd Pyrazine derivative and application thereof in inhibiting SHP2
US11884664B2 (en) 2019-04-02 2024-01-30 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
US11634417B2 (en) 2019-04-02 2023-04-25 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
US11208399B2 (en) 2019-05-17 2021-12-28 Novartis Ag NLRP3 inflammasome inhibitors
US11254653B2 (en) 2019-05-17 2022-02-22 Novartis Ag NLRP3 inflammasome inhibitors
RU2826735C2 (en) * 2019-05-17 2024-09-16 Новартис Аг Nlrp3 inflammasome inhibitors
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
WO2020261156A1 (en) 2019-06-28 2020-12-30 Array Biopharma Inc. Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
WO2021018287A1 (en) * 2019-08-01 2021-02-04 上海奕拓医药科技有限责任公司 Spiroaromatic compound, preparation and application thereof
CN114269746A (en) * 2019-08-01 2022-04-01 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound, preparation and application thereof
EP3772513A1 (en) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
WO2021028362A1 (en) 2019-08-09 2021-02-18 Irbm S.P.A. Shp2 inhibitors
CN114127053A (en) * 2019-09-06 2022-03-01 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compound, preparation method and application thereof
WO2021043077A1 (en) * 2019-09-06 2021-03-11 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compound and preparation method therefor and use thereof
CN114127053B (en) * 2019-09-06 2023-06-13 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compound, preparation method and application thereof
US11890281B2 (en) 2019-09-24 2024-02-06 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of making and using the same
CN112724145A (en) * 2019-10-14 2021-04-30 杭州雷索药业有限公司 Pyrazine derivatives for inhibiting SHP2 activity
WO2021073439A1 (en) * 2019-10-14 2021-04-22 杭州雷索药业有限公司 Pyrazine derivative for inhibiting shp2 activity
WO2021143680A1 (en) 2020-01-16 2021-07-22 浙江海正药业股份有限公司 Heteroaryl derivative, preparation method therefor, and use thereof
CN114761394A (en) * 2020-01-16 2022-07-15 浙江海正药业股份有限公司 Pyridine or pyrimidine derivative and preparation method and application thereof
CN114761394B (en) * 2020-01-16 2024-03-29 浙江海正药业股份有限公司 Pyridine or pyrimidine derivative and preparation method and application thereof
WO2021171261A1 (en) 2020-02-28 2021-09-02 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
WO2021259077A1 (en) 2020-06-22 2021-12-30 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compound, pharmaceutical composition comprising same, and use thereof
WO2022093856A1 (en) 2020-10-27 2022-05-05 Amgen Inc. Heterocyclic spiro compounds and methods of use
WO2022161222A1 (en) * 2021-01-29 2022-08-04 四川科伦博泰生物医药股份有限公司 Heterocyclic shp2 inhibitor, preparation method therefor, and use thereof
EP4039685A1 (en) 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors
WO2022167682A1 (en) 2021-02-08 2022-08-11 Irbm S.P.A. Azabicyclic shp2 inhibitors
WO2022208391A1 (en) 2021-03-31 2022-10-06 Pfizer Inc, 3,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitors
EP4067358A1 (en) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
WO2022207924A1 (en) 2021-04-02 2022-10-06 C.N.C.C.S. S.C.A.R.L. Collezione Nazionale Dei Composti Chimici E Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo [1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
WO2022232332A1 (en) 2021-04-29 2022-11-03 Amgen Inc. 2-aminobenzothiazole compounds and methods of use thereof
US12097203B2 (en) 2021-05-05 2024-09-24 Huyabio International, Llc Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors
WO2022237367A1 (en) * 2021-05-13 2022-11-17 中国科学院上海药物研究所 Heterocyclic compound for inhibiting shp2 activity, preparation method therefor and use thereof
WO2022258612A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment
WO2022259157A1 (en) 2021-06-09 2022-12-15 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
WO2022258600A1 (en) 2021-06-09 2022-12-15 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
WO2022269525A1 (en) 2021-06-23 2022-12-29 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
US12029739B2 (en) 2021-07-09 2024-07-09 Kanaph Therapeutics Inc. SHP2 inhibitor and use thereof
WO2023031781A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
WO2023078881A1 (en) 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
WO2023122938A1 (en) * 2021-12-28 2023-07-06 Js Innomed Holdings Ltd. Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
WO2023159086A1 (en) 2022-02-16 2023-08-24 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
WO2023159087A1 (en) 2022-02-16 2023-08-24 Amgen Inc. Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2024068976A1 (en) 2022-09-29 2024-04-04 Irbm S.P.A. Azole derivatives as shp2 inhibitors
EP4345101A1 (en) 2022-09-29 2024-04-03 Irbm S.P.A. Azole derivatives as shp2 inhibitors
WO2024126660A1 (en) 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Also Published As

Publication number Publication date
US20240067636A1 (en) 2024-02-29
EP3694848A1 (en) 2020-08-19
AU2018347516A1 (en) 2020-05-07
IL273756A (en) 2020-05-31
US20200339552A1 (en) 2020-10-29
PH12020550216A1 (en) 2021-02-15
SG11202002941WA (en) 2020-04-29
CN111212834B (en) 2024-01-19
US11702411B2 (en) 2023-07-18
TW201930292A (en) 2019-08-01
RU2020115095A3 (en) 2022-01-31
MX2020003579A (en) 2020-07-22
CO2020003714A2 (en) 2020-04-24
RU2020115095A (en) 2021-11-12
CA3078565A1 (en) 2019-04-18
JP2020536881A (en) 2020-12-17
KR20200070295A (en) 2020-06-17
BR112020007058A2 (en) 2020-10-06
CN111212834A (en) 2020-05-29

Similar Documents

Publication Publication Date Title
EP3694848A1 (en) Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
AU2018210196B2 (en) Pyridine compounds as allosteric SHP2 inhibitors
EP3724189B1 (en) Polycyclic compounds as allosteric shp2 inhibitors
CN110382499B (en) FGFR inhibitor and application thereof
TWI736578B (en) Certain protein kinase inhibitors
EP4302834A2 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
KR20160144378A (en) Polyfluorinated compounds acting as bruton&#39;s tyrosine kinase inhibitors
KR20140048968A (en) Inhibitors of bruton&#39;s tyrosine kinase
KR20190032420A (en) Heterocyclic compounds used as FGFR inhibitors
CN115368373A (en) Spirocyclic compound and use thereof
CN114008042A (en) Substituted pyrrolo [2,3-b ] pyridine and pyrazolo [3,4-b ] pyridine derivatives as protein kinase inhibitors
EP3632903A1 (en) Compound used as autophagy regulator, and preparation method therefor and uses thereof
CN115551859B (en) Aza condensed ring amide compound and application thereof
CN116568681A (en) SOS1 inhibitor, pharmaceutical composition containing same and application thereof
WO2014100540A1 (en) Pyrazole substituted imidazopyrazines as casein kinase 1 d/e inhibitors
TW202028209A (en) Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI827869B (en) Substituted pyrrolo [2, 3-b] pyridine and pyrazolo [3,4-b] pyridine derivatives as protein kinase inhibitors
RU2824583C2 (en) Substituted pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18795913

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3078565

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020519790

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018347516

Country of ref document: AU

Date of ref document: 20181011

Kind code of ref document: A

Ref document number: 20207013076

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018795913

Country of ref document: EP

Effective date: 20200512

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020007058

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020007058

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200408